



COMMUNICATIONS/ PUBLIC RELATIONS
DEPARTMENT

Reference: **AR Template**

Enquiries: **Laticia Pienaar/Rozaun Botes**

DEPARTMENT OF PAEDIATRICS AND CHILD HEALTH

**Annual Report for Tygerberg Hospital
and Stellenbosch University 2018**

**HEAD OF DEPARTMENT
REPORT COMPILED BY**

Professor Mariana Kruger

Editor: Professor Mariana Kruger

Authors: Personnel

Administrative assistance: JP Adams, AE Fourie & S
Engelbrecht

Tel: (021) 938-9220/938-4538

Table of Contents

Head of Department	1
Professor Mariana Kruger	1
Report compiled by.....	1
Editor: Professor Mariana Kruger.....	1
Administrative assistance: JP Adams, AE Fourie & S Engelbrecht	1
Tel: (021) 938-9220/938-4538	1
EXECUTIVE SUMMARY – 2018	4
Part 1	5
RESOURCES AND OUTPUT	5
Human Resources.....	5
Output	5
Subspecialist Paediatrics	5
Total patient admissions 2018 (Clinicom data)	5
Bed Occupancy Rate 2018(Clinicom data)	5
Neonatology.....	6
A9 Neonatal Intensive Care Unit	6
Ward G1: Neonatal Unit – Babies born outside TBH.....	6
Highly Specialized Paediatrics	7
A9 Paediatric Intensive Care Unit.....	7
A9 Paediatric High Care Unit	9
A9 Tracheostomy Unit.....	9
Ward G9 Paediatric Pulmonology and Allergy*	9
Ward G9 Neurology.....	9
Ward G9 Paediatric Endocrinology	10
Ward G10 Gastroenterology	10
Ward G10 Infectious Diseases Unit	11
G10 Cardiology	11
Ward G3 Oncology & Haematology	11
Ward G3 Rheumatology & Immunology	12
Ward G3 Nephrology.....	12
OUTPATIENT COMPLEX	13
Subspecialist Clinics.....	13
general specialist services	14
Total Patient Admissions 2018 (Clinicom data).....	14
Bed Occupancy Rate 2018 (Clinicom data)	14
Neonatology.....	14
Ward G2 Neonatal Unit – Babies born in TBH.....	14
Ward J3 Neonatal Unit – Babies born in TBH	14
Ward G8 Low Care Neonates & Kangaroo-mother Care – Step-down Facility	15
Short-stay G Ground: <48-hour Admissions.....	15
Ward G7 General Paediatrics	15
General Paediatrics: Emergency & Clinics	15
2018 Morbidity & Mortality	16
Infrastructure Development	21
Part 2	23
Community Outreach Programmes/Community Service and Interaction & Partnerships .	23
Expert Members.....	23
Outreach.....	24
Tygerberg Children’s Hospital Trust	25

HOPE Cape Town.....	25
Hear the TYGER ROAR (Reach out and Read) PROJECT at Tygerberg Hospital	26
Media Exposure.....	26
International visitors:	27
Part 3	28
Teaching & Training.....	28
Education-related Activities.....	28
Postgraduate Students	28
Successful PhD Candidates.....	28
Enrolled PhD students	28
Successful MMed(Paed) Candidates	29
Colleges of Medicine of South Africa (CMSA)	29
• Certificate in Paediatric Pulmonology	29
• Certificate in Medical Oncology.....	29
• Certificate in Neonatology	29
• FC Paed (SA) Part II	29
• FC Paed (SA) Primary	30
University of Stellenbosch Business School (USB).....	30
Undergraduate Students	30
Education-related Activities.....	30
Part 4	31
Achievements and Highlights.....	31
<i>Appointments</i>.....	31
<i>Grants/Awards</i>.....	31
<i>Sabbaticals</i>.....	32
<i>Organizing and Presentations at Conferences</i>	33
<i>Conferences Attended</i>	36
<i>Courses Organized and Presented</i>	38
<i>Courses Attended</i>	38
<i>Publications</i>.....	40
CENTRES.....	50
THE FAMILY CLINICAL RESEARCH UNIT (FAMCRU).....	50
Director: Prof MF Cotton.....	50
DESMOND TUTU TB CENTRE (DTTC)	56
Director: Prof AC Hesseling	56

EXECUTIVE SUMMARY – 2018

The year 2018 had posed many challenges as patient numbers were steadily increasing (respectively 6.5% for highly specialized paediatrics and 10.5% for general paediatrics), without the subsequent increase in staffing. Bed occupancy rate was especially high for general paediatrics (90%), neonatal ICU (86%) and paediatric ICU (86%). A further limitation was the lack of dedicated financial resources, which necessitated additional cost saving measures to be taken to ensure expenditure within allocated budget. Inborn survival rate of neonates was excellent with 98.5% of infants 500 grams and more surviving. Critical staff shortages include the lack of a second paediatric oncologist and a dedicated paediatric subspecialist for primary immunodeficiencies. Furthermore, without the assistance of the supernumerary recruited registrars (n=15) and senior registrars (n=5), we would not have been able to provide adequate service delivery – this is another major cost saving for Tygerberg hospital. The most important death causes remained septicaemia (16.9%) and pneumonia (10.5%), while the majority of patients that died were in the under-weight-for-age category (12.1%). Major infrastructure improvements were funded by the Tygerberg Children's hospital Trust and included equipment to the value of **R 672 866,35** and upgrading of the A9 intensive care complex to the value of **R 193 400,70**. The department successfully hosted the biannual South African Paediatric Association conference in August 2018 (chairs were Proff Ronald van Toorn and Pierre Goussard). Education programmes were successful with a high undergraduate pass rate (98%), and excellent postgraduate pass rate (12 completed Master's degrees) and an additional 6 postgraduate students were awarded their PhDs. The two research centres were successful in grant applications and contributed to the excellent number of research publications (n=132).

Professor Mariana Kruger

Part 1

RESOURCES AND OUTPUT

Human Resources

<u>Posts (full-time)</u>	<u>Number</u>	<u>Filled</u>
Executive Head of Department/ Chief Specialist	1	1
Head of Clinical Department/ Chief Specialist	1	1
Principal Specialists	5	5
Senior Specialists	25+1(5/8)	25+1(5/8)
Senior Registrars	9 (5 Supernumeraries)	9 (5 Supernumeraries)
*Registrars	41 (including 15 Supernumeraries)	41 (15 Supernumeraries)
Medical Officers	24	24
<u>Posts (sessional – hours per week)</u>		
Specialist	4 (52 hours)	4 (52 hours)
Number of beds	271	271

Subspecialist Paediatrics	2018	2017	2016
Inpatients	6269 (6.5%)	5885 (4.0%)	5658 (-4.1%)
Outpatients	13694 (-0.1%)	13721 (3.7%)	13224 (-1%)
Summary of Output General Paediatrics			
Inpatients	10847 (10.5%)	9810 (-0.9%)	9906 (-11.8%)
Outpatients	12921 (2.2%)	12637 (5.4%)	11983 (-18%)

*6 registrars are appointed respectively Worcester (2), Paarl (2), KBH (1), KH (1)

Output

SUBSPECIALIST PAEDIATRICS

Total patient admissions 2018 (Clinicom data)

*A9 NICU	A9 PICU	A9 High Care	Trachea Unit	G1	G3	G9	G10	Total
509	803	209	51	1052	1064	1645	832	6165

*A9 NICU includes High-care beds, since Clinicom cannot separate data.

Bed Occupancy Rate 2018(Clinicom data)

*A9 NICU	A9 PICU	A9 High Care	Trachea Unit	G1	G3	G9	G10	Total
----------	---------	--------------	--------------	----	----	----	-----	-------

86%	86%	41%	56%	89%	76%	72%	71%	72%
-----	-----	-----	-----	-----	-----	-----	-----	-----

*A9 NICU includes High-care beds, since Clinicom cannot separate data.

#BOR low due to nursing staff shortages.

Neonatology

Staff: Prof J Smith, A Bekker, Drs S Holgate, G Kali, JCF du Preez, H Hassan, L Van Wyk, L Lloyd; 3 Senior Registrars (2 supernumerary) – Dr N Paulse, Dr MW Kariuki, Dr K Onwona-Agyeman; 6 Registrars; 7 Medical Officers

A9 Neonatal Intensive Care Unit

Staff: 1 Consultant (on rotation), 2 Registrars, 1 Medical Officer

Beds n=8	2018	2017	2016
Admissions	510	461	442
Average NICU Stay in Days	8	8	9
Average Bed Occupancy %	86%	81%	88%
% Growth	+10.6%	+4.3%	-12.6%
Deaths	97 (19%)	108 (23.4%)	76 (17.1%)

- **Referrals from outside TCH** (outborns) (n) = 178; 34.9% of admissions
- **Top 5 referring hospitals:**
 - KBH 67
 - Paarl 62
 - HH 37
 - Worcester 22
 - KH 4
- **Referrals for therapeutic hypothermia (TH): total 108 (21.2% of admissions)**
 - Inborn babies treated with therapeutic hypothermia (n) = 47
 - Referrals from referral hospitals (n) = 61: (75.4% of outborn referrals from HH & KBH)
 - 16 from HH
 - 30 from KBH
 - 13 from Paarl
- Surgical admissions: 92 (18.04% of admissions)
- Cranial ultrasounds: ±950
- Neonatal echocardiography: ±150

Ward G1: Neonatal Unit – Babies born outside TBH

Staff: 2 Consultants (on rotation), 2 Registrar, 1 Medical Officers, 1 Intern

Beds n=30	2018	2017	2016
Admissions	1052	989	1115
Average Ward Stay in Days	9	10	9
Average Bed Occupancy %	89%	85%	91%
% Growth	+6.4%	-11.3%	-3.2%
Deaths	21 (2%)	22 (2.2%)	36

Highly Specialized Paediatrics

A9 Paediatric Intensive Care Unit

Staff: Prof P Goussard, Drs N Parker, Dr I Appel, 3 Registrars, Medical Officer

Beds n=10	2018	2017	2016
Admissions	818	728	745
Average Hospital Stay in Days	4	4	4
Average Bed Occupancy %	86%	84%	81.6%
% Growth	+10.3%	+10.1%	+4.6%
Deaths	65 (7.9%)	79 (10.9%)	62

Paediatric Intensive Care Unit (PICU) bookings and admitted for elective postoperative beds 2018

(Table 1 and 2)

- Total bookings: n=372
 - Elective admissions: n=225 (60.5% of bookings and 27.5% of total PICU admissions)
 - Paediatric surgery: 26.7%
 - Thoracic surgery: 19.6%
 - Ear Nose and Throat (ENT): 15.6%
 - Other (as detailed in Table 1)
 - Patients with booking but not admitted to PICU: 39.5% (n=147)
 - 33.3% did not need a bed after surgery (n=49)
 - Cancellations of surgery: 22.4% (n=33)
 - Unknown reasons: 17% (n=25)
 - PICU refusal as patients not deemed to need intensive care: n=2 (Ophthalmology and MRI)
 - Bed not available: 15.6% (n=23) – especially during the months March to July 2018.
 - Paediatric surgery: n=7
 - ENT: n=5
 - Other reasons: nursing shortage n=2; CRE n=3; MRSA n=1

Table 1. Outcome of all Bookings for elective post-op beds in PICU (number / %)

Surgical discipline	Admitted	NA* - not required adm to surgical / medical ward postop	NA* - bed cancelled by surgeon	Surgery cancelled	NA – PICU Bed NA	NA – PICU bed cancelled by anaesthetist	Bed refused by PICU – not required (adm to ward post op)	Not contacted for bed space	Nursing short-staffed	PICU bed NA* - CRE**	PICU bed NA – MRSA*
Thoracic	44 (19.6%)	6	1	6	1			2	1		
General	60 (26.7%)	13	4	12	4			7		3	
ENT	35 (15.6%)	5	4	10	4			8			1
Orthopaedic	7 (3.1%)	1			1	1					
Spinal	25 (11.1%)			3	2						
Plastics	10 (4.4%)	2		1	2			2			

Urology	19 (8.4%)	6	2		2	1		2			
Post CT / MRI bed booked	3 (1.3%)	4					1	1			
Ophthalmol ogy	3 (1.3%)		1				1	1			
Neurosurger y	16 (7.1%)	7	1	1	1			2	1		
Post Bronchos- copy	3 (1.3%)	5									
Total 372	225 (60.5%)	49 (13.2%)	13 (3.5%)	33 (8.9%)	17 (4.6 %)	2 (0.5%)	2 (0.5%)	25 (6.7%)	2(0.5%)	3 (0.8 %)	1 (0.3 %)

*NA Patients booked for post-op bed and not admitted to PICU

**CRE *Carbapenem resistant Enterobacteriaceae*

***MRSA Methicillin resistant *Staphylococcus Aureus*

Table 2. Patients booked postoperatively for PICU bed and not admitted to PICU (number/%)

Surgical discipline	Admitted to surgical / medical ward postop	PICU bed cancelled by surgeon	Not contacted for PICU bed	Surgery cancelled	PICU Bed not available	PICU bed cancelled by anaesthetist	Bed refused by PICU - not required
Thoracic	6	1	2	6	2		
General	13	4	7	12	7		
ENT	5	4	8	10	5		
Orthopaedic	1				1	1	
Spinal				3	2		
Plastics	2		2	1	2		
Urology	6	2	2		2	1	
Post CT / MRI bed booked	4		1				1
Ophthalmol- ogy		1	1				1
Neurosurger y	7	1	2	1	2		
Post Bronchos- copy	5						
Total 147	49 (33.3%)	13 (8.8%)	25 (17.0%)	33 (22.4%)	23 (15.6%)	2 (1.4%)	2 (1.4%)

A9 Paediatric High Care Unit

Staff as mentioned above.

Beds n=4	2018	2017	2016
Admissions	209	181	108
Average Hospital Stay in Days	3	4	3.2
Average Bed Occupancy %	41%	34%*	25%
Growth %	15.4%	67.5%	
Deaths	2	2	3

* Due to nursing staff shortages

A9 Tracheostomy Unit

Staff as mentioned above:

Beds n=6	2018	2017	2016
Admissions	51	109	96
Average Bed Occupancy %	56%	62%	44%
Growth %	-53%	13.5%	
Deaths	1	1	0
Decannulation		10	/

Ward G9 Paediatric Pulmonology and Allergy*

Staff: Prof P Goussard, Dr J Morrison, 2 Senior Registrars (Dr L Green & Dr Y Mulambia), 2 Registrars, Shared Medical Officer in G9. *Allergy (largely outpatients service) *Prof S Kling, *Prof E Zöllner, *Dr Y Kooblal (4hrs per week)

Pulmonology Beds n=10	2018	2017	2016
Admissions Pulmonology	995	956	977
Average Hospital Stay in Days	5.8	4.5	5.6
Average Bed Occupancy %	65%	93%	94%
% Growth	+4%	-2%	9%
Deaths	1	1	2

*Doctors attached to other services, but responsible for allergy clinics

Theatre procedures and Other Activities

- Bronchoscopies: 465
- Thoracic surgery: 63
- 6 Outreach clinical teaching sessions and ward rounds to Karl Bremer hospital

Ward G9 Neurology

Staff: Prof R van Toorn, Prof R Solomons, Dr P Springer, 1 Senior Registrar (Dr T Katangwe), Dr A Thomas(8hrs per week), Dr Y Kooblal(4hrs per week) 2 Registrars

Beds n=10	2018	2017	2016
Admissions	501	421	388
Average Hospital Stay in Days	6	6.0	6.1
Referral other wards	740	680	550

Average Bed Occupancy %	76%	72%	65%
% Growth	+19%	+10.8%	-8.8%
Deaths	8	4	5

Other Activities

- Paediatric neurology consultations in other wards/PICU/NICU: 245
- Paediatric EEG from Worcester hospital: 134
- Paediatric and neonatal EEG's from TBH reported by the 2 consultants: 480
- 6 Outreach clinics to Paarl hospital (patients seen): 95
- 4 Outreach clinics Worcester hospital (patients seen): 105
- 2 Clinics at Alta du Toit special school (patients seen): 40

Ward G9 Paediatric Endocrinology

Staff: Prof E Zöllner, Dr M Grantham (25 hrs per week), Registrar, and shared intern for G9

Beds n=5	2018	2017	2016
Patients admitted	102 Diabetic	120 Diabetic	95
	150 Endocrinology	131 Endocrinology	167
<i>Admission Subtotal</i>	252	251	262
Admissions other wards, day cases	8	10	14
<i>Admissions total</i>	260	261	275
Ward reviews	14	6	98
Average Hospital Stay in Days	6	6	6
Average Bed Occupancy %	88% (not counting outliers)	81% (not counting outliers)	84% (not counting outliers)
% Growth	N/A	-5%	17% (not counting ward reviews)
Deaths	0	0	0

Endocrine tests performed on; 53 patients

Ward G10 Gastroenterology

Staff: Prof ED Nel, 2 Senior Registrars (Dr LT Radebe & Dr U Chowdhury), Registrar, and 1 Intern.

Beds n=9	2018	2017	2016
Admissions	262	254	185
Average Hospital Stay in Days	7	8	11
Average Bed Occupancy %	70%	82%	75%
% Growth	+3%	+37%	-19%
Deaths	7	4	5 (2,7%)

Theatre procedures

- Paediatric Endoscopy: 47

- Adult Colonoscopy: 281
- Other endoscopic procedures: 445

Ward G10 Infectious Diseases Unit

Staff: Prof MF Cotton, Prof H Rabie (HIV Clinic), Dr P Rose, 2 Registrars

Beds n=14	2018	2017	2016
Admissions	374	353	269
Average Hospital Stay in Days	9	9	14
Average Bed Occupancy %*	77%	82%	75%
% Growth	+6%	+31%	-15%
Deaths	14	4	2

* Clinicom data combined for gastroenterology, cardiology and infectious diseases

- 10 new referrals per week.
- Telephonic referrals: 100 per week (including outside calls)
- Stewardship rounds: 2 per week.
- Transfers out: 17
- Transfers in: 50

G10 Cardiology

Cross Platform Staff:

Tygerberg Hospital (TBH): Prof J Lawrenson, Dr B Fourie, 2 Registrars

Red Cross War Memorial Children's Hospital (RXH): 2 Consultants, 2 Senior Registrar

Beds n=10 (G3=5, G10=5)	2018	2017	2016
Admissions	159	146	171
Average Hospital Stay in Days	*	*	7
Average Bed Occupancy %	*	*	*
Inpatient Echocardiography	923	845	836
Inpatient Consultations	945	882	875
Growth numbers	63	7	
Growth %	7.1%	0.8%	/
Deaths	2	2	3

* Clinicom data combined for gastroenterology, cardiology and infectious diseases

Worcester Clinic: 164

Paarl Clinic: 132

Ward G3 Oncology & Haematology

Staff: Prof M Kruger, Drs A van Zyl, R Uys, 1 Senior Registrar (Dr Lillian Gesami-Steytler, later replaced by Dr L Schoonraad), 2 Registrars

Beds n=9	2018	2017	2016	2015
New patients Haematology	44	46	43	42

New patients Oncology	70	60	72	73
<i>New patients Total</i>	114	106	115	114
Admissions	783	734	759	678
% Growth	+6.7%	-3.2%	11.4%	11.9%
Average Hospital Stay in Days	5.25	5.25	6.05	4.9
Average Bed Occupancy %	123%	120.5%	148.25%	93.8%
Total deaths in G3	12	12	14	9
Expected palliative	8	8		
Sepsis/other	4	*4		
Referrals	Haematology 70	Haematology 73		
G3 Day Patients (Haem/Onco)= Ward attenders	1698	2094	2806	1905
Chemotherapy administrations	2051	2044	2590	1944
Bone marrow aspirations and biopsies	101	108	143	122
Intra-thecal chemotherapy procedures	309	396	263	286

*G3Ward data

Ward G3 Rheumatology & Immunology

Staff: Prof M Esser, Dr D Abraham (15 hrs per week), Registrar Shared with G3, Shared Medical Officer for G3

Beds n=4	2018	2017	2016
Admissions (Ward attenders)	130	110 (82)	90
Average Hospital Stay in days	5	2	3
Average bed occupancy %	36%	16%	
% Growth	18%	22%	36%
G3 Day Patients (Rheuma&Imm)	94	6	
Deaths	0	0	0

Ward G3 Nephrology

Staff: Dr CJ du Buisson, Dr JL Shires – part-time, Registrar shared with haematology & Immunology, Shared Intern for G3

Beds n=5	2018	2017	2016
-----------------	-------------	-------------	-------------

Admissions	138	120	134
Average Hospital Stay in days	5	5	5
Average bed occupancy %	41%***	31% ***	45%
% Growth	15%	-32% ***	-44%
Deaths	1	0	
Renal Biopsies*	22	23	21
Acute Dialysis**	16	11	12
Renal patients outside of G3***	276 28% decrease	384 9% increase	354 26% increase
Referrals****	431	428	345

* Done in C4B Theatre under general anaesthesia

** All done in PICU and NICU, 1 patient was dialysed in G3 for 5weeks

*** Double the amount of nephrology patients are admitted outside of G3. 42% are in Neonatal wards (postnatal or antenatal diagnosis), 33% in G7 and 25% in G10 (due to infectious infections or lack of space in G3). 40% of admissions to G7 and G10 is due to a lack of space in G3.

**** These are patients on which only advice needed in the acute phase, not continuous care and referred to outpatient service for further treatment. 91 of these patients were seen on a regular basis in G4 as part of our cross disciplinary partnership with urology.

**** These are patients on which only advice needed in the acute phase, not continuous care and referred to outpatient service for further treatment

OUTPATIENT COMPLEX

Subspecialist Clinics

	2018	2017	2016
Clinics	Total	Total	Total
Haematology	306	285	307
Immunology	169	229	191
Oncology	484	471	361
Pulmonology	1194	1130	1063
Gastroenterology	635	581	563
High-risk Babies	2018	2056	2005
Neurology & Developmental paediatrics	2375	2176	2185
Allergy	566	550	580
Premature Follow-up	210	262	234
Nephrology*	1547	1482	1469
Cardiology	1099	1108	1073
Diabetic	742	720	703
Endocrinology	685	666	689
Rheumatology	359	367	348
Infectious diseases			
TB	**752	855	890
HIV	473	467	
Genetics	468	529	393
Pharmacy prescriptions	153	254	170
Total	13694	13721	13224

*Centre for Referral for Congenital Anomalies of the Kidney and Urinary Tract.

**68 Patients seen in GGround due to limited number to be seen in C3A

Neuro-development:

- Developmental Medicine functions largely as an outpatient service:
 - 8 Clinics at Paarl School (patients seen): 80
 - Autism Diagnostic Observations Schedule (ADOS) evaluation: 14 children
 - Griffith Developmental Scales assessments: 20.

HIV service:

- Total new patients initiating ART: 77 children (46 infants <12 months)

GENERAL SPECIALIST SERVICES

Total Patient Admissions 2018 (Clinicom data)

GG Short Stay	G2	G7	G8	J3	Total
5306	2072	1308	1169	992	10 847

Bed Occupancy Rate 2018 (Clinicom data)

GG Short Stay	G2	G7	G8	J3	Total
79%	94%	78%	90%	108%	90%

Neonatology

Ward G2 Neonatal Unit – Babies born in TBH

Staff: 2 Consultants (on rotation), 1 Registrar, 3 Medical Officers, 1 Intern (if available)

Beds n=27	2018	2017	2016
Admissions	2072	2142	2087
Average Ward Stay in Days	4	5	5
Average Bed Occupancy	94%	105%	104%
% Growth	-3.2%	+2.6%	0.96%
Deaths	71 (3.4%)	70 (3.3%)	94 (4.5%)

Ward J3 Neonatal Unit – Babies born in TBH

Staff: 1 Consultant (on rotation), 1 Registrar, 1 Medical Officer, 1 Intern

Beds n=25	2018	2017	2016
Admissions	992	908	972
Average Ward Stay in Days	10	10	10
Average Bed Occupancy	108%	101%	109%
% Growth	+9.3%	-6.6%	-3.4%

Deaths	3 (0.3%)	2 (0.2%)	1(0.1%)
--------	----------	----------	---------

Ward G8 Low Care Neonates & Kangaroo-mother Care – Step-down Facility

Staff: 1 Consultant (on rotation), 1 Medical Officer, 2 Interns

Beds n=30	2018	2017	2016
Admissions	1169	1057	1013
Average Ward Stay in Days	8	9	10
Average bed occupancy %	90%	87%	88%
% Growth	+9.2%	+4.3%	10.4%
Deaths	4 (3.2%)	0 (0%)	3 (0.3%)

Postnatal wards (J5, J2, C2A)

Staff: 1 intern from neonatal pool

3640 clinical contacts/year

Short-stay G Ground: <48-hour Admissions

Staff: Prof S Schaaf, Drs E Malek, L Smit, A Redfern, 2 Registrars, (1 Emergency Medicine Registrar), 2 Medical Officers, 2 Interns

Beds n=24	2018	2017	2016
Admissions	5306	4567	4643
Average Hospital Stay in Days	1	1	1
Average Bed Occupancy %	79%	63%	62%
% Growth	+16%	-2%	-22%
Average Admissions per day	15	13	13
Deaths	11	7	16

Ward G7 General Paediatrics

Staff: Prof S Kling, Dr H Finlayson, 1 Registrar, 2 Medical Officers, 2 Interns

Beds n=25	2018	2017	2016
Admissions	1308	1136	1191
Admissions to HCU	441	134 (6mo)	
Average Hospital Stay in Days	6	6	6
Average Bed occupancy	78%	74%	77%
Increase in Admissions	+15%	-4.3%	-3.3%
Deaths	15	10	17

*Clinicom data

General Paediatrics: Emergency & Clinics

Clinics	2018	2017	2016
----------------	-------------	-------------	-------------

OPD 8am-4pm: Emergency & Routine	8 282 (GG total)	8 017 (GG total) 1203 OPD 6814 Emergency	7 661 (GG total) 1643 OPD 6018 Emergency
Daily average seen	33	32	31
Annual after hours: 4pm-8am & weekend – Emergency	4 639	4 620	4 322
Daily average seen after hours (4pm- 8am)	13	13	12
Emergencies after hours: 4pm-8am %	36%	36%	36%
Total	12 921	12 637	11 983
Increase	+2%	+5%	

2018 Morbidity & Mortality

PIIP data from PPIP database 2018

Total inborn births in TCH (TBH): = 8068
(Stillbirths = 541) (Total live births = 7527)

Inborn mortality rates at TCH:

- Perinatal Mortality Rate (PNMR) ($\geq 500g$) = 77.2/1000
- Perinatal Mortality Rate (PNMR) ($\geq 1000g$) = 44.1/1000
- Early Neonatal Death Rate (ENNDR) ($\geq 500g$) = 10.9/1000
- Early Neonatal Death Rate (ENNDR) ($\geq 1000g$) = 5.1/1000
- Late Neonatal Death Rate (LNNDR) ($\geq 500g$) = 4.1/ 1000
- Late Neonatal Death Rate (LNNDR) ($\geq 1000g$) = 1.9/ 1000

Inborn Survival Rate for babies born alive at TCH:

- Survival Rate ($\geq 500g$) = 98.5%
- Survival Rate ($\geq 1000g$) = 99.3%

Inborn mortality of babies born alive per birth weight category:

Birth Weight	% Mortality 2018	% Mortality 2017	% Mortality 2016
< 1000g	22.1	26.3 (58/220)	27.6
1000 to 1499g	3.6	6.5 (31/471)	5.6
1500 to 1999g	1.6	2.5 (18/722)	2.3
2000 to 2499g	0.4	1.1 (12/1124)	0.9
$\geq 2500g$	0.3	0.56 (28/4928)	0.2

Mortality % calculated for each weight category as: number of deaths per number of live births in that weight category for 2018.

Causes of death of babies born in TCH (TBH):

Total inborn neonatal deaths on PPIP = 113

Cause of Death	% of Total 2018*	% of Total 2017	% of Total 2016
Prematurity-related Complications	49.4	44.4	61.4
Infection-related	15.3	12.9	10.5
Peripartum Hypoxia	15.3	16.9	7.9
Congenital Anomalies	12.9	19.4	14.9
Other	7.1	6.4	5.3

*Reflects estimated figures as only ~80% of data complete, and is thus not fully validated yet.

% Deaths of babies referred to TCH per weight category:

Total neonatal deaths in babies referred to TCH = 45

Birth Weight	% Mortality 2018 (n= 45)	% Mortality 2017 (n=62)	% Mortality 2016 (n= 56)
<1000g	11.1% (5/45)	7.8 (4/51)	25
1000 to 1499g	22.2% (10/45)	17.6 (9/51)	35
1500 to 1999g	2.2% (1/45)	17.6 (9/51)	10
2000 to 2499	13.3% (6/45)	7.8 (4/51)	7.5
≥2500g	28.9% (13/45)	49 (25/51)	25
Wt not recorded	22.2% (10/45)		

% calculated as the number of referred (outborn) deaths in each weight category out of all the referred (outborn) neonatal deaths (all weight categories).

Outborn babies mortality (total numbers) according to referral area of origin:

Geographic Service Area	2018 (n= 45)	2017 (n=62)	2016 (n=56)
Metro East	17	30	26
Winelands (Paarl area)	15	11	14
Overberg (Worcester drainage area)	6	10	5
Helderberg	5		
Khayelitsha	2		
Unknown		0	17

CHPIP MORTALITY for all sub-specialist paediatric wards (2018)

Table 1: All deaths per ward and age as on Clinicom excluding children >29 days of age dying in the neonatal deaths

Ward	Total	0-7 days	8-28 days	29 days - 11months	12 -59 months	>5-years
PICU	66 (48.89%)	1	4	31	17	13
PICU -HC	4 (0.03%)			3		

G10	14 (10.37%)	0	0	6	5	3
G9	11 (8.15%)	0	0	4	3	4
G3	13 (9.63%)	0	0	1	5	7
G7	16 (11.85%)	0	2	5	8	1
GG	11 (8.15%)	0	0	3	5	3
Total	135*	1 (0.74%)	6 (4.44%)	53 (39.26%)	43 (31.85%)	32 (23.70%)

Median duration of stay at death 4 days IQR 1 – 14) [mean 11 days]

*Excludes children that died in neonatal service

Table 2: Audited deaths per age and firm as per Child PIP

Ward	0 - 7 days	8 - 28 days	28 days - 1 Year	1 - 5 years	5 - 13 years	13 – 18 Years	Unknown	Total
A9 PICU	0	4	28	17	15	2	0	66
Oncology	0	0	0	5	6	0	1	12
Gastroenterology	0	0	5	3	0	0	0	8
Neurology	1	0	0	2	2	0	0	5
ID	0	0	1	0	0	1	2	4
Neonatology*	0	0	3	0	0	0	0	3
Cardiology	0	0	0	2	0	0	0	2
Nephrology	0	0	1	0	0	0	0	1
G7	0	1	5	5	1	0	0	12
GGround	0	1	4	3	3	0	0	11
Total	1	6	47	37	27	3	3	124
Girls	1	1	20	17	14	2	3	58 (47,8%)
Boys	0	5	27	20	13	1	0	66 (53,2%)

*22 infants older than 28 days of age died in neonatal service (only 3 audited deaths)

Table 3: Length of stay as per Child PIP

Length of stay	Number	Percent
DOA	4	3,2
< 24 Hours	33	26,6
1-3 Days	27	21,8
4-7 Days	21	16,9
8-14 Days	19	15,3
> 14 Days	20	16,1
Unknown	0	0

Table 4:

Main Cause Of Death	Number	%
---------------------	--------	---

Septicaemia, possible serious bacterial infection	21	16,9
Pneumonia, ARI	13	10,5
Acute diarrhoea, hypovolaemic shock	10	8,1
Other Respiratory System (specify)	8	6,5
Other Nervous System (specify)	8	6,5
Heart failure, Pulmonary Oedema	7	5,6
Other diagnosis (specify)	6	4,8
Tumours	6	4,8
Status epilepticus	5	4
Other Digestive System (specify)	5	4
Other Circulatory System (specify)	4	3,2
TB: Meningitis	3	2,4
Cirrhosis, Portal Hypertension, Liver Failure, Hepatitis	3	2,4
Myocarditis	2	1,6
Other accidents (incl. Drowning; specify)	2	1,6
Acute renal failure	2	1,6
Cardiomyopathy	2	1,6
Hospital-acquired infection	2	1,6
Other possible serious infection (specify)	2	1,6
Other Endocr, Nutritional, Metabol. (specify)	1	0,8
Other Oncology/Haematology (specify)	1	0,8
Other Poisoning (specify)	1	0,8
TB: Miliary, other extra-pulmonary	1	0,8
Surgical (Appendix, hernia, intestines, peritoneum)	1	0,8
Hypoglycaemia	1	0,8
IDDM, DKA	1	0,8
Ill-defined/Unknown cause of mortality	1	0,8
Leukaemias	1	0,8
Meningitis: bacterial	1	0,8
Meningitis: viral (meningo-encephalitis)	1	0,8
Chronic renal disease	1	0,8
Congenital Heart Disease	1	0,8

Table 5:

Weight Category	Number	%
1. OWFA	3	2,4
2. Normal	71	57,3
3. UWFA	15	12,1
4. Marasmus	8	6,5
5. Kwashiorkor	10	8,1

6. M-K (Marasmic-Kwashiorkor)	11	8,9
Unknown	6	4,8

Table 6: Death by HIV status

HIV status	Number
Negative	77
Unknown	16
Exposed	13
Not tested	12
Infected	4
No result	2

Table 7: Referring facilities

District	Subdistrict	Number	%
Unknown	Unknown	58	46,8
Cape Winelands District Municipality (13=10,5%)	Breede River/Winelands Local Municipality	7	5,6
	Drakenstein Local Municipality	4	3,2
	Stellenbosch Local Municipality	2	1,6
City of Cape Town Metropolitan Municipality (47 =37.9%)	Cape Town Eastern Health sub-District	14	11,3
	Cape Town Northern Health sub-District	6	4,8
	Cape Town Southern Health sub-District	1	0,8
	Khayelitsha Health sub-District	12	9,7
	Tygerberg Health sub-District	14	11,3
Overberg District Municipality (3=2.4%)	Overstrand Local Municipality	2	1,6
	Theewaterskloof Local Municipality	1	0,8
West Coast District Municipality (3=2.4%)	Bergrivier Local Municipality	1	0,8
	Matzikama Local Municipality	1	0,8
	West Coast District Managed Area	1	0,8

INFRASTRUCTURE DEVELOPMENT

Tygerberg Children's Hospital Trust Contribution

MEDICAL EQUIPMENT PROCURED FOR THE PERIOD

Date	Payment made to:	For:	Amount
25/01/2018	East Coast Medical	Cabinets & storage carts	R 206 872,24
14/02/2018	Grobir Medical Suppliers (Pty) Ltd	3 X Oxygen saturation monitors for Bronchoscopy & G9	R 67 857,76
26/02/2018	East Coast Medical	1 Storage Transportation Cart for Paediatric Oncology	R 30 181,67
30/07/2018	East Coast Medical	Paediatric Oncology (6 mini carts + 1 storage transportation cart	R 72 396,95
05/09/2018	Tecmed Africa	Toshiba probe for transcranial doppler - Oncology	R 122 393,73
12/12/2019	Medsci (Pty) Ltd	Inbody S10 with accessories	R 173 164,00
Total			R 672 866,35

UPGRADE OF FACILITIES FOR THE PERIOD

Date	Payment made to:	For:	Amount
06/07/2018	De Klerk Painters & Maintenance	Painting of Ward A9	R 12 750,00
05/09/2018	AC Flooring Services CC	Flooring Ward A9	R 25 190,70
05/09/2018	De Klerk Painters & Maintenance	50% deposit - painting Ward A9	R 15 930,00
03/10/2018	De Klerk Painters & Maintenance	Ward A9 - painting & fixing of corridor	R 16 550,00
29/10/2018	De Klerk Painters & Maintenance	Maintenance to Ward A9	R 20 000,00
29/10/2018	Dustin Juries	Kitchen cupboards Ward A9	R 9 500,00
12/11/2018	De Klerk Painters and Maintenance	Ward A9 - painting of 43 doors	R 8 800,00
19/11/2018	Dustin Juries - JTD's	Ward A9 - kitchen cupboards (bottom)	R 4 800,00
21/11/2018	Jaco De Klerk	Billing for additional work done to corridor of Ward A9	R 9 300,00
06/12/2018	De Klerk Painters & Maintenance	50% balance payment for painting and maintenance A9	R 15 930,00
12/12/2018	De Klerk Painters & Maintenance	Ward A9 - preparation for painting corridor walls & door frames	R 54 650,00
Total			R 193 400,70

DONATIONS RECEIVED FOR THE PERIOD

DATE	SUPPLIER	PROJECT/WARD	AMOUNT
05/01/2018	Roskim's Christmas Lights	A9 ICU project	R 7 908,20
08/01/2018	Roskim's Christmas Lights	A9 ICU project	R 250,00
19/01/2018	Sanbonani Holdings	Kangaroo Chairs Epoxy coated X3	R14 550,00
19/01/2018	Sanbonani Holdings	Bedside Lockers Cream X3	
31/01/2018	Bosmansdam High – Donation	Paediatric Oncology	R 6 000,00
22/02/2018	Dis-chem Pharmacies		R449,00 R1179,60
23/03/2018	Sanbonani Holdings	Children's cotX3	
25/03/2018	Ms Logandree Gounden	Paediatric Oncology	R 10 000,00
19/04/2018	Mrs B. Lotz	Television Set Hisense Flat screen	R3000,00
	Mrs B. Lotz	Television Set Diamond 24 Inch	R3000,00
	Mrs B. Lotz	Television Set Sinotec 24 Inch	R3000,00
	Mrs. B. Lotz	Television Set Sinotec 32 Inch	R3000,00
	Mrs. B. Lotz	Television Set Diamond 32 Inch	R3000,00
24/04/2018	Sanbonani Holdings	Movable table X3	R8 472,84
30/07/2018	Oasis Group	A9 UCI project	R 10 000,00
07/09/2018	Oasis Group	Purchase a transcranial Doppler probe for Paediatric Oncology	R250 000,00
07/12/018	Accordian Street Primary School	Paediatric Oncology	R1000,00
31/12/2018	Roskim's Christmas Lights	A9 ICU project	R31 880,00
08/2018	Dis-chem Pharmacies		R7417.65
27/09/2018	Sanbonani Holdings	Kangaroo Chair Epoxy and Plastic Coated X1	R4 850.00
Total			R332 139,64

Part 2

Community Outreach Programmes/Community Service and Interaction & Partnerships

Expert Members

Prof M Kruger

- Member of the Central Clinical Committee of the South African Health Products Regulatory Authority (SAHPRA) since November 2014
- Member of the Provincial Clinical Governance Committee (PCGC)
- Member of the Senate Research Ethics Committee of Stellenbosch University
- Member of the Research Ethics Executive Committee of the Faculty of Medicine and Health Sciences, Stellenbosch University
- Member of the Postgraduate Research Committee of the Faculty of Medicine and Health Sciences, Stellenbosch University
- Chair of the Health Research Ethics Committee 1 of the Faculty of Medicine and Health Sciences, Stellenbosch University
- Trustee of the Tygerberg Children's Hospital Trust

Prof S Kling

- Immediate Past President, Council of College of Paediatricians
- Ethics accreditor, CPD Committee, Faculty of Medicine and Health Sciences.
- Vice-chair, Undergraduate Research Ethics Committee since 2015
- Member of the Research Ethics Executive Committee of the Faculty of Medicine and Health Sciences, Stellenbosch University
- Member, Clinical Ethics Committee Tygerberg Hospital (2002 – 2004 and 2009 to current).
- Allergy Society of South Africa (ALLSA)
 - Member of Executive Committee since 1998
 - Chairman, Research Subcommittee (2011 to date)

Prof AC Hesselning

- NRF SARChi Chair in Paediatric Tuberculosis.
- Associate editor: International Journal against Tuberculosis and Lung Diseases, since 2009
- Site PI, CDC TBTC Network, Site 33, Stellenbosch University, since 2009
- Chair, Tuberculosis Scientific Committee, IMPAACT network, since 2011
- Co-chair: Pediatric Interest Group, TBTC network, since 2010
- Consultant: TB Alliance, Pediatric TB Unitaid program, since 2013
- Co-chair: PhD Committee, Department of Paediatrics and Child Health, Stellenbosch University, since 2015
- Member, Research committee (subcommittee C), Faculty of Medicine and Health Sciences, Stellenbosch University, since 2016
- South African TB Think Tank, TB Prevention Task force core member, since 2017
- Consortium Chair: South African Gates TB Demonstration and Scale-up, since 2018

Prof MF Cotton

- Member of the Clinical Guideline Development Group (GDG) to support the update of the World Health Organization Consolidated Guidelines on the use of antiretroviral drugs for treating and preventing HIV infection
- WHO HIV/TB Task Force Advisor

Prof N Beyers

- POPART Zambia & RSA

Prof HS Schaaf

- Board of Directors and Chairperson of Adult and Child Lung Health section, The Union (International Union Against Tuberculosis and Lung Disease)
- Expert on ATS/CDC committee for new TB guidelines
- MDR-TB Review Board Western Cape
- Member of the Subcommittee C of the Research Committee, Faculty of Medicine and Health Sciences

Dr B Fourie

- Safety representative on Health and Safety Committee, Faculty of Medicine and Health Sciences

Prof P Goussard

- Health Research Ethics Committee, Faculty of Medicine and Health Sciences
- Chair of the Tygerberg Children's Hospital Trust

Prof A Bekker

- International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) P1106 vice-chair
- CDC: Tuberculosis Trials Consortium (TBTC) Tuberculosis and Pregnancy Working Group – membership
- Health Research Ethics Committee, Faculty of Medicine and Health Sciences
- Paediatric HIV advisory Board for ViiV
- Collaborating with GARDP/DNDi on a NeoAMR global neonatal sepsis study

Prof J Lawrenson

- Ethics and Guidelines committee – SA Heart Association

Dr S Holgate

- USANA executive committee member – treasurer

Dr G Kali

- Neonatal Encephalopathy with Suspected Hypoxic Ischemic Encephalopathy (NESHIE) study local PI

Prof R van Toorn

- PANDA executive committee member – treasurer

Dr CJ du Buisson

- South African Renal Society Executive Committee

Outreach

International

- Profs PB Hesselring & M Kruger – Childhood cancer Cameroon

Regional and District

- Worcester – Profs R van Toorn, R Solomons, J Lawrenson, B Fourie & Dr C du Buisson
- Paarl – Profs P Goussard, H Rabie, R van Toorn, R Solomons, Lawrenson and Dr B Fourie. HIV outreach: Dr Frigati/Rose
- George – Prof J Lawrenson, Dr B Fourie
- East London - Prof J Lawrenson, Dr B Fourie
- Delft - Drs L Smit, R Gioio (HIV outreach)
- Helderberg – Dr T Wessels; Perinatal – Dr H Hassan, Dr Frigati/Rose, (HIV outreach)
- Khayelitsha district hospital – Prof H Rabie, Dr P Rose
- Eersterivier – Drs H Finlayson (HIV outreach), JCF du Preez

- Ikwezi clinic HIV outreach
- Bishop Lavis clinic, HIV outreach
- Grabouw CHC HIV outreach
- Kraaifontein CHC HIV outreach
- Scottsdene – MDR TB outreach clinic – Prof Schaaf, Dr Rose
- Town 2 Khayelitsha – MDR TB outreach clinic – Prof Schaaf, Dr Rose
- City of Cape Town - DTTC
- DTTC - skills development in the community
- Karl Bremer Hospital, Haemophilia, Childhood Cancer - Dr A van Zyl; Perinatal – Dr H Hassan, Prof S Kling (General Paediatrics) and Dr H Finlayson (Antibiotic Stewardship), Neonatal – Neonatal team
- George – Dr B Fourie, Prof J Lawrenson
- East London – Prof J Lawrenson
- Brooklyn Chest Hospital – Prof HS Schaaf, Dr H Finlayson
- Paarl School for Children with Cerebral Palsy, Brackenfell---Dr Cilla Springer
- Western Cape Education Department outreach meeting for autism spectrum disorder, Chere Botha Centre, Bellville – Dr Cilla Springer
- Neurodevelopmental clinic - HOPE doctors and occupational therapist have been assisting once a week in a voluntary basis.

Tygerberg Children’s Hospital Trust

Trustees: Prof P Goussard (Chair), Dr D Erasmus, Profs M Kruger, J Smith

The TCH Trust had a number of successful events in 2018, including the annual golf day. In 2018 the trust started a reconstruction process, which will continue into 2019. The plan is a major overhaul of the current trust, including new trustees and also the employment of a company to run the daily administrative of the trust and to launch some major fund-raising events. A number of projects have been started and we will continue to be developed in the coming years. We also had radio campaigns during the early part of 2019 in efforts to create awareness of the trust under local communities. Snapscan accounts have been created for easier donation of funds. New systems of Champions of the trust have been created. In 2018 the trust also was selected as one of a few, being officially supported by the Arch Bishop Tutu Foundation. We would also like to thank everyone who supported the trust in 2018 and for their continuing support in 2019. We had many donations in 2018, not only financial support but also the donation of medical equipment.

We value all of these contributions as they not only improve the medical care of the patients but also improve the comfort of the mother and child during their hospital stay.

HOPE Cape Town

Drs I Reyneke, M Esser

HOPE Cape Town is an NGO (Rotary Signal Hill and the German Speaking Catholic Community Cape Town) with offices in the department and link community paediatric HIV and TB community care with the department. In ward G7 HOPE CT has re-established a playroom, well stocked with age appropriate toys – specifically selected by the HOPE Occupational Therapist. Volunteers are involved to entertain and engage with children three times per week. A crafts program has been established in G7 in 2018 with a facilitator who visits the ward twice a week – teaching caregivers various craft techniques – knitting, crocheting, needle felting and. Caregivers also receive a support “starter pack” to keep them occupied during the long hours they spend next to their children’s beds. HOPE CT employs two doctors both of whom are experienced HIV/ARV clinicians. These doctors assist the Tygerberg Infectious Diseases doctor to initiate and manage paediatric patients on ARVs at the Delft

CHC on a Friday. On average 26 children are seen per week at this clinic requiring comprehensive care. HOPE CT has also established an ART youth clinic Delft CHC – an adolescent friendly afternoon clinic – as well as adolescent support groups. For research support In 2018, HOPE CT co-funded Dr Lisa Frigati's study: *Serologic correlates of protection against vaccine-preventable disease in Perinatally HIV-infected (PHIV) Adolescents at Tygerberg Hospital.*

Hear the TYGER ROAR (Reach out and Read) PROJECT at Tygerberg Hospital

Dr JCF du Preez

The Baby Book Project: We are aiming to move 16 000 books into patients homes this year. Currently, all children admitted or seen at Tygerberg Hospital receive a nursery rhyme book in their native language. The book includes a referral "script" to the closest library and book sharing tips for parents.

Volunteers service the outpatient's waiting rooms regularly. They hand out picture books from a book trolley and explain the importance, fun and joy of reading to the parents. Waiting rooms also have permanent bookshelves and children can browse through the books while waiting to be seen by the doctors. Medical students take the book trolleys around the wards once a week to ensure that in-patients share in the book reading project..

Media Exposure

TV/Radio Interviews:

- DSTV (KYKNet) - Die dag in die lewe van 'n ouer met 'n kind met kanker, 10 April 2018: Prof M Kruger
- Bush Radio interview: meningitis - 25 June 2018: Dr P Rose

Articles:

Name of publication: Tygerburger

Name of article: Generous donation made to Tygerberg (Profs M Kruger, P Goussard, J Smith, Dr N Parker)

Date: 24 January 2018

Name of publication: VIVUS Medicine and Health Sciences

Name of article: SU researchers receive prestigious Fogarty awards (Prof A Dramowski, Dr A Slogrove)

Date: March 2018

Name of publication: Stellenbosch University Web News

Name of article: 'Om gemeenskap te help' die motivering after Rory se PhD (Dr R Dunbar)

Date: 20 March 2018

Name of publication: Stellenbosch University Web News

Name of article: SU researchers receive prestigious Fogarty awards (Prof A Dramowski, Dr A Slogrove)

Date: 17 April 2018

Name of publication: Stellenbosch University Web News

Name of article: Ukwanda bied kritieke navorsing platform (Prof N Beyers)

Date: 5 Junie 2018

Name of publication: Timeslive

Name of article: Desmond and Leah Tutu spend wedding anniversary with team caring for sick children (Profs M Kruger, N Beyers, RP Gie, Dr A van Zyl)

Date: 2 July 2018

Name of publication: News24

Name of article: Archbishop Tutu and wife spend wedding anniversary at Tygerberg Hospital

Date: 2 July 2018

Name of publication: Stellenbosch University Web News

Name of article: FMHS researchers reveal pivotal work on managing TB, HIV (Profs M Kruger, N Beyers, Drs P Bock, F Marx, S-A Meehan, R Dunbar)

Date: 10 April 2018

International visitors:

Prof Paul Rogers, Clinical Professor, University of British Columbia & BC Children's Hospital, 10 April 2018:

- Provided expert advice as co-supervisor towards the PhD of Dr Anel van Zyl titled: *'Long-term follow-up and care of childhood cancer survivors in South Africa'* and Ms Judy Schoeman titled: *'Nutritional interventions in children with cancer.'* (both are supervised by Prof Mariana Kruger)
- Led training rounds in Tygerberg Hospital for senior registrars in Paediatric Oncology
- Discussed future collaboration between Stellenbosch University and University of British Columbia

Archbishop Desmond Tutu and Mrs Leah Tutu celebrated their wedding anniversary at Tygerberg Children`s Hospital, 2 July 2018.

Prof Einspieler, University of Austria, General movement trust. 22 – 26 August 2018

Prof Chris van Geet, Vice Rector of Biomedical Sciences Group, Katolieke Universiteit, Leuven - Platelet function disorders, 28 August 2018

Prof Mirjam M van Weissenbruch, Pediatrician-Neonatologist, Department Pediatrics /IC Neonatology, Amsterdam UMC - The vulnerable new-born, how feasible is a healthy later life? – 19 September 2018

Prof Monika Bullinger gave a lecture on *"Quality of life in children with chronic conditions"*, on 3 December 2018.

Prof Mary Rutherford; Neuroradiologist, Kings College London. Neonatal Brain MRI discussions as co-supervisor of Dr Gugu Kali's PhD.

Part 3

Teaching & Training

Education-related Activities

Postgraduate Students

Successful PhD Candidates

- **Dr P Bock:** Title: Impact of a Universal Test and Treat strategy on clinical outcomes amongst HIV - infected adults in South Africa: Supervisor: Prof N Beyers, Dr S Fidler
- **Mr R Dunbar:** Title: How can virtual implementation modelling inform the scale-up of new molecular diagnostic tools for tuberculosis? Supervisor: Prof N Beyers, Mr I Langley
- **Dr F Marx:** Title: Mathematical modelling to project the impact of interventions targeted to previously treated individuals on the trajectory of the tuberculosis epidemic in high tuberculosis prevalence settings Supervisors: Prof N Beyers, Prof T Cohen
- **Dr S-A Meehan:** Title: The contribution of a community-based HIV counselling and testing (HCT) initiative in working towards increasing access to HIV counselling and testing in Cape Town, South Africa. Supervisors: Proff N Beyers, R Burger
- **Dr AJ Garcia-Prats:** Title: Addressing critical knowledge gaps to improve and shorten MDR-TB treatment regimens in children. Supervisors: Profs Anneke Hesselning and Simon Schaaf
- **Dr E Walters:** Title: Novel diagnostic strategies and markers of treatment response for paediatric pulmonary tuberculosis. Supervisors: Proff AC Hesselning, RP Gie

Enrolled PhD students

- **Mr G Mbah Afungchwi:** Title: Advocacy for childhood cancer in Cameroon: improving early diagnosis and referrals to life-saving care. Supervisor: Prof M Kruger, Prof PB Hesselning
- **Dr K du Preez:** Title: Complementary surveillance strategies and interventions to inform a tuberculosis care cascade for children. Supervisors: Proff AC Hesselning, HS Schaaf and Dr P Naidoo
- **Dr GTJ Kali:** Title: A comparative study of neuroprotective strategies in neonatal hypoxic ischaemic encephalopathy. Supervisors: Prof J Smith, Dr M Rutherford
- **Dr Y Kooblal:** Title: The relationship of body composition on nutritional and immunological status in childhood tuberculosis. Supervisors: Prof Ronald van Toorn, Dr Martijn van der Kuip and prof Marceline Tutu van Furth
- **Dr B Laughton:** Title: The effects of early versus delayed antiretroviral treatment on the short- and long-term neurodevelopmental outcome of children who are HIV positive. Supervisor: Prof MF Cotton, Prof M Kruger
- **Dr M Osman:** Title: TB-associated mortality in South Africa: longitudinal trends and the impact of health system interventions. Prof AC Hesselning and Dr P Naidoo
- **Prof L Pepeta:** Title: Novel medical and percutaneous modalities in the management of a patent ductus arteriosus in middle income and low income countries. Supervisors: Prof M Kruger, Dr HN Ntsinjana
- **Prof H Rabie:** Title: Pharmacokinetics and therapeutic outcomes of children with tuberculosis/HIV co-infection treated with lopinavir/ritonavir and a rifampicin-containing anti-tuberculosis regimen. Supervisors: Proff MF Cotton, HS Schaaf, RP Gie

- **Me J Schoeman:** Title: Nutritional status of children at cancer diagnosis and during treatment, with a focus on the association with their clinical outcome . Supervisors: Profs M Kruger, Elena J. Ladas and Paul Rogers.
- **Dr P Springer:** Neurodevelopmental Outcome of the HIV exposed but uninfected Infant and evaluation of a developmental screening tool. Supervisors: Prof Mariana Kruger, Prof Christopher Molteno
- **Dr J van Heerden:** Title: Neuroblastoma In Low And Middle Income Countries. Supervisors: Prof M Kruger
- **Dr L van Wyk:** Title: Non-invasive cardiac output monitoring in preterm infants . Supervisors: Prof Johan Smith, Dr John Lawrenson and Prof Willem-Pieter de Boeck
- **Dr A van Zyl:** Title: Long-term follow-up and care of childhood cancer survivors in South Africa. : Supervisors: Profs M Kruger and P Rogers

Successful MMed(Paed) Candidates

- Dr E du Plooy
- Dr B Wentzel
- Dr S Abumhara
- Dr I Abrahams
- Dr C Richardson
- Dr L Scheepers
- Dr L Schoonraad
- Dr K Opper
- Dr L van Heerden
- Dr L Mfingwana
- Dr F Adeniyi
- Dr SH Fry

Colleges of Medicine of South Africa (CMSA)

- **Certificate in Paediatric Pulmonology**
 - Drs Lindy-Lee Green with distinction (Connor Farrel Medal)
- **Certificate in Medical Oncology**
 - Dr Lillian Gesami-Steytler
- **Certificate in Neonatology**
 - Drs Natalie Pause, Mary Kariuki, Onwona Agyeman
- **FC Paed (SA) Part II**
 - Dr S Marais
 - Dr F Adeniyi
 - Dr L Mfingwana
 - Dr L Schoonraad
 - Dr L Scheepers
 - Dr M van Velden
 - Dr L van Heerden

- Dr K Opperl
- Dr CJ Richardson
- **FC Paed (SA) Primary**
 - Dr C van der Merwe (Leslie Rabinowitz Medal)

University of Stellenbosch Business School (USB)

Dr I Appel - Postgraduate Diploma in Business Management and Administration (PGD BMA)

Undergraduate Students

98% pass rate (2017 = 99%)

Education-related Activities

- The Education Committees of the Department comprised as follows:
 - Undergraduate: Dr L Smit (Chairperson), Dr A Redfern (secundus)
 - MBChB II: Drs P Rose, R Uys, E Malek, S Holgate, L Lloyd
 - Early rotation: Drs I Appel, L Frigati, prof H Rabie, H Hassan, Drs A Thomas, M Morkel, Sr L Yzelle
 - Middle rotation: Drs N Parker, B Fourie, C du Buisson, H Finlayson, G Kali, A Bekker
 - SI: Prof R Solomons, Drs JCF du Preez, L Smit, A van Zyl, S Holgate, C Springer, Prof E Zöllner, Drs M Morkel
 - Remedial: Dr M Morkel, Sr L Yzelle
 - Elective students: Drs H Finlayson, I Appel, Prof M Kruger
 - Postgraduate: Dr G Kali (chairperson), Proff R van Toorn, A Bekker, M Kruger, ED Nel, H Rabie, P Goussard, HS Schaaf
 - PhD: Proff M Kruger (Chairperson), MF Cotton, AC Hesseling, HS Schaaf, J Smith
- All consultants are involved with under- and postgraduate teaching on a daily basis. Additional education activities included:
- External examiners at universities in South Africa:
 - Undergraduate:
 - Dr JCF du Preez: Sefako Makgatho Health Sciences University
 - Drs Y Kooblal, N Paulse, L Smit: University of Kwazulu-Natal
- Senior registrars in training:
 - Neonatology: Drs AD Daniels, N Paulse, A van Eck, I Abrahams, M Kariuki (Supernumerary from Kenya), K Onwona-Agyeman (Supernumerary from Ghana)
 - Paediatric Oncology: Drs L Schoonraad, L Gesami-Steytler (Supernumerary from Namibia)
 - Paediatric Rheumatology: Dr DR Abraham
 - Paediatric Pulmonology: Drs Y Mulambia, L-L Green
 - Paediatric Neurology: Dr T Katangwe
 - Paediatric Gastroenterology: Drs LT Radebe, U Chowdhury, sponsored by a Nestle Nutrition Institute Fellowship endorsed by the European Society of Paediatric Gastroenterology
- Educational Outreach:
 - Prof M Kruger - Accreditation visit (accreditor with Prof Vic Davies), CMSA College Paediatrics, Botswana, 5-6 March 2018

- Prof M Kruger - Paediatrics and Child Health Research Day, UCT, 30-31 October 2018. Judge for best research with Prof Marion Jacobs.
- Colleges of Paediatricians (CMSA)
 - Prof Ronald Van Toorn (Convenor) and Etienne Nel (co-convenor)
 - Prof Mariana Kruger – examiner FCPII & Moderator, Cert Medical Oncology
 - Prof Sharon Kling Convenor, Cert Allergology (Fam Phys)(SA); examiner Dip Allerg(SA), Moderator FCPaed I & II
 - Dr Anel Van Zyl – convenor, Cert Medical Oncology
 - Dr. Ilse Appel – observer Cert Critical Care
 - Prof Regan Solomons - examiner FCPII
 - Prof Johan Smith – convenor Cert Neonatology
 - Prof Adrie Bekker- examiner Cert Neonatology
 - Dr Sandi Holgate – examiner Cert Neonatology
 - Dr Gugu Kali – Examiner Cert Neonatology
 - Dr Pricilla Springer – convenor Cert in Neurodevelopment
 - Prof Etienne Nel - convenor GIT certificate exams
 - Dr Andrew Redfern – examiner DCH exams
 - Dr Amy Slogrove – examiner DCH exams
 - Dr Thandi Wessels – moderator DCH exams
 - Monika Esser – convenor, Cert Rheumatology
 - Prof Pierre Goussard – convenor Cert Pulmonology Diseases
 - Dr Christelle du Buisson – convenor Cert Nephrology
 - Prof Rabie – convenor Infectious diseases
 - Dr Barend Fourie, convenor, Cert Cardiology
 - Prof Lawrenson – examiner , Cert Cardiology
- South African Research Ethics Training Initiative (SARETI) UKZN, funded by Fogarty International Fogarty International Center (FIC) of the National Institutes of Health (NIH), grant number 6R25TW001599-13: Prof M Kruger (Co-principal Director)

Part 4

Achievements and Highlights

Appointments

Prof Sharon Kling

Re-elected onto the Executive Committee of the Allergy Society of South Africa.

Prof Pierre Goussard

Elected to the South African Thoracic Society (SATS) Council.

Prof Adrie Bekker, Dr Heather Finlayson and Dr Angela Dramowski will serve on the newly formed National Neonatal Sepsis Task Force to advise the NDOH on surveillance, outbreak response, infection prevention and control, antimicrobial stewardship and case management of neonatal sepsis, focused particularly on antibiotic resistant infections and hospital-acquired sepsis in the public- and private-sectors.

Dr Amy Slogrove

Appointed as a member of the South African Young Academy of Science.

Grants/Awards

Prof ED Nel

Awarded an Erasmus+ Capacity Building Grant: to Improve Early Nutrition and Health in South Africa (ImpENSA)

Dr Lizelle van Wyk

The Southampton Faculty nominated her for the Deans List – which was awarded in October 2018 for achieving the highest academic performance in the year and being nominated by a tutor performance or achievement.

She is doing her MSc Neonatology with an MSc by dissertation, an on-line degree from the University of Southampton, United Kingdom. The final dissertation was a systematic review of the accuracy and precision of non-invasive cardiac output monitoring methods in neonates with a PDA.

Dr Angela Dramowski

Awarded a Discovery Foundation Distinguished Visitor Award to work with Dora Nginza Hospital in the Eastern Cape over the next 2 years to improve Infection Prevention and Antibiotic Stewardship practices.

Dr Barbara Laughton:

Awarded NIH grant as part of the study: “The Association of Perinatal HIV infection and hearing loss in children of Cape Town, South Africa” with UCLA for 5 years.

Prof Ekkehard Zöllner:

Awarded NRF grant as part of the “Competitive Programme for Rated Researchers” for 3 years for project “Genetic predictors of HPA suppression in children treated with corticosteroids”.

NRF ratings:

- Prof PR Donald A2
- Prof MF Cotton A2
- Prof HS Schaaf A2
- Prof AC Hesseling B1
- Prof J Smith C2
- Prof R Van Toorn C2
- Prof P Goussard C2
- Prof PB Hesseling C2
- Dr A Dramowski C3
- Prof EWA Zöllner C3
- Dr A Bekker C3
- Dr H Rabie C3
- Dr S Innes Y2
- Prof R Solomons Y2

Sabbaticals

Prof Sharon Kling - 1-28 February 2018

Prof Kling is enrolled at Stellenbosch University for her PhD in Applied Ethics, titled: ‘*Models of clinical ethics consultation services in South Africa: A critical appraisal.*’ During her sabbatical leave Prof Kling wrote up 4 chapters of her thesis.

Prof Adrie Bekker - 28 May to 27 July 2018

Prof Bekker was the recipient of The Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Growing the Leaders of Tomorrow Fellowship Programme of the International AIDS Society (IAS). Funding of a total amount of US \$70,000.00 was awarded to her for the research project entitled "Pharmacokinetic and safety characteristics of nevirapine and lopinavir/ritonavir in HIV-exposed and infected low birth weight infants".

Prof Bekker attended pharmacology training in San Diego, the IMPAACT annual meeting in Washington and the International AIDS conference in Amsterdam.

Dr Elmarie Malek - 15 October to 14 December 2018

During her sabbatical, Dr Malek developed projects for the Provincial Department of Health:

- Project 1: Document the process and outputs of the PSG3 Parent Infant Child Health and Wellness Working Group May 2013- October 2018
- Project 2: Produce a 1st draft of a Framework for a Provincial DOH Well Child Policy

Organizing and Presentations at Conferences

The **seventh annual Here by Lungs Congress**, organised by Profs P Goussard and J Smith, was held on 15-16 March 2018 at Spier, Stellenbosch.

Goussard, P

Bronchoscopy in PTB, 14 March 2018

Interventional Pulmonology, 15 March 2018

The department successfully organised the **bi-annual ALLPAEDS conference** (the joint South African Paediatric Association (SAPA) & Allergy Society of South Africa (ALLSA) conference), held at Century City Conference Centre from 29 August – 2 September 2018.

Presentations were also given by members of the department as follows:

Invited Speakers:

- Dr Ilse Appel - Adverse events
- Dr Angela Dramowski - IPC management of drug resistant bacterial organisms in the hospital
- Prof Anneke Hesseling - TB exposure in the preschool setting
- Dr Barend Fourie
 - Paediatric cardiology for the general paediatrician 2018: the role of ECG in the care of the patient
 - Paediatric cardiology for the paediatrician 2018: the role of CXR interpretation in the care of the patient
- Prof Pierre Goussard - Imaging of Pneumonia
- Prof Etienne Nel
 - Functional gastrointestinal disease: how can the general paediatrician use the Rome IV criteria?
 - Recognising IBD in children
- Prof Sharon Kling - Futility at end-of-life care – who decides? (Ethics)
- Prof Mariana Kruger - Emergencies in Paediatric Oncology
- Prof John Lawrenson - Paediatric cardiology for the paediatrician 2018: preventative cardiology and child health
- Dr Julie Morrison - Approach to persistent bacterial bronchitis
- Dr Andrew Redfern - Investigating the paediatric patient with first time seizure
- Dr Penelope Rose - Approach to chronic abdominal pain in children (GIT workshop at SAPA)
- Dr Lizelle van Wyk - Minimally invasive SRT use in neonates
- Dr Anel van Zyl - Late effects of childhood cancer
- Prof Ekkehard Zöllner - Hyperglycaemic emergencies-pitfalls & challenges

Selected abstracts for presentation:

- Dr Ilhaam Abrahams - The correlation between the placental pathology and the neurological outcome of neonates \geq 36 weeks with neonatal encephalopathy treated with therapeutic hypothermia.

- Dr Elri Du Plooy - PMTCT and clinical profile of hospitalized HIV-infected children in an era of high pMTCT uptake and efficacy (**Dr Du Plooy won the prize for the best registrar presentation**).
- Dr Ruth Arayo - Clinical presentation and treatment outcomes of infants with tuberculosis in Cape Town, South Africa
- Dr Sebastian Gericke - Changes in cerebral blood flow and cardiac output in premature infants in the first 72 hours of life
- Dr Barbara Laughton - Neurodevelopmental outcome at 11 months in HIV-infected infants initiating very early Antiretroviral therapy
- Dr Barbara Laughton - HIV infected children show decreased activation in the auditory cortex
- Dr Lydia Mapala - Burden, pathogen spectrum and outcome of paediatric community-acquired infections at Tygerberg Hospital
- Dr Lyn Scheepers - Assessing the rate and factors associated with unscheduled return visits to a medical paediatric emergency department in a resource limited setting
- Dr Leilah Schoonraad - Descriptive review of the health supervision received by children with Down syndrome at Worcester Provincial Hospital from 2010 to 2015

Sessions Chairs:

- Dr Ilse Appel - SAPA SESSION – CRITICAL CARE
- Prof Mark Cotton - SAPA SESSION - INFECTIOUS DISEASES
- Dr Christel du Buisson - SAPA SESSION – RENAL
- Dr Christel du Buisson & Prof Etienne Nel - SAPA SESSION - ABSTRACT PRESENTATIONS
- Prof Pierre Goussard - THE CAS MOTALA JOINT PLENARY - SAPA/ALLSA
- Dr Sandi Holgate - USANA SESSION
- Prof Sharon Kling - JOINT PLENARY SESSION 6 AND CLOSING - SAPA/ALLSA
- Prof Mariana Kruger - JOINT PLENARY SESSION 4 - SAPA/ALLSA & SAPA SESSION ABSTRACT PRESENTATIONS
- Prof John Lawrenson - SAPA SESSION - CARDIOLOGY
- Prof Etienne Nel - SAPA SESSION GASTROENTEROLOGY
- Dr Andrew Redfern - GENERAL PAEDIATRICS
- Prof Regan Solomons - PLENARY SESSION 2 – SAPA
- Prof Ronald van Toorn – PANDA
- Dr Anel van Zyl - SAPA SESSION - HAEMATOLOGY AND ONCOLOGY
- Prof Ekkehard Zöllner - SAPA SESSION – ENDOCRINOLOGY & PLENARY SESSION 5 - SAPA

The **fourth Annual Paediatric Registrar Research Day** was held on Wednesday 7 November 2018 here in the Faculty where 6 registrars presented their research. The prize for best research was awarded to Drs Sebastian Gericke & Folasade Adeniyi.

The **eight annual Paediatric Academic Day of Excellence** (WOW! Women of Worth) was held on Wednesday 7 November 2018 in the Faculty. It included invited speakers: Dr Aneesa Vanker (UCT) and Prof Mphele Mulaudzi (Wits).

OTHER CONFERENCES

Afungchwi, Mbah, Glenn

- *Development of a competency-based orientation programme for pediatric oncology nursing in rural Cameroon & Strategies and priorities for dissemination of the SIOP baseline nursing standards: leadership and advocacy workshop outcomes.* SIOP 2018 Congress, Kyoto, Japan, 13-19 November 2018

Bekker, A

- *Stewardship & Managing neonatal infection outbreaks*. Kenyan Paed Assoc Annual Conference, Mombassa, Kenya, April 2018

Cotton, MF

- *Pharmacokinetics, Safety, And Efficacy Of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Single-tablet Regimen In Children (6 To <12 Years) Living With HIV-1* - International AIDS Conference, Amsterdam, 23-27 July 2018
- Organizing Committee - 10th Paeds HIV Workshop, Amsterdam, 20 - 21 July 2018
- Organizing Committee , SA HIV Clin SOC Conference, JHB, 24 -27 October 2018

Donald, PR

- *Paediatric tuberculosis and the pharmacokinetics/pharmacodynamics sciences: what do we know and what don't we know?; What is the right dose of isoniazid?* 49th Union World Conference on Lung Health, The Hague, Netherlands, 24-27 October 2018:

Goussard, P

- *Imaging in complicated pulmonary TB & Neonatal IND*. Pan African Thorasic Society/South African Thorasic Society Congress, Durban, 12 – 15 April 2018
- *Roles and pitfalls of computed tomography and magnetic resonance imaging in intrathoracic TB in HIV+/-children*. The Union Congress .The Hague Holland October 2018
- *Managing foreign bodies of the airway*. 54th South African ENT Congress and 4th World Congress on Cochlear Implants in Emerging Countries, Cape Town, 28 October – 2 November 2018

Grobbelaar, M

- *Lumbar cerebrospinal fluid evolution in childhood tuberculous meningitis*. 14th International Conference on Clinical Pediatrics, 14-16 June, Rome, Italy 2018. **(Dr Grobbelaar received a certificate of recognition for her phenomenal and worthy oral presentation).**

Kali, GTJ

- Invited speaker: *HIE – can we do better?* Kenyan Paediatrics Association Annual Conference, Mombassa, Kenya, April 2018

Kling, S

- *Ethics of Paediatric Palliative Care*. PG Dip in general and community at Red Cross, UCT, 01 March 2018
- *Clinician integrity, patient autonomy and the patient's best interests; and Ethical dilemmas in clinical practice*. GP refresher Course, 25 May 2018

Kruger, M

- *Population Specific Issues in HIV Cure Research: Implication for Children ETHICS*. Regulation of clinical research related to HIV care Conference, Bethesda, MD, 23-26 January 2018.
- African Health Research Ethics Symposium III (AHRES): SARETI, Umhlanga Rocks, South Africa, 29-31 January 2018
- *Opening Address*. Here be Lungs 7 Conference, Spier Estate, Stellenbosch, 15-16 March 2018
- *Ethical Issues on HIV Cure Research in Pediatric Populations*. NIAID DAIDS workshop: "Framework for Children, HIV Cure Research & Ethics. Initiating Pediatric Studies of HIV Cure Interventions: Scientific Knowledge Gaps, Regulatory and Ethical Considerations", 21 – 25 May 2018, Rockville, MD.
- *Ethical issues in paediatric clinical trials in both developed and developing countries*. Improving the lives of patients with CF in the 21st century. Catholic University of Leuven Campus Gasthuisberg, UZ Leuven, 21-22 September 2018.
- *Report of first national collaborative treatment protocol of Retinoblastoma in South Africa – An interim analysis*. 50th SIOOP Congress of the International Society of Paediatric Oncology

(SIOP): November 16-19, 2018, Kyoto, Japan.

Nel, ED

- SAGES Conference, Session Chair, Speaker: *Paediatric Reflux Disease (GP Update)*, Johannesburg, 8-11 August 2018

Schaaf, S

- *New/Repurposed Drugs/MDR TB Drug and Treatment in Children*. 22nd Annual Conference of the Union-North America, Chicago, IL, USA. 28 Feb – 3 March 2018.
- 49th Union World Conference on Lung Health, The Hague, Netherlands, 22-26 October 2018:
 - *Speaker: Introductions and overview of course*
 - *Preventative treatment consideration of multidrug-resistant tuberculosis*
 - *Treatment of multidrug-resistant tuberculosis: paediatrics*
 - *EP04-132-26 Culture-confirmed tuberculosis in infants less than 3 months of age: clinical presentation and management*
 - *Injectable-free regimens, and the role of injectable agents, in the treatment of children with DR-TB*
 - *Chair: PGC02 TB prevention in children in high TB burden settings: implementing the child contact management (CCM) care cascade (Postgraduate Course)*

Slogrove, A

- *Debate: All infants should receive oral antiretroviral prophylaxis throughout breastfeeding* - 10th Paeds HIV Workshop, Amsterdam, 21 July 2018

Solomons, RS

- Plenary, *Challenges in early diagnosis of tuberculous meningitis*, International child neurology congress, Mumbai, 15-18 November 2018

Springer, P

- Launch meeting of the European Union-AIMS-2 Trials, which has included the Safe Passage Cohort in a prospective study on "*Early bioMarkers of autism spectrum disorder and other neurodevelopmental disorders*", EU-AIMS, Munich, Germany, 13-15 June 2018

Conferences Attended

Bekker, A

- Conference on Retroviruses and Opportunistic Infections, Washington, 13-16 February 2018
- Conference on Retroviruses and Opportunistic Infections (CROI), Boston, Massachusetts, 4-7 March 2018

Cotton, MF

- Infectious Diseases Week (IDSA), San Francisco, US, 3-7 October 2018
- InterAmerica Congress of Paediatric Infectious Diseases, Mexico, 28-30 November 2018

Du Preez, JCF

- Ipokrates-Managing a neuroprotective NICU, Torino, Italy, 21- 25 October 2018
- Panorama Annual Neonatal Seminar Panorama Hospital, 10 November 2018

Finlayson, H

- Antibiotic Resistance MAC, Pretoria, 09 May 2018
- ICAN Conference, Century City, CPT, 09-11 July 2018

Fourie, B

- Cardiology Congress, Sun City, JHB, 11-12 October 2018
- CSI Africa, Egypt, 29-30 November 2018

Innes, S,

- Conference on Retroviruses and Opportunistic Infections (CROI), Boston, USA, 4-7 March 2018

- U.S.-South Africa Program for Collaborative Biomedical Research (NIH - SA-MRC) Grantee meeting, Durban, SA, 11 June 2018
- International AIDS Conference, Amsterdam, 23-27 July 2018

Kali, G

- Neonatal Neurology Conference, London, UK, May 2018
- SAPA Allpaeds Congress, Century City Convention Centre, CPT, 30-31 August 2018

Kruger, M

- AMC Sub-Saharan Africa (SSA) Meeting, Dar Es Salaam, Tanzania, 10-13 July 2018

Lloyd, L

- Here Be Lungs, Spier Estate, CPT, 15 -16 March 2018
- INAC Congress, Belgium, 21-26 June 2018

Malek, E

- Priorities in Perinatal Care Conference, KZN, 14 March-16 March 2018
- Violence in Childhood-High level learning engagement Conference, George, 10 May 2018
- 16th WAIMH World Congress, Rome, 25 May - 01 June 2018
- Safe Passage Symposium, CPT, 06 July 2018
- Breastfeeding Symposium, 03-10 August 2018
- FARR workshop, CTICC, 15 August 2018
- ECD Strategy Workshop, Lentegeur Hosp., CPT, 21 August 2018
- South African Academy of Family Physicians 21st National Conference, CPT, 24 August 2018
- SAPA Allpaeds Congress, Century City Convention Centre, CPT, 30-31 August 2018

Morrison, J

- SATS/PATS Conference, Durban, 12-13 April 2018
- SAPA Allpaeds Congress, Century City Convention Centre, CPT, 30-31 August 2018

Nel, E

- Fellow Weekend (Gastroenterology Foundation of South Africa). Spier, Stellenbosch, 2-4 February 2018

Parker, N

- CCSSA Congress Presenter Durban, UKZN, Durban, 18 July 2018

Redfern, A

- BadEM Conference, Greyton, CPT, 22 March 2018
- SAPA Allpaeds Congress, Century City Convention Centre, CPT, 29-31 August 2018
- APLS, Red Cross, CPT, 15-16 November 2018

Rose, P

- ESPGHAN Conference, 08-11 May 2018
- SAPA Allpaeds Congress, Century City Convention Centre, CPT, 29 August 2018
- Annual International Child TB training Course, Goudini, 29 August-02 Sept 2018
- 49th Union World Conference on Lung Health, The Hague, Netherlands, 31 October 2018

Schaaf, HS

- SATS/PATS, Conference, Durban, 12-13 April 2018

Smit, L

- New RTHB National Orientation session, Ruslamere Hotel and Conference Centre workshop, Evertsdaal, CPT, 26Jan 2018
- SAAHE Congress, Durban, 27-29 June 2018

Solomons, R

- SAPA Allpaeds Congress, Century City Convention Centre, CPT, 30-31 August 2018
- Convenor- Paediatric Epilepsy Training (PET) Course, Red Cross, CPT, Convention Centre, CPT, 19 October 2018

Springer, P

SAPA Allpaeds Congress, Century City Convention Centre, CPT, 30-31 August 2018

Van Zyl, A

- SAPA Allpaeds Congress, Century City Convention Centre, CPT, 30-31 August 2018

Van Toorn, R

- SAPA Allpaeds Congress, Century City Convention Centre, CPT, 30-31 August 2018
- Paediatric Epilepsy Training (PET) Course, Red Cross, CPT, 19 October 2018

Van Wyk, L

- Attending Conference, Germany, 29 May-01 June 2018
- SAPA Allpaeds Congress, Century City Convention Centre, CPT, 31 August 2018

Zollner, E

- SAPA Allpaeds Congress, Century City Convention Centre, CPT, 31 August 2018
- 18th International Congress of Endocrinology in Cape Town, 1-4 December 2019

Courses Organized and Presented**Appel, I**

- APLS - instructor, Skills lab, Red Cross Children's Hospital, March and November 2018

Cotton, M

- Paediatric HIV Consultation, Bethesda, USA, 21-23 May 2018
- 10th Paeds HIV Workshop, Amsterdam, 20 July 2018

Du Buisson, CJ

- *Instructor, Saving Young Lives skills course*, UCT, Cape Town, February 2018

Lawrenson, J

- APLS Instructors Course, 24 -25 May 2018

Schaaf, HS

- Annual International Child TB training Course, Goudini, 10-13 Sept 2018

Solomons, R

- Paediatric Epilepsy Training (PET) Course, Red Cross, CPT, Convention Centre, CPT 19 October 2018

Courses Attended**Afaa, T**

- Pre-Doctoral Programme in Health Sciences SU, ADA Health Sciences SU, 12 - 23 February 2018

Afungchwi, Mbah, G

- ADA Summer School, EDP Programme, US, 08-13 January 2018

Du Preez, JCF

- PreOctoberoral programme in Health Sciences, Stellenbosch University, 12-23 February 2018

Finlayson, H

- Annual International Child TB training Course, Goudini, 13 September 2018

Gesami-Steytler, L

- Hemofilie lesson, Red Cross, UCT, 12 March 2018

Hassan H

- PreOctoberoral programme in Health Sciences, Stellenbosch University, 12-23 February 2018.

Holgate S

- NIV Worksop, Pinelands, CPT, NIV Worksop, Pinelands, CPT, 18 July 2018

Innes, S

- 10th HIV Pediatrics Workshop, Amsterdam, 20 July 2018
- 2nd Adolescent HIV workshop. Cape Town, SA, 10-11 October 2018
- 20th Comorbidities and Adverse Drug Reactions in HIV workshop, New York, USA, 13-14 October 2018
- 2nd Microbiome in HIV workshop, Bethesda, USA, 16-17 October 2018

Kali, GTJ

- Safe Passage Symposium, Faculty of Medicine & Health Sciences Faculty, Stellenbosch University, Tygerberg, 6 July 2018

Kooblal, Y

- PREDAC, Goudini, CPT, US, 17-19 July 2018

Lloyd, L

- Medtronic Capnography Master Class, Germany, 8, 9 October 2018

Malek, E

- Slide+Guide Content Workshop, CPT, 09 May 2018
- Antenatal Class Curriculum Expert Workshop, Claremont, CPT, 11 April 2018
- Provincial Inter-Departmental Committee for ECD, CPT, 24 May 2018
- Safe Passage Symposium, CPT, 06 July 2018
- RTHB Training, George, 12-13 July 2018
- Metro RTHB Training, 27 July 2018
- Breastfeeding Symposium, 03-10 August 2018
- Multidisciplinary district level allergy training program, RCWMCH, CPT, 06 August 2018
- NRTHB Training, Bellville Health Park, CPT, 08 August 2018
- RTHB Training, UWC, CPT, 10 August 2018
- RTHB Training, Paarl, 17 August 2018
- Child PIP Workshop, Paarl, 20 August 2018
- ECD Strategy Workshop, Lentegeur Hospital, CPT, 21 August 2018

Schoeman, J

- ADA Summer School, EDP Programme, US, 08-13 January 2018

Schoonraad, L

- Paediatric Brain Tumour Workshop, Groote Schuur, CPT, 07 December 2018

Smit, L

- MBChB Curriculum workshop, Evertsdal, CPT, 16 Feb 2018
- MBChB 2020 Curriculum Workshop, Feathers Lodge, Durbanville, CPT, 03 Dec 2018

Springer, P

- Autism Diagnostic Observation Schedule, Child and Adolescent Unit, Child Psychiatry Red Cross Children's Hospital, 13-15 June 2018
- GCP Refresher, Stellenbosch University, July 2018
- Safe Passage Symposium, Faculty of Medicine & Health Sciences Faculty, Stellenbosch University, Tygerberg, 6 July 2018

Uys, R

- Haemophilia with Inhibitors lecture by international expert, Prof Giangrande, Red Cross, UCT, 12 March 2018
- PREDAC, Goudini, CPT, 17-19 July 2018

Van Zyl, A

- Haemophilia with Inhibitors lecture by international expert, Prof Giangrande, Red Cross, UCT, 12 March 2018
- Paediatric Brain Tumour Workshop, Groote Schuur, CPT, 03 December 2018

Publications

Journal Articles (subsidised)

1. ALLWOOD BW, GILLESPIE R, BATEMAN M, OLCKERS H, TABORDA-BARATA L, CALLIGARO G, VAN ZYL-SMIT RN, COOPER CB, BEYERS N, BATEMAN ED. Five-year follow-up of participants diagnosed with chronic airflow obstruction in a South African Burden of Obstructive Lung Disease (BOLD) survey. *SAMJ South African Medical Journal* 2018; **108**(2):138-143.
2. ALLWOOD BW, MAARMAN GJ, KYRIAKAKIS CG, DOUBELL AF. Post-pulmonary tuberculosis complications in South Africa and a potential link with pulmonary hypertension: Premise for clinical and scientific investigations. *SAMJ South African Medical Journal* 2018; **108**(7):529.
3. APPEL I. Airway management in the critically ill patient. *Medical Chronicle* October 2018
4. ARAUJO DA SILVA AR, MARQUES AF, BISCAIA DI BIASE C, ZINGG W, DRAMOWSKI A, SHARLAND M. Interventions to prevent urinary catheter-associated infections in children and neonates: a systematic review. *Journal of Pediatric Urology* 2018; **14**(6):556.e1-e6.
5. BARNARD BW, DU PLESSIS A, GOUSSARD P, PITCHER RD. Infantile intrathoracic large airway obstruction in a setting with a high prevalence of tuberculosis/HIV. *Paediatrics and International Child Health* 2018; **38**(2):106-112.
6. BEYERS N, BURGER R, DRAPER HR, MEEHAN S, NAIDOO P, SLOOT R. Factors associated with linkage to HIV care and TB treatment at community-based HIV testing services in Cape Town, South Africa. *PLoS One* 2018; **13**(4):1-13.
7. BOCK PA, FATTI G, FORD N, JENNINGS K, KRUGER J, GUNST C, LOUIS F, GROBBELAAR CJ, SHANAUBE K, FLOYD S, GRIMWOOD A, HAYES R, AYLES H, FIDLER S, BEYERS N. Attrition when providing antiretroviral treatment at CD4 counts >500cells/ μ L at three government clinics included in the HPTN 071 (PopART) trial in South Africa. *PLoS One* 2018; **13**(4):e0195127.
8. BOCK PA, JENNINGS K, VERMAAK R, COX HS, MEINTJES G, FATTI G, KRUGER J, DE AZEVEDO V, MASCHILLA LS, LOUIS F, GUNST C, GROBBELAAR CJ, DUNBAR R, BEYERS N, ET AL . Incidence of Tuberculosis among HIV-positive individuals initiating antiretroviral treatment at higher CD4 counts in the HPTN071 (PopART) Trial in South Africa. *Journal of Acquired Immune Deficiency Syndromes* 2018; **77**(1):93-101.
9. BOIVIN M, BARLOW-MOSHA L, CHERNOFF M, LAUGHTON B, ZIMMER B, JOYCE C, BWAKURA-DANGAREMBIZI M, RATSWANA M, ABRAHAMS N, FAIRLIE L, GOUS H, KAMTHUNZI P, MCCARTHY K, DU PLESSIS J, COTTON MF, ET AL . Neuropsychological performance in African children with HIV enrolled in a multisite antiretroviral clinical trial. *AIDS* 2018; **32**:189-204.
10. BOND V, NGWENYA F, THOMAS A, SIMUYABA M, HODDINOTT G, FIDLER S, HAYES R, AYLES H, SEELEY J. Spinning plates: livelihood mobility, household responsibility and anti-retroviral treatment in an urban Zambian community during the HPTN 071 (PopART) study. *Journal of the International AIDS Society* 2018; **21**(s4):e25117.
11. BRADLEY J, FLOYD S, PIWOWAR-MANNING E, LAEYENDECKER O, YOUNG A, MANDLA NF, BWALYA J, BOCK PA, FIDLER S, AYLES H, HAYES RJ. Sexually Transmitted Bedfellows: Exquisite Association Between HIV and Herpes Simplex Virus Type 2 in 21 Communities in Southern Africa in the HIV Prevention Trials Network 071 (PopART) Study. *Journal of Infectious Diseases* 2018; **218**(3):443-452.
12. BYAMUNGU NL, DU PREEZ K, WALTERS E, NACHEGA JB, SCHAAF HS. Timing of HIV diagnosis in children with tuberculosis managed at a referral hospital in Cape Town, South Africa. *International Journal of Tuberculosis and Lung Disease* 2018; **22**(5):488-495.
13. CHABALA C, TURKOVA A, THOMASON MJ, WOBUDEYA E, HISSAR S, MAVÉ V, VAN DER ZALM MM, PALMER M, KAPASA M, BHAVANI PK, BALAJI S, RAICHUR PA, DEMERS A, HODDINOTT G, HESSELING AC, COTTON MF, ET AL . Shorter treatment for minimal tuberculosis (TB) in children (SHITE): a study protocol for a randomised controlled trial. *Trials* 2018; **19**:237.

14. CHERNOFF M, LAUGHTON B, RATSWANA M, FAMILIAR I, FAIRLIE L, VHEMBO T, KAMTHUNZI P, KABUGHO E, JOYCE C, ZIMMER B, ARIANSEN JL, JEAN-PHILIPPE P, BOIVIN M. Validity of Neuropsychological Testing in Young African Children Affected by HIV. *Journal of Pediatric Infectious Diseases* 2018; **13**(3):185-201.
15. COTTON MF, LIBERTY A, TORRES-ESCOBAR I, GONZALEZ-TOME MI, LISSENS J, ZARU L, KLAUCK I, CAMBILARGIU D, PIKORA C, CORRELL TA. Safety and efficacy of atazanavir powder and ritonavir in HIV-1-Infected infants and children from 3 months to <11 years of age. *Pediatric Infectious Disease Journal* 2018; **37**(6):e149-e156.
16. CRANMER LM, DRAPER HR, MANDALAKAS A, KIM S, MCSHERRY GD, KRZESINSKI EI, DU PLESSIS J, MITCHELL C, NACHMAN S, VAN DER LINDE MV, COTTON MF, HESSELING AC. High incidence of tuberculosis infection in HIV-exposed children exiting an isoniazid preventive therapy trial. *Pediatric Infectious Disease Journal* 2018; **37**(10):e254-e256.
17. CRICHTON H, O'CONNELL N, RABIE H, WHITELAW AC, DRAMOWSKI A. Neonatal and paediatric bloodstream infections: Pathogens, antimicrobial resistance patterns and prescribing practice at Khayelitsha District Hospital, Cape Town, South Africa. *SAMJ South African Medical Journal* 2018; **108**(2):99-104.
18. DENTI P, GARCIA-PRATS AJ, DRAPER HR, WIESNER L, WINCKLER JL, THEE S, DOOLEY KE, SAVIC R M, MCILLERON H, SCHAAF HS, HESSELING AC. Levofloxacin Population Pharmacokinetics in South African Children treated for multidrug-resistant tuberculosis. *Antimicrobial Agents and Chemotherapy* 2018; **62**(2):e01521-17.
19. DHANSAY MN. Conventional Indicators of the Burden of Young Child Malnutrition: time for a rethink?. *South African Journal of Clinical Nutrition* 2018; **31**(2):4-5.
20. DODD PJ, YUEN CM, BECERRA MC, REVILL P, JENKINS HE, SEDDON JA. Potential effect of household contact management on childhood tuberculosis: a mathematical modelling study. *Lancet Global Health* 2018; **6**:e1329-38.
21. DONALD PR, DIACON AH, LANGE C, DEMERS A, VON GROOTE-BIDLINGMAIER F, NARDELL EA. Droplets, dust and guinea pigs: an historical review of tuberculosis transmission research, 1878-1940. *International Journal of Tuberculosis and Lung Disease* 2018; **22**(9):972-982.
22. DOWLING WB, VELDSMAN KA, KATUSIIME MGK, MARITZ J, BOCK PA, MEEHAN S, VAN SCHALKWYK M, COTTON MF, PREISER W, VAN ZYL GU. HIV-1 RNA testing of pooled dried blood spots is feasible to diagnose acute HIV infection in resource limited settings. *Southern African Journal of Infectious Diseases (Formerly Southern African Journal of Epidemiology and Infection)* 2018; **33**(2):50-53.
23. DRAMOWSKI A, LLOYD LG, BEKKER A, HOLGATE SL, AUCAMP M, REDDY K, FINLAYSON H. Neonatal listeriosis during a countrywide epidemic in South Africa: A tertiary hospital's experience. *SAMJ South African Medical Journal* 2018; **108**(10):818-827.
24. DU PREEZ K, DU PLESSIS L, O'CONNELL N, HESSELING AC. Burden, spectrum and outcomes of children with tuberculosis diagnosed at a district-level hospital in South Africa. *International Journal of Tuberculosis and Lung Disease* 2018; **22**(9):1037-1043.
25. DU PREEZ K, SCHAAF HS, DUNBAR R, WALTERS E, SWARTZ A, SOLOMONS RS, HESSELING AC. Complementary surveillance strategies are needed to better characterise the epidemiology, care pathways and treatment outcomes of tuberculosis in children. *BMC Public Health* 2018; **18**:397.
26. DUNBAR R, NAIDOO P, BEYERS N, LANGLEY I. Improving rifampicin-resistant tuberculosis diagnosis using Xpert® MTB/RIF: modelling interventions and costs. *International Journal of Tuberculosis and Lung Disease* 2018; **22**(8):890-898.
27. DZIKITI M, ESSER MM, SLOGROVE AL, BETTINGER JA, MACHEKANO R, COTTON MF. Early Breastfeeding Cessation Among HIV-Infected and HIV-Uninfected Women in Western Cape Province, South Africa. *AIDS and Behavior* 2018; **2018**(22):114-120.

28. ENGELBRECHT JG, MUKINDA FK, GREEN BM, SKINNER D. How clinicians experience a simulated antiretroviral therapy adherence exercise: A qualitative study. *African Journal of Primary Health Care and Family Medicine* 2018; **10**(1):a1836.
29. FLOYD S, AYLES H, SCHAAP AB, SHANAUBE K, MACLEOD D, PHIRI M, GRIFFITH S, BOCK PA, BEYERS N, FIDLER S, HAYES R. Towards 90-90: Findings after two years of the HPTN 071 (PopART) cluster-randomized trial of a universal testing-and-treatment intervention in Zambia. *PLoS One* 2018; **13**(8):e0197904.
30. FREGONESE F, AHUJA SD, AKKERMAN OW, ARAKAKI-SANCHEZ D, AYAKAKA I, BAGHAEI P, BANG D, BASTOS M, BENEDETTI A, BONNET M, CATTAMANCHI A, CEGIELSKI P, CHIEN J-Y, GARCIA-PRATS AJ, SCHAAF HS, ET AL . Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. *Lancet Respiratory Medicine* 2018; **6**:265-275.
31. FRIGATI LJ, ARCHARY M, RABIE H, PENAZZATO M, FORD N. Priorities for Decreasing Morbidity and Mortality in Children with Advanced HIV disease. *Clinical Infectious Diseases* 2018; **66**(Suppl 2):S147-S151.
32. FRIGATI LJ, BEKKER A, STROBELE S, GOUSSARD P, SCHAAF HS. Culture-confirmed tuberculosis in South African infants younger than 3 months of age: clinical presentation and management of respiratory complications. *Pediatric Infectious Disease Journal* 2018; **1**(1):1.
33. FRY S, BARNABAS SL, COTTON MF. Update on trends in childhood tuberculosis. *CURRENT OPINION IN PEDIATRICS* 2018; **30**(1):152-160.
34. GARCIA-BASTEIRO AL, SCHAAF HS, DIEL R, MIGLIORI GB. Adolescents and young adults: a neglected population group for tuberculosis surveillance. *European Respiratory Journal* 2018; **51**:1800176.
35. GARCIA-PRATS AJ, DRAPER HR, FINLAYSON H, WINCKLER JL, BURGER A, FOURIE B, THEE S, HESSELING AC, SCHAAF HS. Clinical and cardiac safety of long-term levofloxacin in children treated for multidrug-resistant tuberculosis. *Clinical Infectious Diseases* 2018; **67**(11):1777-1780.
36. GARCIA-PRATS AJ, ROSE PC, DRAPER HR, SEDDON JA, NORMAN J, MCILLERON HM, HESSELING AC, SCHAAF HS. Effect of Co-Administration of Lidocaine on the pain and pharmacokinetics of intramuscular amikacin in children with multidrug-resistant tuberculosis: A randomized crossover trial. *Pediatric Infectious Disease Journal* 2018; **37**(12):1199-1203.
37. GARCIA-PRATS AJ, SVENSSON EM, WELD E, SCHAAF HS, HESSELING AC. Current status of pharmacokinetic and safety studies of multidrug-resistant tuberculosis treatment in children. *International Journal of Tuberculosis and Lung Disease* 2018; **22**(5):s15-s23.
38. GLANZMANN B, ABRAHAM DR, MOLLER M, GLASHOFF RH, VAN COLLER A, UREN CP, DURRHEIM GA, URBAN MF, VAN HELDEN EG, ESSER MM, RICE GI, CROW YJ, KINNEAR CJ. Variable expression in SAMHD1-Associated familial aicardi-Goutieres syndromes. *Current Allergy and Clinical Immunology* 2018; **31**(4):194-198.
39. GOUSSARD P. The role of bronchoscopy in wheezing preschool children. *Current Allergy and Clinical Immunology* 2018; **31**(2):75-79.
40. GREEN L, GOUSSARD P, VAN ZYL A, KIDD M, KRUGER M. Predictive Indicators to Identify High-Risk Paediatric Febrile Neutropenia in Paediatric Oncology Patients in a Middle-Income Country. *JOURNAL OF TROPICAL PEDIATRICS* 2017; **64**(1):395-402.
41. GROBBELAAR M, VAN TOORN R, SOLOMONS RS. Lumbar cerebrospinal fluid evolution in childhood tuberculous meningitis. *JOURNAL OF CHILD NEUROLOGY* 2018; **33**(11):700-707.
42. HARAUSZ EP, GARCIA-PRATS AJ, LAW S, SCHAAF HS, KREDO T, SEDDON JA, MENZIES D, TURKOVA A, ACHAR J, AMANULLAH F, BARRY PM, BECERRA C, CHAN ED, ET AL , HESSELING AC. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. *PLoS Medicine* 2018; **15**(7):e1002591.

43. HARGREAVES JR, KRISHNARATNE S, MATHEMA HT, LILLESTON PS, SIEVWRIGHT K, MANDLA NF, MAINGA T, VERMAAK R, PIWOWAR-MANNING E, SCHAAP AB, DONNELL D, AYLES H, HAYES R, HODDINOTT G, BOND V, STANGL A. Individual and community-level risk factors for HIV stigma in 21 Zambian and South African communities: analysis of data from the HPTN071 (PopART) study. *AIDS* 2018; **32**(6):783-793.
44. HESSELING PB, AFUNCHWI G, NJAMSHI V, KIMBI C, NFOR P, NJODZEKA B, WHARIN P, KOUYA F, DRAPER HR. Burkitt lymphoma (BL): effect of cyclophosphamide (CPM) on the menarche and fertility rate in 113 Cameroonian patients. *BRITISH JOURNAL OF HAEMATOLOGY* 2018; **182**(Suppl 1):7.
45. HESSELING PB, KOUYA F, KATAYI E, MBAH G, WHARIN P. Burkitt's lymphoma: The prevalence of HIV/AIDS and the outcome of treatment. *SAMJ South African Medical Journal* 2018; **108**(2):84-85.
46. HIRSCH-MOVERMAN Y, MANTELL JE, LEBELO L, WYNN C, HESSELING AC, HOWARD AA, NACHMAN S, FREDERIX K, MAAMA LB, EL-SADR W. Tuberculosis preventive treatment preferences among care givers of children in Lesotho: a pilot study . *International Journal of Tuberculosis and Lung Disease* 2018; **22**(8):858-862.
47. HODDINOTT G, HESSELING AC. Social science is needed to understand the impact of paediatric MDR-TB treatment on children and their families. *International Journal of Tuberculosis and Lung Disease* 2018; **22**(1):4.
48. HODDINOTT G, MYBURGH H, NDUBANI R, MANTANTANA J, THOMAS A, MBEWE M, AYLES H, BOCK PA, SEELEY J, SHANAUBE K, HARGREAVES JR, BOND V, REYNOLDS LJ. Households, fluidity, and HIV service delivery in Zambia and South Africa - an exploratory analysis of longitudinal qualitative data from the HPTN 071 (PopART) trial. *Journal of the International AIDS Society* 2018; **21**(s4):e25135.
49. HODDINOTT G, STAPLES S, BROWN RA, SIMWINGA M, MUBEKAPI-MUSADAIDZWA C, HESSELING AC, HENDRICKS GA, DE KOKER P, MCKENNA L. Community engagement for paediatric MDR-TB clinical trials: principles to support ethical trial implementation. . *International Journal of Tuberculosis and Lung Disease* 2018; **22**(5):s40-s45.
50. HONETH IE, LAUGHTON B, SPRINGER PE, COTTON MF, PRETORIUS C. Diagnostic accuracy of the Molteno Adapted Scale for developmental delay in South African toddlers. *Paediatrics and International Child Health* 2018; **1**(1):1-7.
51. HUFNAGEL M, VERSPORTEN A, BIELICKI J, DRAPIER N, SHARLAND M, GOOSSENS H, FINLAYSON H, DRAMOWSKI A. High rates of prescribing antimicrobials for prophylaxis in children and neonates: results from the antibiotic resistance and prescribing in European children point prevalence survey. *Journal of the Pediatric Infectious Diseases Society* 2018; **1**(1):1.
52. INNES SEV, HARVEY J, COLLINS IJ, COTTON MF, JUDD A. Lipoatrophy/lipohypertrophy outcomes after antiretroviral therapy switch in children in the UK/Ireland. *PLoS One* 2018; **13**(4):1-10.
53. INNES SEV, VAN DER LAAN LE, ANDERSON PL, COTTON MF, DENTI P. Can we improve stavudine's safety profile in children? Pharmacokinetics of intracellular stavudine triphosphate with reduced dosing. *Antimicrobial Agents and Chemotherapy* 2018; **62**(11):e00761-18.
54. Innes S, Patel K. Non-communicable diseases in adolescents with perinatally acquired HIV-1 infection in high-income and low-income settings. *Current opinion in HIV and AIDS* 2018; **13**(3):187-195. PMID: PMC5934760
55. ISRAELS T, PAINTSIL V, NYIRENDA D, KOUYA F, AFUNGCHWI GM, HESSELING PB, TRUMP C, KASPERS G, BURNS L, ARORA RS, CHAGALUKA G, NANA P, RENNER L, MOLYNEUX E. Improved outcome at end of treatment in the collaborative Wilms tumour Africa project. *Pediatric Blood and Cancer* 2018; **65**(5):e26945.

56. JACOBS CM, GOUSSARD P, GIE RP. Mycobacterium tuberculosis, a cause of necrotising pneumonia in childhood: a case series. *International Journal of Tuberculosis and Lung Disease* 2018; **22**(6):614-616.
57. KAMAT AS, GRETSCHER A, VLOK AJ, SOLOMONS RS. CSF protein concentration associated with ventriculoperitoneal shunt obstruction in tuberculous meningitis. *International Journal of Tuberculosis and Lung Disease* 2018; **22**(7):788-792.
58. KAMPMANN B, SEDDON JA, PATON J, NADEMI Z, KEANE D, RIDDELL A. Evaluating UK national guidance for screening of children for tuberculosis. A prospective multicenter study. *American Journal of Respiratory and Critical Care Medicine* 2018; **197**(8):1058-1064.
59. KAY A, GARCIA-PRATS AJ, MANDALAKAS A. HIV-associated pediatric tuberculosis: prevention, diagnosis and treatment. *Current Opinion in HIV and AIDS* 2018; **13**(6):501-506.
60. KIM S, SEDDON JA, GARCIA-PRATS AJ, MONTEPIEDRA G. Statistical considerations for pediatric multidrug-resistant tuberculosis efficacy trials. *International Journal of Tuberculosis and Lung Disease* 2018; **22**(5):s34-s39.
61. KLING S. Deciding for children at the end of life - whose decision?. *Current Allergy and Clinical Immunology* 2018; **31**(3):166-169.
62. KLING S. Disclosing medical error – changing the culture of medicine. *Current Allergy and Clinical Immunology* 2018; **31**(2):85-87.
63. KLING S. Is publishing children's medical information and photographs ethical?. *Current Allergy and Clinical Immunology* 2018; **31**(1):41-44.
64. KOOPMANS LR, FINLAYSON H, WHITELAW AC, DECLOEDT EH, DRAMOWSKI A. Paediatric antimicrobial use at a South African hospital. *International Journal of Infectious Diseases* 2018; **74**:16-23.
65. Kruger M, Makiwane MM, Ramoroka S, Van Elsland SL, Lawrence K, Rosenkranz B. *Off-label use in ambulatory paediatric clinics in a central South African hospital*. *Journal of Tropical Pediatrics* 2018 Nov 26. doi: 10.1093/tropej/fmy065.
66. LACOURSE SM, CRANMER LM, BEKKER A, STEINGART KR, BLACK D, HORNE J, OREN E, PALS S, MODI S, MATHAD J. Symptom screening for active tuberculosis in pregnant women living with HIV. *Cochrane Database of Systematic Reviews* 2018; **1**:1-20.
67. LAUGHTON B, CORNELL M, KIDD M, SPRINGER PE, DOBBELS EFM, JANSE VAN RENSBURG A, OTWOMBE K, BABIKER A, GIBB D, VIOLARI A, KRUGER M, COTTON MF. Five year neurodevelopment outcomes of perinatally HIV-infected children on early limited or deferred continuous antiretroviral therapy. *Journal of the International AIDS Society* 2018; **21**(5):e25106, 11 pages.
68. LAUGHTON B, CORNELL M, KIDD M, SPRINGER PE, DOBBELS EFM, JANSE VAN RENSBURG A, OTWOMBE K, BABIKER A, GIBB D, VIOLARI A, KRUGER M, COTTON MF. Five year neurodevelopmental outcomes of perinatally HIV-infected children on early limited or deferred continuous antiretroviral therapy. *Journal of the International AIDS Society* 2018; **21**:e25106.
69. LIU C, LYON CL, BU W, DENG Z, WALTERS E, LI Y, ZHANG L, HESSELING AC, GRAVISS EA, HU Y. Clinical Evaluation of a Blood Assay to Diagnose Paucibacillary Tuberculosis via Bacterial Antigens. *CLINICAL CHEMISTRY* 2018; **64**(5):791-800.
70. MAARMAN GJ. Pulmonary arterial hypertension and the potential roles of metallothioneins: A focused review. *Life Sciences* 2018; **214**:77-83.
71. MADHI SA, RIVERA LM, SAEZ-LLORENS X, MENENDEZ C, CARRIM-GANEY N, COTTON MF, KATZMAN D, LUTTIG MM, CANDELARIO R, BAKER S, ROYCHOUDHURY M. Factors influencing access of pregnant women and their infants to their local healthcare system: a prospective, multi-centre, observational study. *BMC Pregnancy and Childbirth* 2018; **18**:29.

72. MANN TNC, SCHAAF HS, DUNN RN, DIX-PEEK S, DU PREEZ K, LAMBERTS RP, DU TOIT J, DAVIS JH. Child and adult spinal tuberculosis at tertiary hospitals in the Western Cape, South Africa 4-year burden and trend. *Epidemiology and Infection* 2018; **146**:2107-2115.
73. Makiwane, Memela; Decloedt, Eric; Chirehwa, Maxwell; Rosenkranz, B; Kruger, Mariana. *Adverse drug reactions in paediatric in-patients in a South African tertiary hospital*. *Journal of Tropical Pediatrics* 2018, 0, 1–8; doi: 10.1093/tropej/fmy067.
74. MARX FM, YAESOUBI R, MENZIES NA, SALOMON JA, BILINSKI A, BEYERS N, COHEN T. Tuberculosis control interventions targeted to previously treated people in a high-incidence setting: a modelling study. *Lancet Global Health* 2018; **6**:e426-e435.
75. MASEKELA R, JEEVANATHRUM A, KLING S, GRAY TC, MORRISON J, VANKER A, PUTERMAN AS, RHODE D, ZÖLLNER EWA, DE WAAL P, MANJRA AI, LEVIN M, ZAR H, GREEN RJ, KRITZINGER FE. Asthma treatment in children: A pragmatic approach. *SAMJ South African Medical Journal* 2018; **108**(8):612-618.
76. MASEKELA R, RISENGA SM, KITCHIN OP, WHITE DA, DAVIS G, GOUSSARD P, MANJRA AI, KRITZINGER FE, LEVIN M, ZAR H, GREEN RJ. The diagnosis of asthma in children: An evidence-based approach to a common clinical dilemma. *SAMJ South African Medical Journal* 2018; **108**(7):540-545.
77. MBUAGBAW L, SLOGROVE AL, SAS J, MORFAW F, MUKONZO JK, CAO W, DZIKITI M, ONGOLO-ZOGO P, NANA PN, COCKCROFT A, ANDERSON N, COTTON MF, YOUNG TN, ET AL . Output from the CIHR Canadian HIV Trials Network international postdoctoral fellowship for capacity building in HIV clinical trials. *HIV/AIDS - Research and Palliative Care* 2018; **2018**(10):151-155.
78. MORRISON J, GIE RP. Are infant wheezing and childhood asthma risk factors for the development of COPD?. *Current Allergy and Clinical Immunology* 2018; **31**(2):65-69.
79. MYBURGH H, CALITZ E, RAILTON JP, MALULEKE C, MASHAO E, KETELO P, JOBSON G, GROBBELAAR CJ, STRUTHERS H, PETERS RPH. Breaking down barriers to tell: A mixed methods study of health worker involvement in disclosing to children that they are living with HIV in rural South Africa. *Journal of the Association of Nurses in AIDS Care* 2018; **29**(6):902-913.
80. NEL EDLR. Severe acute malnutrition. *CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE* 2018; **21**(3):195-199.
81. NEMES E, HESSELING AC, TAMERIS M, MAUFF K, DOWNING K, MULENGA H, ROSE PC, VAN DER ZALM MM, MBABA S, VAN AS A, HANEKOM W, WALZL G, SCRIBA T, MCSHANE H, HATHERILL M. Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial. *Clinical Infectious Diseases* 2018; **1**(66):554-563.
82. NWOSU EC, ROBERTSON FC, HOLMES MJ, COTTON MF, DOBBELS EFM, LITTLE F, LAUGHTON B, VAN DER KOUWE A, MEINTJES E. Altered brain morphometry in 7-year old HIV-infected children on early ART. *Metabolic Brain Disease* 2018; **33**:523-535.
83. OBIHARA NJ, WALTERS E, LAWRENSON J, GARCIA-PRATS AJ, HESSELING AC, SCHAAF HS. Tuberculous pericardial effusions in children. *Journal of the Pediatric Infectious Diseases Society* 2018; **7**(4):346-349.
84. OLIVIER CM, KUNNEKE H, O'CONNELL N, VON DELFT E, WATES M, DRAMOWSKI A. Healthcare-associated infections in paediatric and neonatal wards: A point prevalence survey at four South African hospitals. *SAMJ South African Medical Journal* 2018; **108**(5):418-422.
85. OPOLLO VS, WU X, HUGHES MD, SWINDELLS S, GUPTA A, HESSELING AC, CHURCHYARD G, KIM S, LANDO R, DAWSON R, MAVE V, MENDOZA A, GONZALES P, GARCIA-PRATS AJ, ET AL . HIV testing uptake among the household contacts of multidrug-resistant tuberculosis index cases in eight countries. . *International Journal of Tuberculosis and Lung Disease* 2018; **22**(12):1443-1449.

86. PANAYIDOU K, DAVIES M-A, ANDEREGG N, EGGER M, FATTI GL, RABIE H, ET AL . Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation. *Journal of the International AIDS Society* 2018; **21**:e25200, 16 pages.
87. PATTEN G, BERNHEIMER J, FAIRLIE L, RABIE H, SAWRY S, TECHNAU K, ELEY B, DAVIES M-A. Lamivudine monotherapy as a holding regimen for HIV-positive children. *PLoS One* 2018; **13**(10):e0205455.
88. PEPPER MS, POPE A, KLING S, ALESSANDRINI M, VAN STADEN W. Ethical considerations in the application of cel and gene therapies in children. *SAMJ South African Medical Journal* 2018; **108**(12):1027-1029.
89. ROBERTSON FC, HOLMES MJ, COTTON MF, DOBBELS EFM, LITTLE F, LAUGHTON B, VAN DER KOUWE AJW, MEINTJES E. Perinatal HIV infection or exposure is associated with low N-Acetylaspartate and lutamate in basal ganglia at age 9 but not 7 years. *Frontiers in Human Neuroscience* 2018; **12**(Article 145):1-10.
90. ROSSER A, MARX FM, PAREEK M. Recurrent tuberculosis in the pre-elimination era. *International Journal of Tuberculosis and Lung Disease* 2018; **22**(2):139-150.
91. RUISEÑOR-ESCUADERO H, FAMILIAR I, NYAKATO M, KUTESSA A, JOYCE C, LAUGHTON B, GRAB J, CHERNOFF M, VHEMBO T, FAIRLIE L, KAMTHUNZI P, BIOVIN M. Building capacity in neurodevelopment assessment of children in sub-Saharan Africa: A quality assurance model to implement standardized neurodevelopment testing. *CHILD NEUROPSYCHOLOGY* 2018; **1**(1):1.
92. SABAPATHY K, MATHEMA HT, MUBEKAPI-MUSADAIDZWA C, HODDINOTT G, HARGREAVES JR, FLOYD S, AYLES H, HAYES R. Is home-based HIV testing universally acceptable? Findings from a case-control study nested within the HPTN 071 (Pop ART) trial. *Tropical Medicine and International Health* 2018; **23**(6):678-690.
93. SCHAAF HS, GARCIA-PRATS AJ, MCKENNA L, SEDDON JA. Challenges of using new and repurposed drugs for the treatment of multidrug-resistant tuberculosis in children. *Expert Review of Clinical Pharmacology* 2018; **11**(3):233-244.
94. Schoeman J, Ladas EJ, Rogers PC, Aryal S, Kruger M. Unmet Needs in Nutritional Care in African Paediatric Oncology Units. *Journal of Tropical Pediatrics* 2018; doi: 10.1093/tropej/fmy068.
95. SCHULTHEIS M, KLING S, LENKER U , VON BIBRA M, ROSENKRANZ BF, KLINKER H. Lopinavir serum concentrations of critically ill infants: a pharmacokinetic investigation in South Africa. *MEDICAL MICROBIOLOGY AND IMMUNOLOGY* 2018; **207**(5-6):339-343.
96. SEDDON JA, ESMAIL H, COUSSENS K. The Wonder Years: What Can Primary School Children Teach Us About Immunity to Mycobacterium tuberculosis?. *Frontiers in Immunology* 2018; **9**:2946.
97. SEDDON JA, GARCIA-PRATS AJ, PURCHASE SE, OSMAN M, DEMERS A, HODDINOTT G, CROOK AM, OWEN-POWELL E, THOMASON MJ, TURKOVA A, GIBB DM, FAIRLIE L, MARTINSON N, SCHAAF HS, HESSELING AC. Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP). *Trials* 2018; **19**:693:1-11.
98. SEDDON JA, SCHAAF HS, MARAIS BJ, MCKENNA L, GARCIA-PRATS AJ, HESSELING AC, HUGHES JA, HOWELL P, DETJEN AK, AMANULLAH F, SINGH UB, MASTER I, PEREZ-VELEZ CM, MISRA N, BECERRA C, FURIN J. Time to act on injectable-free regimens for children with multidrug-resistant tuberculosis. *Lancet Respiratory Medicine* 2018; **6**:662-664.
99. SEDDON JA, WELD E, SCHAAF HS, GARCIA-PRATS AJ, KIM S, HESSELING AC. Conducting efficacy trials in children with MDR-TB: what is the rationale and how should they be done?. *International Journal of Tuberculosis and Lung Disease* 2018; **22**(5):s24-s33.

100. SLOGROVE AL, POWIS KM, BETTINGER JA, COTTON MF. Considerations in evaluating infectious morbidity and mortality in HIV-exposed uninfected infants. *AIDS* 2018; **32**(18):2855-2856.
101. SLOOT R, MAARMAN GJ, OSMAN M, MARX FM. Variation in HIV prevalence and the population-level effects of antiretroviral therapy in reducing tuberculosis incidence in South Africa. *SAMJ South African Medical Journal* 2018; **108**(8):606.
102. SPRINGER PE, SLOGROVE AL, LAUGHTON B, BETTINGER JA, SAUNDERS HH, MOLTENO CD, KRUGER M. Neurodevelopmental outcome of HIV-exposed but uninfected infants in the Mother and Infants Health study, Cape Town, South Africa. *Tropical Medicine and International Health* 2018; **23**(1):69-78.
103. STROBELE S, NEL EDLR. Successful treatment of a South African paediatric case of acute liver failure caused by perinatal transmission of hepatitis B. The Pediatric Infectious Disease Journal. *Pediatric Infectious Disease Journal* 2018; **1**(1):1.
104. STRYDOM K, NEL DG, DHANSAY MA, VAN NIEKERK E. The effect of maternal HIV status and treatment duration on body composition of HIV-exposed and HIV-unexposed preterm, very and extremely low-birthweight infants. *Paediatrics and International Child Health* 2018; **38**(3):163-174.
105. SWINDELLS S, GUPTA A, KIM S, HUGHES MD, SANCHEZ J, MAVÉ V, DAWSON R, KUMARASAMY N, COMINS K, SMITH B, RUSTOMJEE R, NAINI L, SHAH NS, HESSELING AC, CHURCHYARD G. Resource utilization for multidrug-resistant tuberculosis household contact investigations (A5300/I2003). . *International Journal of Tuberculosis and Lung Disease* 2018; **22**(9):1016-1022.
106. TANUMIHARDJO SA, KALIWILE C, BOY E, DHANSAY MA, VAN STUIJVENBERG ME. Overlapping vitamin A interventions in the United States, Guatemala, Zambia, and South Africa: case studies. *Annals of the New York Academy of Sciences* 2018; **1**(1):1.
107. THOMAS A, DOBBELS EFM, SPRINGER PE, ACKERMANN C, COTTON MF, LAUGHTON B. Favourable outcome in a child with symptomatic diagnosis of Glutaric aciduria type 1 despite vertical HIV infection and minor head trauma. *Metabolic Brain Disease* 2018; **33**(2):537-544.
108. THUBOY B, KELLERMANN T, CASTEL S, NORMAN J, JOUBERT A, GARCIA-PRATS AJ, HESSELING AC, WIESNER L. The determination of capreomycin in human plasma by LC-MS/MS using ion-pairing chromatography and solid-phase extraction . *BIOMEDICAL CHROMATOGRAPHY* 2018; **32**(9):e4269.
109. TOICH JTF, TAYLOR PA, HOLMES MJ, GOHEL S, COTTON MF, DOBBELS EFM, LAUGHTON B, LITTLE F, VAN DER KOUWE A, BISWAL B, MEINTJES E. Functional connectivity alterations between Networks and associations within networks in HIV infected children on early treatment: A study at 7 years. *Frontiers in Human Neuroscience* 2018; **11**(Article 635):1-15.
110. Torborg A, Cronje L, Thomas J, Meyer H, Bhattay A, Diedericks J, et al. South African Paediatric Surgical Outcomes Study: a 14-day prospective, observational cohort study of paediatric surgical patients. *Br J Anaesth.* 2019;122(November 2018):224–32.
111. VAN DER LAAN LE, GARCIA-PRATS AJ, SCHAAF HS, TIKISO T, WIESNER L, DE KOCK M, WINCKLER JL, NORMAN J, MCILLERON H, DENTI P, HESSELING AC. Pharmacokinetics and drug-drug interactions of lopinavir/ritonavir administered with first and second-line antituberculosis drugs in HIV-infected children treated for multidrug-resistant tuberculosis. *Antimicrobial Agents and Chemotherapy* 2018; **62**(2):e00420-17.
112. Laughton B, Cornell M, Kidd M, Springer PE, Dobbels EF, Janse van Rensburg A, Otwombe K, Babiker A, Gibb DM; Violari A, Kruger M, Cotton MF. *Five year Neurodevelopment Outcomes on early limited or deferred continuous antiretroviral therapy: Prospective longitudinal observational study.* *Journal of International Aids Society* 2018 May;21(5):e25106. doi: 10.1002/jia2.25106.

113. VAN ELSLAND SL, COTTON MF. Paediatric ART adherence in South Africa: A comprehensive analysis. *AIDS and Behavior* 2018; **1**(1):1.
114. VAN ELSLAND SL, PETERS RPH, KOK MO, VAN TOORN R, SPRINGER PE, COTTON MF, GROBBELAAR CJ, AARNOUTSE R, VAN FURTH AM. A treatment-support intervention evaluated in South African paediatric populations with HIV infection or tuberculous meningitis. *Tropical Medicine and International Health* 2018; **23**(10):1129-1140.
115. VAN ELSLAND SL, VAN DONGEN SI, BOSMANS JE, SCHAAF HS, VAN TOORN R, VAN FURTH AM. Cost-effectiveness of home-based vs. in-hospital treatment of paediatric tuberculosis meningitis. *International Journal of Tuberculosis and Lung Disease* 2018; **22**(10):1188-1195.
116. VAN RENSBURG L, VAN ZYL JM, SMITH J. Deposition and transport of linezolid mediated by a synthetic surfactant Synsurf® within a pressurized metered dose inhaler: a Calu-3 model. *Drug Design, Development and Therapy* 2018; **12**:1107-1118.
117. VAN STUIJVENBERG ME, SCHOEMAN SE, NEL J, LOMBARD CJ, DHANSAY MA. Serum retinol in post-partum mothers and newborns from an impoverished South African community where liver is frequently eaten and vitamin A deficiency is absent. *Maternal and Child Nutrition* 2017; **13**:e12223.
118. VELDSMAN KA, MARITZ J, ISAACS S, KATUSIIME MGK, JANSE VAN RENSBURG A, LAUGHTON B, MELLORS JW, COTTON MF, VAN ZYL GU. Rapid decline of HIV-1 DNA and RNA in infants starting very early ART may pose a diagnostic challenge. *AIDS* 2018; **32**:629-634.
119. VIVIAN L, COMITIS G, NAIDU C, HUNTER C, LAWRENSON J. A first qualitative snapshot: cardiac surgery and recovery in 10 children in the Red Cross War Memorial Children's Hospital, Cape Town, South Africa (2011-2016). *CARDIOLOGY IN THE YOUNG* 2018; **28**(2):322-328.
120. WALTERS E, DEMERS A, VAN DER ZALM MM, WHITELAW DA, PALMER M, BOSCH C, DRAPER HR, GIE RP, HESSELING AC. Reply to Drancourt, "Culturing stools to detect mycobacterium tuberculosis". *Journal of Clinical Microbiology* 2018; **56**(5):e00056-18.
121. WALTERS E, SCOTT L, NABETA P, DEMERS A, REUBENSON G, BOSCH C, DAVID A, VAN DER ZALM MM, HAVUMAKI J, PALMER M, HESSELING AC, NCAYIYANA J, STEVENS W, ALLAND D, DENKINGER CM, BANADA P. Molecular detection of mycobacterium tuberculosis from stools in young children by use of a novel centrifugation-free processing method. *Journal of Clinical Microbiology* 2018; **56**(9):e00781-18.
122. WOOD LF, BROWN BP, LENNARD K, KARAOZ U, HAVYARIMANA E, PASSMORE JS, HESSELING AC, EDLEFSEN PT, KUHN L, MULDER N, BRODIE EL, SODORA DL, JASPAN HB. Feeding-related gut microbial composition associates with peripheral t-cell activation and mucosal gene expression in african infants. *Clinical Infectious Diseases* 2018; **67**(8):1237-1246.
123. YATES TA, AYLES H, LEACY FP, SCHAAP AB, BOCCIA D, BEYERS N, GODFREY-FAUSETT P, FLOYD S. Socio-economic gradients in prevalent tuberculosis in Zambia and the Western Cape of South Africa. *Tropical Medicine and International Health* 2018; **23**(4):375-390.
124. ZÖLLNER EWA. Is adrenal suppression in asthmatic children reversible? A case series. *SAMJ South African Medical Journal* 2018; **108**(6):502-505.
125. OPPEL KB, HOLGATE SL, FINLAYSON H. A retrospective review of *Listeria Monocytogenes* infection at Tygerberg Children's Hospital, Cape Town, South Africa, from 2006 to 2016: Is empirical ampicillin still indicated after the first month of life? *Afr Med J* 2018; **108**(11) 937-943
126. DIPPENAAR R, SMITH JS. Impact of pulsed xenon ultraviolet disinfection on surface contamination in a hospital facility's expressed human milk feed preparation area. *BMC Infect Dis.* 2018 Feb 23; **18**(1):91, doi 10.1186/s12879-018-2997-9.
127. Zenhäusern J, Bekker A, Wates M, Schaaf HS, Dramowski A. Tuberculosis transmission in a hospitalized neonate: need for optimized tuberculosis screening of pregnant and post-partum women. *S Afr Med J.* (accepted for publication 2018)

128. Daskapan A, Idrus LR, Postma MJ, Wilffert B, Kosterink JGW, Stienstra Y, Touw DJ, Andersen AB, Bekker A, Denti P, Hemanth Kumar AK, Jeremiah K, Kwara A, McIlleron H, Meintjes G, van Oosterhout JJ, Ramachandran G, Rockwood N, Wilkinson RJ, van der Werf TS, Alffenaar JC. A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs. *Clin Pharmacokinet*. 2018 Nov 8. doi: 10.1007/s40262-018-0716-8
129. LaCourse SM, Cranmer LM, Bekker A, Steingart KR, Black D, Horne DJ, Oren E, Pals S, Modi S, Mathad J. Symptom screening for active tuberculosis in pregnant women living with HIV. *Cochrane Database Syst Rev*. 2018;2018(1). pii: CD012934. doi: 10.1002/14651858.CD012934.

Journal Articles (NON-subsidised)

130. DE WILDE C, DU PLESSIS A, GOUSSARD P. Unusual presentation of pulmonary hydatidosis mimicking thoracic malignancy in a paediatric South African patient. *Journal of the Belgian Society of Radiology* 2018; **102**(1):70, 1-4.
131. HESSELING PB, TAMANNAI M, LADAS EJ, AFUNGCHWI GM, KATAYI E, KOUYA F. Burkitt lymphoma - Nutritional support during induction treatment: Effect on anthropometric parameters and morbidity of treatment. *South African Journal of Oncology* 2018; **2**:a53.
132. MARX FM, THERON GDV. Intensifying tuberculosis case finding - opportunities, challenges and open questions. *South African Centre for Epidemiological Modeling and analysis (SACEMA)* 2018; **1**(1):6.

Chapters in Books

133. KRUGER M. Childhood Cancers and its warning signs. In: de Villiers M (ed.) *Handbook of Oncology*, MIMS, Saxonworld, South Africa, 2018: 119-122.
134. KRUGER M. Common Childhood Cancers. In: de Villiers M (ed.) *Handbook of Oncology*, MIMS, Saxonworld, South Africa, 2018: 123-127.
135. SCHAAF HS, MARAIS BJ, CARVALHO I, SEDDON JA. Challenges in childhood tuberculosis. In: Migliori GB (ed.) *Tuberculosis*, European Respiratory Society, Sheffield, United Kingdom, 2018: 234-262.

CENTRES

THE FAMILY CLINICAL RESEARCH UNIT (FAMCRU)

Director: Prof MF Cotton



In 2018, FAMCRU conducted 20 clinical trials and research studies, two thirds of which were in paediatric participants. These studies are conducted within the NIH funded IMPAACT (International Maternal Pediatric Adolescent AIDS Clinical Trials Group) and ACTG (AIDS Clinical Trials Group) networks, the European PENTA-ID (Paediatric European Network for Treatment of AIDS – Infectious Diseases) network, pharmaceutical funded trials and investigator driven trials. We screened 564 potential participants and enrolled 322. There were 6041 clinic visits comprising 4179 scheduled visits and 1862 unscheduled during 2018. Additions to the staff complement include 2 pharmacists, 2 doctors, one 1 administrative and a human resources assistant.

1. RESOURCE SHARING AND COLLABORATION

Dr Barbara Laughton conducts the following neurodevelopment studies:

- 1.1 The Association of Perinatal HIV infection and Hearing Loss in Children of Cape Town, South Africa.
Funding: R01DC015984, NIH
Collaborators: P Torre (PI) San Diego State University, Tj Yao, Harvard University, Andre van Der Kouwe Massachusetts General Hospital, Ernesta Meintjes UCT, Marcin Jankiewicz UCT.
- 1.2 Neuroimaging and gut microbiome markers of development in HIV-exposed uninfected infants.
Funding: R01HD093578, NIH
Collaborators: MJ Holmes (UCT), M Kaba (UCT), A van der Kouwe (MGH), F Little (UCT)
- 1.3 Neonatal Imaging as a marker of neurodevelopment and predictor of cognitive Performance in infants exposed to HIV and ART in utero and perinatally.
Funding: R01 HD085813, NIH
Collaborators: A van der Kouwe (MGH), E Meintjes (UCT), S Jacobson (Wayne State University), J Jacobson (Wayne State University), F Little (UCT)
- 1.4 Latent reservoir characterization and correlations with neurocognitive function.
Funding: R01MH105134, NIH
Collaborators: Virology, Immunology, Neuroimaging at UCT

2. ACHIEVEMENTS AND HIGHLIGHTS

2.1 Appointments

- 1.1.1 Marije van Schalkwyk – voting member of WHISC (Women’s Health Inter-Network Scientific Committee)

- 1.1.2 Shaun Barnabas – member of the ACTG CURE Committee
- 1.1.3 Lynne Cornellisen – member of the South African Board of Trustees and Chair of the Global Programs Committee for Mothers 2 Mothers
- 1.1.4 Sonja Pieterse – Pharmacy Manager at FAMCRU
- 1.1.5 Mark Cotton – serves on the IMPAACT CURE Committee
- 1.1.6 Joan Coetzee serves on:
 - Protocol Development and Implementation Sub-committee (PDISC) – Co-chair
 - Scientific Agenda Steering Committee (SASC) – SMCCC representative
 - Site Management Clinical Care Committee (SMCCC) – member
 - Field Representative Working Group (FRWG) – member
- 2.1.7 Marie Theunissen – serves as a member of the International Community Advisory Board
- 2.1.78 Steve Innes – serves on the IMPAACT Complications Scientific Committee
- 2.2 Grants / Awards**
 - 1.2.1 Gerhard Walzl won GOLD medal MRC reward for Research Excellence
 - 1.2.2 4 CAB members were awarded the Bridgitte Murtagh award for continuous dedication through-out the year as a CAB member
 - 1.2.3 Shalena Naidoo received the International AIDS Society and ANRS Dominique Dormont award for young researchers working on chronic conditions interfacing between HIV. The prize highlights researchers who demonstrate originality, rationale, quality and a multidisciplinary and integrative approach in HIV research for her poster “Persistence of myeloid cell-associated inflammation in HIV-infected children after 8 years on early initiated therapy – the key role players in HIV persistence?”
- 2.3 Educational achievements**
 - 1.3.1 Dr Lindie Rossouw: BTh Honours, Dec 2018
 - 1.3.2 Dr Samantha Fry – MMed Paediatrics

3. TRAINING AND TEACHING

3.1 Academic meetings

- 3.1.1 Quarterly SUN CTU meetings
- 3.1.2 Weekly SUN CTU academic presentations
- 3.1.3 Participation in the weekly Tygerberg Paediatric Infectious Diseases Meeting
- 3.1.4 Regular representation by Samantha Fry and Marije van Schalkwyk at the 2-monthly Tygerberg subdistrict HIV and TB meeting for community clinics and the quarterly Metro East HIV and TB meeting.

3.2 Courses Attended

- 1.2.1 Neuropsychs Tester-Griffiths III Training - Mrs B Fanqa (certified course required to test on the Griffiths)
- 1.2.2 Alarm Distress Baby Scales Scoring - Dr B Laughton (certified course require to test on the Griffiths)
- 1.2.3 National Radiology Refresher Course, August - M van Schalkwyk
- 1.2.4 BLS and ACLS course, Dec – M van Schalkwyk, L Cornellison
- 1.2.5 APLS, Advanced Life Support Group, 15 March 2018 – Magdel Rossouw
- 1.2.6 Performance Management Training, Stellenbosch University, March 2018 – Jeanne Louw

- 1.2.7 SU Staff HIV Counselling and Testing Short course, 25 – 27 Sep 2018:
Veronica Matroos & Shiella Dyan
- 1.2.8 Magdel Rossouw: APLS, Advanced Life Support Group, 15 March 2018
- 1.2.9 Jeanne Louw, Performance Management Training, Stellenbosch University, March 2018
- 1.2.10 Breastfeeding Seminar, Western Cape Government (Health) – 3 Aug 2018
Dr Magdel Rossouw, Dr Lindie Rossouw, Phoebe Ganjana, Nokuza Bonani, Leonie Groepies, Sylvia Pieterse, Desmien Bagus, Bongwiwe Makeleni, Veronica Matroos
- 1.2.11 Stellenbosch University Annual Academic Day – 29 Aug 2018:
Prof Gerhard Theron, Jeanne Louw, Dr Magdel Rossouw, Dr Lindie Rossouw, Phoebe Ganjana, Nokuza Bonani, Wendy Adendorff, Leonie Groepies, Sylvia Pieterse, Desmien Bagus, Bongwiwe Makeleni, Veronica Matroos, Shiella Dyan
- 1.2.12 Paediatrics and Child Health Academic Day of Excellence, Stellenbosch University - 7 Nov 2018:
Dr Magdel Rossouw, Dr Lindie Rossouw, Phoebe Ganjana, Nokuza Bonani, Wendy Adendorff, Leonie Groepies, Sylvia Pieterse, Desmien Bagus, Bongwiwe Makeleni, Veronica Matroos, Shiella Dyan
- 1.2.13 SU Staff HIV Counselling and Testing Short course, 25 – 27 Sep 2018:
Veronica Matroos & Shiella Dyan

Staff training

- 1.2.14 GCP – Anthony Hitchcock, Sharon Kruger
- 1.2.15 **Neurodevelopmental:**
 - 1.2.15.1 Preparation and positioning of newborns for un-sedated MRI scans for research study - F Lindani, T Hamana, S Fry
 - 1.2.15.2 Fagan test of infant intelligence (trained to test) - Mrs B Fanqa
 - 1.2.15.3 WHO Infant Dietary Survey - HBS study team
 - 1.2.15.4 Dubowitz Neurological Assessment of the Newborn - Dr S Fry
 - 1.2.15.5 HIV adolescent workshop, 10-12 Oct - P Zuidewind
 - 1.2.15.6 Performance Management training, 9 March - A J van Rensburg
 - 1.2.15.7 Adherence counselling training, Sept - T Ncgaba
 - 1.2.15.8 HIV Counselling, 25 – 27 Sep - Laurette Siphambo (Counsellor)
 - 1.2.15.9 Nuts and Bolts and Safety training, 3 - 5 Dec - Doreen Willemse, Dr Olivia Arendse, Dr Amy Slogrove
 - 1.2.15.10 IATA Training, 15 -17 Aug – Anthony Hitchcock
- 1.2.16 **IMPAACT / ACTG:**
 - 1.2.16.1 GCP lectures – Developing SOPs and Recruitment and Retention of Research Participants.
 - 1.2.16.2 Mentoring 2 Study Coordinators
 - 1.2.16.3 Staff training in the consent process
 - 1.2.16.4 CAB leadership training for the CAB executive committee

1.3 Undergraduate Teaching

- 1.3.1 Samantha Fry assisted with 3rd year undergraduate paediatric clinical teaching
- 1.3.2 Shaun Barnabas assisted with 3rd year undergraduate paediatric lectures
- 1.3.3 Shaun and Samantha assist with middle rotation and SI clinical examinations

1.4 International Students

1.4.1 FAMCRU. together with HOPE hosted 4 international students completing their clinical elective rotation

4. CONFERENCES: PRESENTATIONS AND ATTENDANCE

Name	Conference	Date (2018)	Attendee / oral presentation / poster presentation / key note speaker / guest speaker / plenary / session chair / other
B Laughton	41 st Paediatrics refresher course UCT	15 Feb	Attendee
B Laughton	10 th International workshop on HIV Pediatrics, Amsterdam	July	Attendee
S Naidoo*	10 th International workshop on HIV Pediatrics Amsterdam	July	Oral presentation of work from study at FAMCRU
I Familiar	10 th International workshop on HIV Pediatrics Amsterdam	July	Oral presentation of work from Multisite study at FAMCRU
E Nwosu	10 th International workshop on HIV Pediatrics Amsterdam	July	Poster presentation of work from study at FAMCRU
F Mberi	10 th International workshop on HIV Pediatrics Amsterdam	July	Poster presentation
B Laughton	HEU workshop	July	Attendee
B Laughton	Adolescent workshop	July	Attendee
B Laughton	22 nd International AIDS conference	July	Attendee
A Ibrahim	22 nd International AIDS conference	July	Poster presentation of work from study at FAMCRU
FMberi	22 nd International AIDS conference	July	Poster presentation of work from study at FAMCRU
JS Madzime	22 nd International AIDS conference	July	Poster presentation of work from study at FAMCRU
EC Nwosu	22 nd International AIDS conference	July	Poster presentation of work from study at FAMCRU
B Laughton	CIPHER Stakeholder Meeting	July	Attendee
T Hamana	22 nd International AIDS conference	July	Poster presentation of work from study at FAMCRU
M. Cotton	22 nd International AIDS conference	July	Oral presentation: Pharmacokinetics, safety, & efficacy of

			bictegravir, emtricitabine & tenofovir alafenamide (B/F/TAF) single-tablet regimen in HIV-1-infected children (6 to < 12 years)
Keri Woods	62 nd AAD Stellenbosch University	August	Poster presentation of work from study at FAMCRU
Shalena Naidoo	62 nd AAD Stellenbosch University	August	Oral presentation of work from study at FAMCRU
B Laughton	SAPA conference	September	Poster presentation X 2
Amy Graham	World Audiology Congress	October	Poster presentation of work from study at FAMCRU
P Torre	World Audiology Congress	October	Oral presentation of work from study at FAMCRU
H Elliot	World Audiology Congress	October	Poster presentation of work from study at FAMCRU
A Janse van Rensburg	IMPAACT 2018 PENTA 20 (Odyssey) HIV Paediatric workshop	June 17-22 July 20-21July	Attendee
M Cotton, S Barnabas, G Fourie	Annual AIDS Clinical Trials Group (ACTG) Scientific Retreat Meeting	June	Attendee
Joan Coetzee	Annual ACTG Network Meeting	June	Attendee/ Facilitator of PDISC committee fair
M Cotton	CROI 2018, Boston Massachusetts	March	
J Louw; G Theron, M Cotton, S Fry, S Barnabas, G Fourie, A Fourie, M Smuts, J Coetzee	IMPAACT Annual Meeting	June	Attendees

5. PUBLICATIONS

- 5.1** Laughton B, Cornell M, Kidd M, Springer PE, Dobbels EFM, Rensburg AJV, Otwombe K, Babiker A, Gibb DM, Violari A, Kruger M, Cotton MF. Five year neurodevelopment outcomes of perinatally HIV-infected children on early limited or deferred continuous antiretroviral therapy. *Journal of the International AIDS Society*. 2018; 21(5):e25106. PubMed [journal] PMID: 29722482, PMCID: PMC5932637
- 5.2** Thomas A, Dobbels EFM, Springer PE, Ackermann C, Cotton MF, Laughton B. Favourable outcome in a child with symptomatic diagnosis of Glutaric aciduria type 1

- despite vertical HIV infection and minor head trauma. *Metabolic brain disease*. 2018; 33(2):537-544. PubMed [journal] PMID: 29427049
- 5.3 Robertson FC, Holmes MJ, Cotton MF, Dobbels E, Little F, Laughton B, van der Kouwe AJW, Meintjes EM. Perinatal HIV Infection or Exposure is associated with low N-Acetylaspartate and Glutamate in Basal Ganglia at age 9 but not 7 years. *Front. Hum. Neurosci.* 12:145. Doi 10.3389/fnhum.2018.00145
 - 5.4 Chernoff MC1, Laughton B2, Ratswana M3, Familiar I4, Fairlie L3, Vhembo T5, Kamthunzi P6, Kabughho E7, Joyce C8, Zimmer B9, Ariansen JL10, Jean-Philippe P11, Boivin MJ. Validity of Neuropsychological Testing in Young African Children Affected by HIV. *J Pediatr .Infect Dis.* 2018 Sep;13(3):185-201. doi: 10.1055/s-0038-1637020.
 - 5.5 Fry S, Barnabas S, and Cotton MF, Update on trends in childhood tuberculosis. *Curr Opin Pediatr* 30 (2018) 152-160.
 - 5.6 Innes S, van der Laan L, Anderson PL, Cotton M, and Denti P, Can We Improve Stavudine's Safety Profile in Children? Pharmacokinetics of Intracellular Stavudine-Triphosphate with Reduced-Dosing. *Antimicrob Agents Chemother* (2018).
 - 5.7 Slogrove AL, Powis KM, Bettinger JA, and Cotton MF, Considerations in evaluating infectious morbidity and mortality in HIV-exposed uninfected infants. *AIDS* 32 (2018) 2855-2856.
 - 5.8 Veldsman KA, Maritz J, Isaacs A, Katusiime MG, Janse Van Rensburg A, Laughton B, Mellors JW, Cotton MF, and Van Zyl GU, Rapid decline of HIV-1 DNA and RNA in infants starting very early ART may pose a diagnostic challenge. *AIDS* (2018).
 - 5.9 Zunza, M. Esser, A. Slogrove, J.A. Bettinger, R. Machezano, M.F. Cotton, and C. Mother-Infant Health Study Project Steering, Early Breastfeeding Cessation Among HIV-Infected and HIV-Uninfected Women in Western Cape Province, South Africa. *AIDS Behav* (2018).

6. COMMUNITY ENGAGEMENT

6.1 Community Advisory Board

- 6.1.1 Combined Community Advisory Board conference 18 – 19 October 2018
- 6.1.2 Gala event for Community Advisory Board members
- 6.1.3 Establishment of the Katlego Mosimangape award for young people belonging to the CAB and have proved to be dedicated in their role as community supporter and peer educator.
- 6.1.4 **Mandela Day** - Contributed to TygerBear knit a teddy project

7. INTERNATIONAL VISITORS

5.1 Neurodevelopmental:

- 5.1.1 Dr Peter Torre from San Diego State University, PI on Audiology study
- 5.1.2 Dr Andre van der Kouwe from Massachusetts General Hosp (Harvard), Co-PI on Healthy Baby study
- 5.2 Cheryl Pikora, Medical monitor from Gilead, 16 Nov 2018
- 5.3 Philip Goulder – Oxford University

DESMOND TUTU TB CENTRE (DTTC)

Director: Prof AC Hesselning

DESMOND TUTU TB CENTRE ANNUAL REPORT: 2018



saam vorentoe · masiye phambili · forward together



Contents

Letter from the Director	3
DTTC Strategy House.....	4
Glossary of Terminology.....	4
Organogram	6
Research Updates	8
Research Focus Area One: Paediatric Tuberculosis	8
Therapeutic trials: prevention of drug-susceptible TB.....	9
Therapeutic trials: treatment of drug-susceptible TB.....	9
Therapeutic trials: prevention of MDR-TB	10
Therapeutic trials: treatment of MDR-TB	10
Lung health, diagnostic and biomarker studies	12
Evaluation of novel TB biomarkers in children	12
Epidemiological and operational research for pediatric TB.....	12
Research focus Area Two: Health Systems and Operational Research.....	13
Health Systems and Operational Research	13
Operational Research.....	13
Operational research focused on childhood TB.....	15
Hospital focused surveillance strategies for childhood TB	15
Research Focus Area Three: HIV Prevention Research	16
Crosscutting Research (Supporting all three research focus areas).....	17
Sociobehavioural Sciences	17
Epidemiological Modelling.....	20
DTTC Grant Awarded: 2018	21
Awards and Other Recognition.....	22
DTTC Academic meetings.....	22
TB Clinical Forum 2018	23
DTTC Academic Meetings 2018.....	23
Advocacy and Community Engagement.....	25
The DTTC Community Advisory Board (DTTC CAB).....	26
The HPTN 071 (PopART) CAB	27
HPTN 071 (PopART) Community Engagement (CE)	28
The HPTN 071 (PopART) P-ART-Y Adolescent Community Advisory Board (ACAB)	28
Conferences.....	29
Scientific Meetings, Workshops and events	33
Visitors at the DTTC during 2018	37
Employees	38
DTTC Governance	40
DTTC Executive Committee Roles and Responsibilities	40
Risk Management	41
Acknowledgements and Funders.....	42
Appendix I. Research outputs - publications	44

Appendix II: Students – Masters, PhD and Postdoctoral.....	52
Appendix III: Media interaction (television, video, radio, printed media).....	57

LETTER FROM THE DIRECTOR

The past year was exciting and challenging for our centre. Large trials like HPTN 071 (PopArt) have come to an end, resulting in much smaller staff component and reduced funding.

At the same time, we have become more efficient, more internally collaborative and our three “research pillars” in our centre have become more integrated. We have pursued new endeavours, notably in paediatric therapeutics and in adult HIV prevention trials.

We continue to build capacity at all levels and have had a record 6 PhD students graduate from our centre during 2018. There is now a strong cadre of young and mid-level career researchers who are not only supporting our scientific agenda, but are mentoring and supporting other researchers.

We have established new local, South African, African and global collaborations and continue to be the global leader in paediatric tuberculosis clinical research.

We have opened two new research sites to support TB and HIV prevention trials, and have grown in key core support areas including regulatory, data, laboratory, logistics and communications.

We are thankful for a highly productive year and look forward to going from strength to strength in 2019.



Professor Anneke C. Hesselning

Director: Desmond Tutu TB Centre


Distinguished Professor in Paediatrics and Child Health

SARcHi Chair in Paediatric Tuberculosis

DTTC STRATEGY HOUSE



Desmond Tutu TB Centre Strategy House



GLOSSARY OF TERMINOLOGY


ACTG	AIDS Clinical Trials Group
AE/AER/EAE	Adverse Event / Adverse Event Report / Expedited Adverse Event
AIDS	Acquired Immunodeficiency Syndrome
ART/ARV	Antiretroviral Therapy / Antiretroviral
BMC	BioMed Central
BMRC	British Medical Research Council
CAB/CAG	Community Advisory Board/Community Advisory Group
CD4	Cluster of Differentiation 4
CDC	US Centers for Disease Control and Prevention
CHIP	Community HIV Care Providers
CRS	Clinical Research Site
CTU	Clinical Trials Unit
CXR	Chest X-ray
DAIDS	Division of AIDS, NIAID
DFID	Department for International Development
DR-TB	Drug-Resistant Tuberculosis
DS-TB	Drug-Susceptible Tuberculosis/Drug-Sensitive Tuberculosis
DST	Drug Susceptibility Testing
EC	Ethics Committee
DTTC	Desmond Tutu TB Centre
EDCTP	The European & Developing Countries Clinical Trials Partnership
FAMCRU	Family Clinical Research Unit
FDA	Food and Drug Administration
FHI 360	Family Health International and Academy for Educational Development
FMHS	Faculty of Medicines and Health Science
HIV	Human Immunodeficiency Virus
HPTN	HIV Prevention Trials Network
HR	Human Resources
HREC	Health Research Ethics Committee
HTS	HIV Testing Services
IMPAACT	International Maternal Pediatric Adolescent AIDS Clinical Trials Group
IT	Information Technology
LAB	Laboratory
MA	Master of Arts
MCC	Medicines Control Council
MDR-TB	Multidrug-Resistant Tuberculosis
MPH	Master of Public Health
MRC	Medical Research Council
MS	Mass Spectrometry
MSF	Médecins sans Frontières

<i>M.tb</i>	<i>Mycobacterium tuberculosis</i>
NIAID	National Institute of Allergy and Infectious Diseases
NICHD	National Institute of Child Health and Human Development
NIH	National Institutes of Health
OR	Operational Research
ORAP	Operational Research Assistance Project
PC	Population Cohort
PEPFAR	President's Emergency Plan for AIDS Relief
PHC	Primary Health Care
PI	Principal Investigator
PK	Pharmacokinetics
PMTCT	Prevention of Mother To Child Transmission
RIF	Rifampicin
RGMO	Research grants management office
QA	Quality Assurance
SACEMA	South African Centre for Epidemiological Modelling & Analysis
STI	Sexually transmitted infections
SU	Stellenbosch University
TBTC	TB Trials Consortium
VMMC	Voluntary Male Medical Circumcision
ZAR	South African Rand (currency)


ORGANOGRAM

SCIENTIFIC FOCUS AREAS

DTTC DIRECTOR: PROF AC HESSELING



SUPPORT COMPONENT



DTTC TOTAL STAFF COMPONENT 152

RESEARCH UPDATES

Research Focus Area One: Paediatric Tuberculosis

The DTTC initially has established its reputation based on its strong track record of clinical research in paediatric tuberculosis (TB). The DTTC is now the global leader in therapeutics for the prevention and treatment of TB in children, especially in the context of drug-resistant TB.

This paediatric TB research programme at the DTTC is led by Anneke Hesselning, centre director, SARCHI Chair in Paediatric Tuberculosis and Distinguished Professor in Paediatrics and Child Health, Stellenbosch University. Key focus areas include 1) therapeutics for Drug Susceptible (DS) and Drug Resistant TB (DR-TB) in children (leads; Anthony Garcia-Prats, Megan Palmer), 2) preventive trial for TB in children (lead: Anneke Hesselning), 3) Lung health, diagnostics and biomarkers in children (lead: Elisabetta Walters, Marieke van der Zalm and Anne-Marie Demers), 4) underpinned by in-depth epidemiological and operational research (leads: Karen du Preez, Muhammad Osman). Major areas of interest specifically include the evaluation of novel therapeutic strategies for Multidrug resistant TB (MDR-TB) in children, where it is a global leader in its field and is generating seminal data on an ongoing basis. The DTTC officially opened its upgraded state of the art paediatric pharmacokinetics clinical research unit at Brooklyn Chest Hospital (medical director: Tony Garcia-Prat) in July 2016 (refer to highlights, 2016), where it has been working since 2011. This unit has been expanded twice since then, reflecting the urgent need for clinical research in this domain, with 9 trials for antituberculosis treatment (including novel drugs like delamanid and bedaquiline) currently ongoing.

During 2018, the paediatric group (n=84 personnel) has specifically actively pursued linking and collaborating with the Sociobehavioural science group at DTTC (lead: Graeme Hoddinott), and on high quality operational research. The group has also expanded to collaborations at the Tygerberg campus on the role of viral pathogens in TB disease pathogenesis in children (Professor Gert van Zijl, Medical Virology), antimicrobial resistance in children and the biome and Medical Microbiology (Professor Andrew Whitelaw) and at the Stellenbosch campus, including health economics (Professor Ronelle Burger) mathematical modelling (SACEMA, Dr. Alex Welte, Eduard Grebe and Juliet Pulham), and basic scientists including biochemists (Professor Jacky Snoep), to support its expanding research agenda.

Expanding national collaboration have included Shandukani (Dr. Lee Fairlie, WHRI), and PHRU (Professor Neil Martinson) and new international collaboration have included the Uppsala pharmacometrics modelling group and Professor Tony Hu, Arizona State University and Professor Bob Husson (Boston Children's). The DTTC is also increasingly collaborating with other African research groups including in Uganda, Zambia, Mozambique and Namibia. During 2018, one of the paediatric team clinicians, Dr Karen du Preez, has been selected and trained as an epidemiological TB program review consultant for the World Health Organization, strengthening our existing collaboration to support paediatric TB at both national and international level.

The DTTC paediatric group is a well-performing clinic site for the DAIDS-funded International Maternal, Paediatric, Adolescent AIDS Clinical Trials (IMPAACT) where it is currently conducting 5 IMPAACT TB trials and also for the US Centres for Disease Control (CDC) TB Clinical Trials Consortium (TBTC), where it leads Study 35, a TB prevention trial of rifapentine and isoniazid, in children.

The paediatric TB research group at the DTTC has been exceptionally productive during 2018. They have graduated 2 Master's degree and 2 PhD students, with 2 new PhD students registered, 1 postdoctoral fellow from Spain (Elise Lopez), and a BMRC-funded research fellow from Imperial College London, James Seddon (who has received an extraordinary appointment at the DTTC as Senior Researcher).

The group's research has resulted in >50 publications in international peer-reviewed journals (Appendix I), participation in several national and international TB treatment guideline meetings, including with WHO, and with the SA National DOH.

The group has had 3 major international grants awarded, and several local grants.

The group has embarked on new collaborations with Imperial College London, Rutgers University, BJMC, Pune, India and La Salle Medical Health Sciences Institute College of Medicine, De La Salle University Medical Center, the Philippines. The group has also developed new national partners in South Africa, and new collaborative partners in Africa (Uganda and Zambia).

The therapeutics group has been shaping the science and implementation of paediatric TB treatment trials through leadership in the National Institutes of Health (NIH) funded IMPAACT and the CDC TBTC trial consortia.

The DTTC paediatric group hosted its 12th International TB Training Course at Goudini very successfully, with 50 international participants. The DTTC paediatric group alone contributed 13 presentations to the 49th annual International Union against Tuberculosis and Lung Disease conference in The Hague, with 7 oral presentations, including a later breaker session.

Therapeutic trials: prevention of drug-susceptible TB

IMPAACT P1078: This IMPAACT-funded network multisite randomized controlled double blinded trial evaluates the safety and tolerability of isoniazid ante- vs. post-partum in HIV- infected pregnant women. DTTC was the last site to join this trial as a newly funded IMPAACT site, in 2015. Twelve women were enrolled and follow-up visits completed July 2017. The overall trial was closed to accrual in 2016 and follow-up (740 maternal-infant pairs) was completed in September 2017 and the data is being disseminated.

TBTC Study 35: This multisite study, funded by the CDC TBTC (PI: Anneke Hesselning,) will evaluate the optimal dosing and safety of the novel 12 dose combination regimen of rifapentine and isoniazid, shown to be efficacious in prevention of TB in adults and children. The protocol has been in development for 4 years and has been finalized and approved by the Medicines Control Council (MCC) and local ethics committees. A novel fixed dose score paediatric formulation has been developed for the trial. The database is in development and the trial is expected to open in 2019 under an FDA IND.

Therapeutic trials: treatment of drug-susceptible TB

SHINE: (Site PI: Anneke Hesselning). The trial PI and sponsor is the Medical Research Council Clinical Trials Unit (MRC CTU) at University College London (PI: Diane Gibb), with the funders: BMRC, Wellcome Trust, DFID. This multi-site open-label international trial is the first ever to evaluate the efficacy and safety of 4 vs. the standard 6-month WHO-recommended regimen for treatment shortening of non-severe DS-TB in children. Recruitment was completed in July 2018, with 1204 children enrolled in South Africa, Zambia, Uganda and India. DTTC enrolled a total of 315 children. Nested Pharmacokinetics (PK) sampling was completed in 31 children. This trial, if successful, will have a major impact on the current long treatment regimens for paediatric TB, which is usually paucibacillary (smear negative). DTTC has led nested qualitative work to evaluate the acceptability and palatability of the new WHO-endorsed fixed dose combination formula used in the trial. DTTC is also coordinating the process for central expert review of the Chest X-rays (CXR) taken on the SHINE trial – an undertaking which will involve review of approximately 3000 CXR images and will form an important part of the final adjudication of certainty of TB diagnosis and classification of outcomes on the trial. The evaluation of baseline CXRs by central experts is due to be completed in 2019.

Project P1026s: Pharmacokinetic properties of antiretroviral and related drugs during pregnancy and postpartum (Site PI: Anneke Hesselning). The Phase IV, observational Pharmacokinetic (PK) study started in November 2017. The primary outcome is to describe the pharmacokinetic parameters during pregnancy of selected ARV drugs currently used in the clinical care of 25 HIV-infected pregnant women, and to compare these parameters to a) historical pharmacokinetic data from non-pregnant women, and b) postpartum pharmacokinetic data from the same women in the study cohorts. In 2018, one of the study clinicians addressed the clinicians at Brooklyn Chest Hospital and gave an overview of the studies currently run at the unit. This oral presentation was held at the clinicians' weekly clinical meeting at the hospital. The study clinician took this opportunity to meet

the newly appointed CEO of the hospital, Waheeda Sonnie, who showed her interest in the unit's work. To date, 8 women have enrolled in the study at the DTTC in the second-line TB drug arm of the protocol. This will provide critically needed information on the pharmacokinetics in pregnant women of medications used for MDR-TB. A follow-up study to 1026s, which will include first and second-line TB drug arms, is in development.

IMPAACT P1101: (Site PI: Anneke Hesselning) this IMPAACT-funded multisite network phase I/II trial is evaluating the PK and safety of raltegravir, a new integrase inhibitor, in combination with first-line TB treatment, including rifampicin. Children must be HIV-infected, on TB treatment but not currently on ARVs. This patient group has been difficult to enroll in Cape Town, given good HIV prevention and treatment services in children. Three participants have been enrolled to date and interim data analysis is ongoing for the overall trial (5 South African sites). A new cohort of children <2 years of age has been opened for the trial.

OptiRif Kids: (PI Anneke Hesselning) this phase I/II open label multi-cohort dose escalation study to evaluate the pharmacokinetics and safety of increased doses of rifampicin in HIV-negative children with TB disease is funded by TB Alliance. The study utilizes a dose escalation approach in a maximum of 5 dosing cohorts of 20 children aged 0-12 years in each cohort. This trial includes collaboration with the University of Cape Town Clinical Pharmacology Division, Radboud University, Nijmegen, and Uppsala University, Sweden as well as with the Shandukani Research Site, Wits Health Research Institute. This study aims to establish the dose of RMP in children required to match RMP exposure targets in adults, using a 35-40 mg/kg dose, over 15 days. In 2018, Cohorts 1 and 2 closed for enrolment (cohort 2 since July 2018; cohort 1 since November 2018). OptiRif Kids will pave the way for the design and evaluation of shorter course regimens for DS-TB in children using higher doses of rifampicin. The third and final cohort opened for enrolment in Q4 of 2018, and completion of this cohort and closing of the study, with final analyses, is expected in 2019.

Therapeutic trials: prevention of MDR-TB

TB-CHAMP (MDR-TB preventive therapy trial): (DTTC PI: Hesselning, Schaaf, Seddon) This is the first ever randomized phase III placebo-controlled trial to assess the efficacy of levofloxacin preventive therapy vs. placebo in child contacts of multidrug-resistant (MDR) TB. The sample size is approximately 1500 children 0-5 years of age. The trial, led by DTTC, is funded by the BMRC/Wellcome Trust/DFID and includes 3 South African sites, including Shandukani (WHRI, Johannesburg, Dr. Lee Fairlie), PHRU Matlosana, Klerksdorp (Prof. Neil Martinson) and DTTC. A formal PK lead-in study was completed in 2017 looking at bio-availability of a novel scored dispersible levofloxacin formulation (to be used in the main trial) in 24 children. This study showed that the paediatric levofloxacin formulation was well tolerated, acceptable, safe, and had adequate exposures in children < 5 years of age. Pharmacokinetic and acceptability data from this study have been recently published in two journal articles. The main trial opened to accrual in Q4 2017 at DTTC, and in Q1 2018 at the other 2 sites. As of 31 January 2019, 393 children had been screened and 3015 enrolled in the study. Additional grant funding has been requested from the The European & Developing Countries Clinical Trials Partnership (EDCTP) and other funders. This trial is likely to have a considerable impact on global and national guidelines and on clinical care.

Therapeutic trials: treatment of MDR-TB

Otuska 232/233: (PI Anthony Garcia-Prats): Along with a site in the Philippines, the DTTC is implementing this industry sponsor-funded (Otuska, Japan) Phase 1 (232) and Phase 2 (233) trials which seek to characterize the pharmacokinetics and safety of delamanid in children with MDR-TB. New drugs are desperately needed for the treatment of children with MDR-TB, and these trials are critical for ensuring timely access to this important new medication. In this age de-escalation trials, all age groups (0 to 17 years) have fully enrolled for both studies. Data from these groups informed WHO guidance in 2016 for the use of delamanid in children 6-17 years of age with MDR-TB, and in 2018 for Group 3 (ages 3-6 years). The 232 study is now closed with final data analysis ongoing, and

long-term follow-up of Group 4 (0 to 2 years) completed at the end of 2018, with the final analysis now ongoing.

MDR PK 1: (PI Anneke Hesseling) This NIH-funded (R01 grant) was completed during 2016. This study of the pharmacokinetics and safety of routine doses of existing second-line anti-TB drugs in HIV-infected and uninfected children, was the first study of its kind, in some cases generating some of the only data on the pharmacokinetics and safety of these medications in children with TB. Over 4 years 312 children aged 0-15 years were enrolled and followed long-term for safety and treatment outcome. This study has already resulted in seminal data on the use of levofloxacin, ofloxacin, moxifloxacin, amikacin, high dose isoniazid, and the effect of MDR-TB treatment on the pharmacokinetics of ARVs commonly used in children. Analysis of para-aminosalicylic acid (PAS), ethionamide, terizidone, clofazimine and linezolid are ongoing. Long-term outcome and toxicity data are being analyzed currently. These data are informing international guidance on the dosing of these medications in children. The platform generated from this study has supported 5 PhD students and 6 master's degree students, to date.

MDR PK 2: (PI Anthony Garcia-Prats) Building on the data, experience, and clinical platform of MDR PK1, this NIH-funded (R01 grant) seeks to evaluate the pharmacokinetics and safety of model-optimized doses of the key second-line anti-TB medications levofloxacin, moxifloxacin, and linezolid in children treated for MDR-TB. The study will also characterize the acceptability and palatability of different dosing strategies and will evaluate the effect of formulation manipulation on pharmacokinetics in children. The total sample size is n= 100; to date, 84 children have been enrolled through the end of 2018, and accrual is now closed with long-term follow-up expected to be completed in 2019. Data from the study on linezolid and moxifloxacin pharmacokinetics was shared with the World Health Organisation (WHO) in 2018 and informed revised dosing guidance for these medications. Multiple analyses on the pharmacokinetics, safety and acceptability of linezolid, moxifloxacin and levofloxacin, as well as analysis of treatment outcomes are planned in 2019.

IMPAACT P1108: (PIs Anneke Hesseling, Simon Schaaf) This NIH-funded IMPAACT network phase I/II trial to determine the optimal and safe dose of bedaquiline in HIV-infected and uninfected children with MDR-TB has been in development for 4 years. The protocol was completely developed and received MCC approval in August 2016. Five international sites, including DTTC, 2 other South African sites, one in India and one in Haiti, opened up to accrual on the 1st of September 2017. Bedaquiline has become a critically important treatment option for adults with MDR-TB, with extensive roll-out of the drug within the routine TB programme setting in South Africa and many other countries; however the lack of data in children has prevented paediatric access. This trial will provide desperately needed data on bedaquiline in both HIV-infected and –uninfected children with MDR-TB in order to ensure paediatric access to this new TB medication. The first participant was enrolled on the 21 September 2017. The first 15 children have been enrolled and the first formal interim analysis has been completed. Interim data was shared with the WHO and informed new dosing recommendations for bedaquiline in children. It is expected that the two youngest cohorts (0 to 2 years, 2 to 5 years) will open in early 2019.

Bedaquiline CRUSH Study (TASK-002): (Protocol Co-Chair – Anthony Garcia-Prats). This study, funded by National Institute of Child Health and Human Development (NICHD) through the IMPAACT network was a randomized, open label, crossover, bioequivalence study to assess the bioavailability of bedaquiline given as whole tablets or suspended (dissolved) in water. The study was conceived in order to facilitate the use of the bedaquiline whole tablets for use in paediatric clinical trials and eventually in routine care, as the paediatric formulation is not available now or expected to become available for some time. Twenty-four healthy male and female volunteers were randomly assigned 1:1 to one of 2 treatment sequences in order to receive either first a single dose of the crushed form of bedaquiline, as the experimental, and secondly a single dose of the whole tablet as the approved dosing form, or vice versa. The study was implemented at TASK Applied Science in Cape Town, and analysis completed in 2017 (E Svensson, Uppsala University). Results, which showed that bedaquiline administered dissolved in water was bioequivalent to whole tablets, were published in

2018 and will inform the practical use of the adult formulation in children in the field, where access to the paediatric formulation is expected to be limited for some time.

Lung health, diagnostic and biomarker studies

(PIs Elisabetta Walters, Marieke van der Zalm and Anne-Marie Demers)

The diagnostic platform nested in the DTTC paediatric programme focuses on improving the diagnosis of TB in children. TB in children is mostly clinically diagnosed as the collection of high-quality sputum samples is resource-intensive and relatively invasive and available laboratory methods are insufficiently sensitive to detect the low organism concentration typically found in samples from children. However, young children are at risk of delayed diagnosis due to poor diagnostic tools, resulting in increased risk of morbidity and mortality from advanced TB. The overall aim of the diagnostic platform is to improve the detection of TB in children using comprehensive strategies that are feasible, child-friendly and adequately sensitive to detect paucibacillary disease, focusing especially on young children.

UMOYA (“breathe”). Intra-thoracic tuberculosis in children: moving towards better diagnosis and improved lung health: (PIs Liz Walters, Marieke van der Zalm). A diagnostic cohort study that builds on a previous diagnostic study led by Liz Walters and has leveraged funding from NIH, Thrasher Foundation, EDCTP and the South African MRC. UMOYA started recruitment November 2017 and currently has 102 children enrolled. The aim is to enroll 300 children with suspected TB and 100 healthy sibling controls from Tygerberg hospital and Karl Bremer hospital. The study will continue to evaluate improved diagnostic strategies for paediatric TB, including novel laboratory techniques for both molecular and culture-based diagnosis on respiratory and stool specimens. It will support ongoing evaluation of blood and urine biomarker work. In addition, the study will continue work to evaluate the interaction between viral and bacterial co-pathogens with TB, and plans to assess and monitor lung function longitudinally in all children

Evaluation of novel TB biomarkers in children

Study 1. Urine proteomics: This project aims to identify host-derived urine proteins that are differentially expressed in children with TB compared to children with non-TB illness. The project is in collaboration with US partners Robert Husson and Hanno Steen from Boston Children’s Hospital, USA. This year, the focus of the project has been to optimise the LC-MS/MS platform to achieve a high detection of proteins in urine samples. This is done in the Steen laboratory at Boston Children’s Hospital, Harvard University. Data analysis will include both traditional logistic regression approaches (lead by Harvard University) as well as bio-informatics methods (lead jointly by Harvard and Stellenbosch Universities). A doctoral student, Ashley Ehlers, under the supervision of Prof D Tabb from SU’s Division of Molecular Biology and Human Genetics, has been awarded a scholarship by Boston Children’s Hospital, to work on this project.

Study 2. Serum bio-signatures. This project aims to identify pathogen-derived serum antigen peptides that are differentially expressed in children with TB compared to children with non-TB illness, using a novel NanoShell-MS assay. The project is in collaboration with US partner Tony Hu from Arizona State University.

Study 3. TB lipoprotein biomarkers. This exploratory study aims to identify whether TB lipoprotein is a useful diagnostic biomarker of active TB disease in children. Results of an initial analysis are in progress. TB Lipoprotein (TLP) is a specific mycobacterial modification of low density lipoprotein (LDL), a host biomolecule.

Epidemiological and operational research for pediatric TB

Please refer to [Research focus Area Two: Health Systems and Operational Research](#) for updates of pediatric focused epidemiological and operational research studies.

Research focus Area Two: Health Systems and Operational Research

The aim of the research in this pillar is to help improve TB and HIV care by building an evidence base for effective programme implementation. Operational research (OR) focuses on identifying gaps in health programme quality, efficiency and effectiveness, evaluating factors that contribute to these, and testing interventions to improve outputs and outcomes.

This research focus area also include epidemiological and routine data analyses, modelling, and health system strengthening research, all contributing to the overall aim of generating evidence to strengthen program implementation. Outputs for 2018 are listed under the following headings: Health systems Research and Operational Research (including TB mortality and childhood TB as specialized focused areas).

Health Systems and Operational Research

LINKEDin: reducing initial loss to follow up among tuberculosis patients: (PIs: Anneke Hesseling and Muhammad Osman). This study is funded by the Bill and Melinda Gates Foundation and will be implemented in 2019. Individuals diagnosed with tuberculosis (TB), but who are lost to follow up before initiation of TB treatment and/or TB notification are referred to as “initial loss to follow up” (ILTFU). This study aims to: 1) demonstrate the impact of an automated notification system of TB patients in hospitals on increasing the number of notified TB cases; and 2) demonstrate the impact of the implementation of an automated alert-and-response TB patient management system on increasing the proportion of TB patients who are linked to TB services and who initiate treatment at different levels of health care. The study will be implemented in 6 hospitals and 31 primary health care facilities in 3 provinces of South Africa; Western Cape (WC), Gauteng (GP) and Kwa-Zulu Natal (KZN). The study will include all laboratory-diagnosed TB patients in the identified study sites as well as clinically diagnosed TB patients in the WC. Using a before/after design, the study will measure the proportion of TB patients who are ILTFU at baseline and again after the 12th month, following the implementation of the study interventions. Between July and December 2018, the study received ethics approval with the Stellenbosch University Health Research Ethics Committee (HREC) and approvals from the relevant health departments/authorities. Numerous stakeholder engagement meetings were held to introduce the study and get buy-in at all levels. Interviews were held for key staff. A baseline data collection tool was designed.

Operational Research

Evaluating 10 years of TB control in South Africa: (PIs: A.C. Hesseling/Muhammad Osman). Routine TB surveillance data have been under-utilised in identifying and understanding programme weaknesses and finding ways to address these. The socio-economic determinants that may be contributing to poor TB control have not been adequately evaluated. As South Africa scales up TB control efforts to achieve the even more ambitious “End TB Strategy” goals, a more data-driven approach to TB control efforts is required. This study aims to undertake a comprehensive, in-depth analysis of TB control in South Africa to review epidemiological trends from 2004 to 2018 and to identify achievements and programme gaps where intervention is required. This project is not funded and is being implemented in collaboration with National Department of Health.

Abstracts presented at the 49th Union World Conference on Lung Health in The Hague in October 2018

1. Trends in the South African tuberculosis epidemic with scale up of TB-HIV integration services (poster) (Muhammad Osman, Karen du Preez, Rory Dunbar, Alex Welte, Pren Naidoo, Anneke C. Hesseling). This poster highlighted HIV testing and ART coverage in SA have improved substantially over 10 years. The burden of TB amongst HIV-infected individuals is declining but remains substantially greater than among HIV uninfected. The overall declining trend in the TB epidemic appears less significant among the HIV-uninfected population.

2. Mortality amongst HIV-positive female tuberculosis patients in South Africa (short oral) (MM Claassens, C van Schalkwyk, R Dunbar, M Osman, P Naidoo, M Borgdorff). This short oral presentation focused on data between 2009 and 2013. It demonstrated a substantial decline of mortality in HIV-positive TB patients, while among HIV-negative TB patients, mortality was stable. Limitation regarding the time of ART initiation, CD4 count or ART adherence were recognized and updated analyses including data through to 2017 is in progress.
3. Ten years of routine paediatric TB surveillance data in South Africa - high disease burden and poor treatment outcomes (oral) (K Du Preez, M Osman, P Naidoo, S Dlamini, AC Hesseling). This oral presentation showed the significant number of children treated for TB and reported in ETR.net in South Africa. The proportion of children overall (11-13%), and proportion of these <5 years of age (62%) are consistent with that expected in high burden TB settings. Documentation of HIV testing has improved over time but the pre-treatment microbiological confirmation of TB disease remains low (9%). Ongoing analysis is exploring age, TB disease spectrum, HIV co-infection and treatment and reasons for poor treatment outcomes in children.

Operational Research Assistance Program: The overall aim of ORAP is to undertake operational research as an integral component of health programmes in South Africa to contribute to improved quality and performance of the health system.

In November 2016, a new miniature version of ORAP was implemented in the Western Cape. Participants (5 from health services) have embarked on an experiential learning course to develop 3 independent study protocols for research to be undertaken. Five mentors from DTTC are supporting the trainees through protocol development, study implementation and publication of their findings. All 3 projects have completed the mentored protocol development stage and were approved for implementation by the Stellenbosch University HREC.

1. Comparing early treatment outcomes in multidrug resistant (MDR) tuberculosis (TB) patients treated with conventional MDR-TB regimens is being implemented by Dr L Naidoo and Dr D Da Costa and supervised by M Osman and A Garcia-Prats. Data collection and capture is complete and 177 records are in the process of data cleaning before analysis. Abstracts were presented at the South African TB Conference in Durban in June 2018 and the 49th Union World Conference on Lung Health in The Hague in October 2018.
2. Identifying risk factors associated with unfavourable treatment outcomes amongst patients treated for Isoniazid mono-resistant TB in Cape Town, South Africa is being implemented by Dr K Joseph and Dr F Solomon-Da Costa supervised by K du Preez. Data has been received on 370 patients and preliminary analysis is in progress. An abstract was presented at the 49th Union World Conference on Lung Health in The Hague in October 2018.
3. Motivations For, Anxieties And Preferences (MAP) About Transitioning To Community-Based Art Adherence Clubs (CAC) Among Patients Attending Facility-Based Art Adherence Clubs is being implemented by Dr R Mabezue and supervised by R Dunbar and M Osman. Data collection is in progress and over 200 participants have been consented and interviewed.

Operational Research focused on TB mortality

Former TB patients as a high-risk group for TB-associated morbidity and mortality in high-incidence communities in Cape Town – a pilot study (PIs: Florian Marx and Muhammad Osman). A high risk of TB, chronic lung disease and mortality have been reported among people with a history of previous TB treatment, but data from high-incidence settings remain limited. This study aims to locate adults who had successfully completed TB treatment in the past five years, and to characterize general morbidity and mortality. Routine electronic TB treatment register data was used to randomly select 256 adults (≥18 years) who successfully completed pulmonary TB treatment between 2013 and 2017. Household visits were conducted in a high-incidence community in suburban Cape Town to locate and survey former TB patients. Individuals who could produce sputum were bacteriologically

investigated for TB. Household interviews and vital registration data were used to estimate mortality among patients who could not be traced.

We have interviewed 51 former TB patients and 52% (19/36) were living with HIV. Approximately half had self-reported symptoms indicative of chronic lung disease and of 28 participants who provided a sputum sample, one (3.6%) had culture-positive TB and another two reported currently being on re-treated for TB treatment, providing 3/51 prevalent cases of TB. Among 256 former TB patients, there were 15 (5.9%) confirmed deaths were confirmed (5.9%) with a median time of 1.43 (IQR: 0.48-2.16) years between the successful completion of the previous TB treatment episode, and death. The mortality rate among former TB patients was 2.7 deaths (95% CI: 2.5-3.0) per 100 person years with a standardized mortality ratio of 4.1 (95% CI: 3.6-4.7) compared to the general local population.

Our preliminary results are consistent with a high prevalence of respiratory disease including prevalent TB among former TB patients, and higher mortality.

The abstract: *Finding former tuberculosis patients - a high-risk group for tuberculosis-associated morbidity and mortality in Cape Town, South Africa: A pilot study*, was published as part of SA MRC 12th annual Early Career Scientist Conference and presented as a poster at the SACEMA Research days 2018.

This study was funded through a research grant (R64 000) provided by the Günther Labes Foundation and the Oskar Helene Heim Foundation (Berlin, Germany) to FMM and an Emerging Research Award (R35 000) provided by DST-NRF South Africa Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University to MO.

Retrospective descriptive study of sudden and unexpected deaths related to TB in Cape Town: (PI: Muhammad Osman). Undiagnosed TB as a final or contributing cause of death is difficult to quantify but has been estimated through post mortem studies. In a low TB incidence setting (Ireland), only 15 cases of TB were diagnosed in a series of 4930 autopsies while in India, a high TB burden setting, 8.7% of autopsy cases were diagnosed with active tuberculosis and 60% of these were not diagnosed before death. The under ascertainment of both TB and TB mortality in a high burden TB/HIV setting warrants further evaluation. We aimed to estimate TB disease as a final or contributory cause of death among sudden unexpected death in adults and children in Cape Town. We have undertaken a collaborative project with SU Forensic Pathology Services (FPS) and have retrieved and captured data on 719 cases of sudden and unexpected death in 2016. 79 records are expected to be complete in Q1 2019. This study has been supported by Prof Anneke Hesseling through SA NRF SARChI funding.

Operational research focused on childhood TB

The aims of this research area are to firstly evaluate and identify gaps in the current health systems preventing and providing care to children with TB, and secondly to pilot and measure the impact of innovative solutions through rigorous implementation science methodology.

This research area is led by Dr Karen du Preez, and current projects focusses on optimizing pediatric TB surveillance strategies and strengthening prevention and routine data for children with TB, including HIV co-infected children.

Hospital focused surveillance strategies for childhood TB

The results of three studies related to hospital surveillance for childhood TB were published in 2018 – two focused on TB surveillance at tertiary hospital level, specifically children with TB meningitis (TBM) and spinal TB, and the other focused on TB surveillance at a district level hospital.

1. The impact of BCG shortages on the burden of childhood TBM (*Published in The Lancet Global Health, January 2019, see Appendix I*)

During 2017, we have observed a substantial increase in the number of children admitted for diagnosis or management of TBM or tuberculomas to the paediatric neurology ward at Tyberberg Hospital. Birth cohort analyses of admitted children <2 years of age with TBM/tuberculomas found

nearly three times as many children born in 2015 compared to the mean number of children born in 2012 to 2014. We hypothesize that this increase is related to the global BCG shortages, which has impacted substantially on the number of BCG available during 2015 in the Western Cape Province.

2. The burden and trend of spinal TB in children (*Published Epidemiology and Infection, 2018, see Appendix I*)

This retrospective study, led by Dr Theresa Mann from the Division of Orthopedic Surgery, assessed the overall burden and trend in spinal TB at tertiary hospitals in the Western Cape Province during 2012-2015. A total of 74 children and 319 adults were identified. The study found a substantial burden of spinal TB cases with a high proportion of children presenting with severe disease and requiring corrective spinal surgery. Although spinal TB affects a relatively small proportion of TB cases, the burden on public health services remains substantial in high TB burden settings, and earlier diagnosis particularly for child cases are needed.

3. The burden, spectrum and outcomes of childhood TB disease at a district level hospital (*Published IJTL, 2018. See Appendix I*)

This retrospective cohort study aimed to characterize the burden, spectrum and TB treatment outcomes of children managed at a district level hospital in Cape Town. Nearly 100 children were managed at the district level hospital over a 7 month period in 2014. The majority (85%) were very young (≤ 2 years), a third (34%) were malnourished and a fifth (19%) had HIV co-infection. Although 96% of children successfully continued care after hospital discharge, favorable TB treatment outcomes (cured/treatment completed) were only recorded for 78%. This study found a substantial burden of paediatric TB are managed at district hospital-level, with patients often being very young and frequently presenting with comorbid diseases. TB prevention opportunities and treatment outcomes could be further improved.

Routine TB treatment surveillance at national level:

Within the study, “**Evaluating 10 years of TB control in South Africa**”, multiple analyses have been completed and are planned to specifically look at the TB epidemic in children in South Africa over time. One abstract was accepted for an oral presentation at the 49th Union World Conference on Lung Health in 2018: Ten years of routine paediatric TB surveillance data in South Africa - high disease burden and poor treatment outcomes (oral) (K Du Preez, M Osman, P Naidoo, S Dlamini, AC Hesselning). Main findings of the abstract have been detailed earlier in this section.

Research Focus Area Three: HIV Prevention Research

The DTTC has made great strides in the field of HIV prevention with two studies as part of the HIV Prevention Trials Network (HPTN) conducted during 2018. While the HPTN 071 (PopART) study concluded in 2018, the HPTN 084 (Life) was initiated early in the year.

HPTN 071 (PopART): (Lead: Nulda Beyers, Peter Bock). The HPTN 071 or PopART study is a cluster-randomized trial which aimed to determine the impact of two community-level combination prevention packages, both of which included universal HIV testing and intensified provision of HIV/ART care, on population-level HIV incidence. The study was conducted in 9 communities in South Africa and 12 in Zambia. Communities were randomized to arms A (full intervention prevention package plus ART regardless CD4 count), B (full intervention prevention package plus ART according to government guidelines) or C (standard of care). Following changes to ART guidelines during the study, Arm A and B both offered ART regardless of CD4 count from Oct 2016 onwards. Despite this change the study was still well powered to evaluate the primary outcome, HIV incidence. At each of the arm A and B sites, interventions were delivered to the entire community by a cadre of Community HIV-care providers (CHiPs) with referrals to government Primary Health Care (PHC) clinics. CHiPs provided clients with condoms, screen and refer relevant clients to government clinics for HIV, TB and STI treatment and voluntary male medical circumcision (VMMC). Primary outcomes were measured in a randomly selected individual level cohort of approximately 2000 individuals in

each community (including the Arm C communities) over 36 months referred to as the population cohort (PC).

Field work for PopART began in January 2014 and finished in June 2018. For the CHiPs intervention, by the end of 2017 152,454 households had been visited in South Africa and Zambia and 168,556 individuals tested for HIV. At the end of PC follow up, in June 2018, more than 38 000 participants had completed the final round of the PC follow up PC36. The PopART data were revealed in Seattle in December 2018 where the team completed the primary analysis comparing HIV incidence across study arms. The primary results will be presented at CROI in March 2019. Dissemination of primary results to key stakeholders including study communities will be completed in March 2019.

HPTN 084 (Life) trial: (PI: Dr PA Bock) The HPTN 084: A Phase 3 Double Blind Safety and Efficacy Study evaluating Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women. The primary end point is HIV incidence. Participants will be followed up for 3 to 4 years. Overall the study aims to enroll 3,200 participants across the 20 sites (approximately 160 participants per site).

The Kuilsriver site office was newly established from January 2018. DAIDS site assessment visit was completed in March 2018, the DAIDS laboratory assessment in April 2018 and the site was activated by DAIDS & HPTN by August 2018. The team enrolled their first participant in September 2018 and by end December 2018 had enrolled a total of 16 participants. The team also successfully completed a further audit in December 2018. The focus in the first two quarters of 2019 will be scale up community activities and recruitment.

Crosscutting Research (Supporting all three research focus areas)

Sociobehavioural Sciences

The Sociobehavioural science team have successfully implemented a broad range of data collection and analysis activities as components of the wider DTTC research portfolio and contributed to all three research focus areas. These activities ranged in scope from innovative ways to assess children's experiences of TB treatment palatability (Project Masterchef) to an exploratory analysis of the potential of technology for TB treatment adherence support (TB PAKS). Across activities, all data collection, management, processing and preparation for analysis is standardised and managed by a dedicated data quality team. In 2018, the team transcribed approximately 780 hours of recorded interview/discussion data and translated over 3000 pages of these transcripts from Xhosa or Afrikaans to English. Further, the team again proved to be highly innovative in designing and refining novel methods to answer research questions with greater sophistication. A priority for 2019/2020 is to support staff in post-graduate studies, and in doing so, building on the culture of academic learning and publication.

Sociobehavioural Science and Paediatric TB

SHINE: In-depth acceptability interviews and observations with caregivers and children about a novel, child-friendly formulation of a fixed-dose combination of first-line TB treatment to be used in the SHINE trial. The SHINE trial offers participants a fixed-dose combination child-friendly formulation of first-line TB treatment. This set of 20 days of semi-structured observations and discussions with 16 caregiver/child dyads informs the acceptability of this formulation for use and clarifies potential misunderstandings by participants about administration of the treatment on trial. A manuscript reporting findings has been developed with submission for publication anticipated in early 2019.

TB-CHAMP: In-depth acceptability interviews and observations with caregivers and children about novel formulation of levofloxacin to be used in the TB-CHAMP trial: The TB-CHAMP trial uses a novel, child-friendly formulation of levofloxacin. This set of 30 days of semi-structured observations and discussions with 17 caregiver/child dyads informs the acceptability of this formulation for use and clarifies potential misunderstandings by participants about administration of the treatment on trial.

Data processing is ongoing, and a manuscript is in preparation for submission in 2019 as part of Dillon Wademan's PhD.

Impact of MDR-TB on children: Exploring caregivers' and health workers' perceptions on the effects of caregiver-child separation during long-term hospitalisation for MDR-TB in the Western Cape: A qualitative study. This qualitative project, conducted by Kyla Meyerson in completion of her MA in Psychology (SUN), addressed the third objective of MDR-PK II namely, to characterise the acceptability of DR-TB treatment. MDR-TB treatment requires extended hospitalisation which currently entails caregiver-child separation. Caregiver-child separation has been shown to cause behavioural and emotional problems in children. We explored caregivers' and health workers' perceptions of the effects of caregiver-child separation during long-term hospitalisation for MDR-TB treatment. We conducted 19 semi-structured, in-depth interviews with caregivers and health workers of children (aged zero to five years) who were receiving hospital-based treatment for MDR-TB. A thematic analysis was conducted to organise and interpret the data. Three major themes were identified: (i) MDR-TB treatment was a traumatic experience; (ii) Children's behavioural and emotional states during MDR-TB treatment included excessive crying, aggression, hyperactivity, and withdrawal; (iii) Caregivers' and health workers' behavioural and emotional management strategies included deception, threat, and prioritisation of biomedical health over psychological health. Children's, caregivers', and health workers' problems that emerged during MDR-TB treatment most likely result from a complex interplay between various factors; including precipitating factors of MDR-TB treatment and caregiver-child separation, and predisposing factors of poverty and exposure to violence.

MDR-PK - Masterchef: To understand children's and caregivers' experiences of acceptability (including palatability) of the key second-line tuberculosis drugs, within the MDR-PK II project. Over a four-week period, we conducted interviews with 16 paediatric participants (and where appropriate their caregivers). Our research consisted of a semi-structured interview schedule and various participatory research activities. In the latter, we asked children to rate various tastes, forms of medicine (for example, tablet, capsule, syrup, chewable pill and injection) and colours and forms of medicine packaging in an attempt to design the ideal MDR-TB medication. We wrote a report on the preliminary findings and disseminated these preliminary findings to DTTC health workers at Brooklyn Chest Hospital. Data has been processed to prepare for an in-depth analysis.

Lung health in Africa across the life course (LuLi): The purpose of this project is to describe the prevalence and clinical characteristics of post-tuberculosis lung disease among former tuberculosis patients in Cape Town, South Africa. The project utilised a multi-disciplinary approach, forming a collaboration between the Departments of Physiotherapy, Pulmonology and Paediatrics and Childhealth (DTTC). Our team at DTTC were involved in the recruitment and implementation of the project in one community in the Western Cape of South Africa. A total of 45 participants were recruited to the project. Participants underwent several physiological and lung function tests, as well as completing a few psycho-social surveys to provide a holistic overview of the participants' health. The project aims to define the burden of symptoms and functional deficits in non-healthcare seeking patients who have completed TB treatment in order to build a platform to address potential interventions for those affected.

TB PAKS: Paediatric Adherence, Knowledge and Support: The TB PAKS project aims to develop and refine an 'app' suitable for smartphones to be used by children (and their caregivers) who are on TB prophylaxis or treatment in order to improve their experience by supporting learning about TB, provide adherence reminders/virtual rewards, and facilitate management of the social impact of TB such as disclosure. Preliminary work on the as-of-yet unfunded project began in 2018, with the Sociobehavioural team hosting two students whose work is helping inform development of the app. Ava Archey, high-school student and daughter of HIV/TB researcher Kelly Dooley (honourary associate professor, Department of Paediatrics and Child Health), visited the DTTC for two weeks during her summer break to develop a prototype of a TB mobile application (app) for children following a literature review of TB disease and technology. She presented the prototype to

stakeholders at the DTTC. Rachel Morse, an undergraduate student from King's College London, interned at the Centre for two months as part of a larger collaboration between Stellenbosch's Faculty of Medicine and Health Sciences and their Department of Global Health and Social Medicine. In her dissertation, which drew on qualitative data and observations collected across various TB projects at the Centre, she explored factors that influence children's adherence to TB treatment and considered ways in which a mobile 'app' could be used to address them. Both these outputs are providing an important foundation for the project.

Sociobehavioural Science and Operational Research

TB-TREATS: Tuberculosis Reduction through expanded antiretroviral therapy and TB screening:

The overall aim of this project is to measure the impact of a combined TB/HIV intervention of population level screening for TB, combined with universal testing and treatment (UTT) for HIV on TB incidence, prevalence and incidence of TB infection. The study is a collaboration between Zambart in Zambia, Health Systems Trust in South Africa, the London School of Hygiene and Tropical Medicine, Imperial College and the University of Sheffield in the UK and KNCV in the Netherlands. Given that the TREATS study is being conducted in the same communities as the HPTN 071 (PopART) in South Africa and Zambia, the Sociobehavioural Sciences Team at the Desmond Tutu TB Centre was contracted by the Health Systems Trust to conduct nested qualitative research as part of the formative work towards the TB-TREATS study. The first part of this research was conducted between October and December 2018. We conducted four in-depth interviews with key TB staff to describe their experience with TB service delivery and the role of other stakeholders (n=1 in each arm A and C site). Further research with TB patients is underway and will contribute to a broader understanding of the impact of TB in people's lives in South Africa.

Sociobehavioural Science and HIV Prevention Research

HPTN 071a (Stigma Ancillary Study) - Health Worker Open Cohort Survey: The Stigma Ancillary Study was a sub-study to the PopART (HPTN071) trial. The stigma study is a mixed method study that nests enquiry about HIV stigma across the PopART study. In particular, it the study examines how health care worker knowledge, attitudes, and experiences of delivering HIV care are influenced by, and influence, the delivery and uptake of the PopART intervention. The quantitative component of the study involved a self-administered questionnaire offered to all health care workers (including CHiPs) working in PopART study communities. Data collection was done in the three waves in 2014, 2015 and 2017. By June 2017, data collection had been completed in South Africa with 797 health workers enumerated. In 2018, the stigma activities included cleaning data from all three rounds and preliminary analysis conducted for health facility dissemination activities. Several manuscripts are in preparation.

HPTN 071 PopART for Young People (P-ART-Y) Study: Uptake and acceptability of a combination HIV prevention package among young people in Zambia and South Africa. The P-ART-Y study concluded in March, 2018. The primary outcome of the study was the uptake of voluntary HIV counselling and testing, within the previous 12 months at the time of survey administration, amongst adolescents aged 15-19 years. This served as a comparator for the primary outcome of the study (knowledge of HIV status). Other outcomes included acceptance of HIV testing and retesting. Linkage to care, antiretroviral therapy (ART) adherence and retention in care, uptake of prevention to mother and child transmission (PMTCT), voluntary medical male circumcision (VMMC) and condoms. Qualitatively, we looked at the acceptability of the PopART interventions and barriers to access in adolescents. We also looked at the experiences of adolescents living with HIV. The particular needs and vulnerabilities of adolescent girls, including those living with HIV, were also studied. Data collection was completed on 4 November 2017. Data cleaning was completed in 2017 and analysis is ongoing with three manuscripts in development for submission in 2018.

P-ART-Y Dissemination: The study team is worked alongside the Adolescent Advisory Board (ACAB) and Community Engagement Team on the planning of dissemination events. These took place in the Arm C site of the HPTN 071 (PopART) trial and were conducted on the 9, 16 and 23rd March and the 13th of April 2018. Preliminary findings of the cross-sectional survey were shared with young people

some of whom participated in the study. These findings included survey uptake frequencies by age and gender and some of the secondary objectives. The primary outcome findings will be disseminated in 2019 together with results from the main trial, the HPTN 071 (PopART) trial. The dissemination events were well received by young people and this forum served as a platform for further discussion on the findings.

Mixed-data in-depth interviews with staff/stakeholders and operational review of clinic-based components of the HPTN 071 (PopART) intervention package: The PopART intervention package included a large number of health system innovations and implementation lessons from the health-facility delivery of universal testing and treatment. Specific focus areas were (a) preparation for transition to treatment regardless of CD4-count, (b) health-facility based HIV testing services, (c) explaining ART regardless of CD4-count to clients, and (d) implementing adherence support structures. Between February and April, 26 in- depth interviews with key informants were collected.

Mixed data observational and discussions with field staff of the community-based components of the HPTN 071 (PopART) intervention package – annual round 5: A set of structured observations and discussions with implementers conducted annually in 9 study communities between January and March. The final round of data were collected without issue in 2018.

HPTN 071 (PopART) Research Collective (PRC): PRC is a collaborative project lead by Dr P Bock, composed of DTTC PopART staff and PopART implementing partners (City of Cape Town, Western Cape DoH, ANOVA Health Institute, Kheth' Impilo and Cape Winelands DoH). This consortium is aimed at formulating lessons learned of implementing the HPTN 071 study at health facilities, over trial period. The PRC consists of five groups each with an aim of developing a manuscripts related to the implementation of the PopART intervention. Data collection was completed in November 2017. A total of 51 interviews were conducted with health services staff at a provincial, district, regional and clinic level. Manuscripts are under development.

Sociobehavioural Science Students Graduated

1. Rene Raad – MA in Anthropology at SUN
2. Hermine Kruger – Honours in Psychology at SUN
3. Arlene Marthinus – Honours in Psychology at UWC
4. Msondezi Ketelo – BA in Anthropology at UWC

Epidemiological Modelling

Modelling of tuberculosis and the impact of TB control interventions constitutes an additional core competency to be built at DTTC in the forthcoming years. In 2018, a DTTC Working Group Data Analysis and Modelling (WGDAM) was established to build and strengthen capacity for in-house modelling (see below). A strategic TB modeling partnership and research programme between DTTC and the South African Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA) was prepared in 2018 and is set to take off in 2019. This novel initiative is intended to provide a platform for mathematical modelling and intervention research to inform decision making for TB control at national level in South Africa as well as internationally.

Working Group: Data Analysis & Modeling (WGDAM)

A DTTC Working Group Data Analysis and Modelling (WGDAM) was established to build and strengthen capacity in mathematical modeling of TB and related control interventions. The working group is led by Dr Florian Marx and holds weekly meetings at DTTC. It currently consists of 10 members with backgrounds in medicine, epidemiology/public health, data management and statistics. In 2018, WGDAM initiated a joint research project which aims to project the population-level impact of ART scale up on TB in incidence and mortality in the nine South African Provinces. Prior to this project, the group reviewed data from the National Antenatal Sentinel HIV Prevalence

Survey and the District Health Barometer to compare rates of TB and HIV in the 52 South African health districts. This study highlighted poor association between HIV prevalence estimates and rates of reported TB at subnational level, which has important implications for TB control in South Africa. Efforts are needed to better understand the determinants of local variation in TB and HIV rates in South Africa. Other modelling projects involving WGDAM members in 2018 include studies estimating the impact of TB household contact investigation and preventive therapy, of rolling out novel rapid diagnostic tests in South Africa, and of targeting TB case finding and prevention to previously treated people. The following manuscripts have been published:

1. Sloot R, Maarman GJ, Osman M, Marx FM. Variation in HIV prevalence and the population-level effects of antiretroviral treatment for reducing tuberculosis incidence in South Africa. (Correspondence), on behalf of the Desmond Tutu TB Centre Working Group Data Analysis and Modelling (DTTC-WGDAM). South African Medical Journal 2018; 108(8): 606.
2. Dunbar R, Naidoo P, Beyers N, Langley I. Improving rifampicin-resistant tuberculosis diagnosis using Xpert((R)) MTB/RIF: modelling interventions and costs. Int J Tuberc Lung Dis 2018; 22(8): 890-8.
3. Marx FM, Yaesoubi R, Menzies NA, Salomon JA, Bilinski A, Cohen T. Tuberculosis control interventions targeted to previously treated people in a high-incidence setting: a modelling study. The Lancet Global Health 2018; 6(4): e426-e35.

The potential impact of household contact management on childhood tuberculosis: a mathematical modelling study (*Published Lancet Global Health*): This study evaluated the impact of carrying out household contact management strategies on the global burden of childhood TB disease and childhood TB mortality. By modelling the current situation for children following household exposure to infectious TB and assuming no household interventions, and then comparing it with two scenarios in which exposed children were screened for disease and then treated for TB infection, the impact of these interventions could be evaluated. Full implementation of household activities could result in a reduction of 160,000 cases of childhood TB and prevent 108,000 child deaths.

1. Dodd PJ, Yuen CM, Becerra MC, Revill P, Jenkins HE, Seddon JA. Potential effect of household contact management on childhood tuberculosis: a mathematical modelling study. The Lancet Global Health 2018; 6(12): e1329-e38.

DTTC GRANT AWARDED: 2018

Description	Funder	PI
LINKEDiN study (Reducing loss to follow up among TB Patients)	Gates Foundation	Anneke C. Hesselning/Muhamad Osman
Consultancy for a systematic review of TB mortality in South Africa	TB THINK TANK	Tamaryn Nicholson & Muhammad Osman
Consultancy paediatric MDR-TB National Guidelines	TB THINK TANK	Jennifer Hughes
Protocol Vice Chair Funding	NIH IMPAACT network	Jennifer Hughes
Consultancy for a review of TB preventative therapy implementation in South Africa	TB THINK TANK	Graeme Hoddinott
HPTN 084 site	NIH (HPTN)	Peter Bock
2 nd year extension of postdoctoral	Ramon Areces Postdoctoral	Elisa Lopez

fellowship	Fellowship	
Travel fellowship Prof. Reza Yaesoubi at the Yale School of Public Health, USA	Stellenbosch University Scientific travel grant	Florian Marx
Impact of viral co-infections on lung health in children with TB	SA MRC	Marieke van der Zalm
Travel to the 22 nd International AIDS conference, Amsterdam in July 2018	Stellenbosch University Scientific travel grant	Sue-Ann Meehan & Lario Viljoen
BEAT Paediatric MDR-TB	UNITAID	Tony Garcia-Prats
IMPAACT 2020	IMPAACT NIH	Tony Garcia-Prats
SA MRC SHIP	MRC grant for collateral funding for TB Champ	Anneke Hesselning, James Seddon
Graduate Internship Programme	NRF	Graeme Hoddinott & Anneke Hesselning
Graduate Internship Programme	NRF	Graeme Hoddinott & Anneke Hesselning
Familial management of paediatric co-morbid HIV, TB, and diabetes	Harry Crossley (PhD scholarship)	Dillon Wademan
Travel to the 49th Union World Conference on Lung Health, Amsterdam in October 2018	Stellenbosch University Scientific travel grant	Muhammad Osman

AWARDS AND OTHER RECOGNITION

1. Professor Simon Schaaf received his 2nd A-rated NRF award in Port Elizabeth. September 2018.
2. Dr. Sue Purchase received the Discovery Award at the Durban TB Conference for overall “The Best Research Paper”. July 2018
3. Dr. Mareli Claassens was appointed as a Research Fellow for DTTC.
4. Dr. Angela Dramowski was promoted to Associate Professor.
5. Professor Nulda Beyers received the Research Development Award. Prof Beyers mentored four successful PhD Graduates
6. Dr. Jana Winckler secured joint 3rd Place in the Young Scientist Award for podium presentation in the category basic and clinical pharmacology which included lab scientist and clinicians. 08 October 2018.

DTTC ACADEMIC MEETINGS

The TB Clinical Forum 2018, hosted by DTTC at the Stellenbosch University FMHS and organized by the City of Cape Town officials was held monthly between February and November 2018 with the objective of creating an interactive platform for academic researchers and government official in health services. Experts from the FMHS and City presented a broad range of relevant scientific research topics. An average of 50 participants attended these lively CPD- accredited interractional meetings on Friday afternoons, facilitating dialogue between service providers for TB and HIV care, and researchers at DTTC and the medical faculty. Four speakers from DTTC presented during 2018.

TB Clinical Forum 2018

DATE	PRESENTER	TOPIC
9 Feb. 2018	Dr. Lenny Naidoo (CCT) Dr. Jennifer Hughes (DTTC)	Highlights from the 48 th Union World Conference on Lung Health, Guadalajara, Mexico
9 Mar. 2018	Prof Marc Nichol –(NHLS/UCT)	Interpreting Ultra- A clinician’s guide Rapid diagnostic test & improved diagnosis
13 Apr. 2018	Prof. Helen Cox (UCT)	What do we need to do to eliminate drug-resistant TB???
11 May 2018	Prof. Gary Maartens(UCT)	Update on drug interactions between ARVs and TB drugs
8 Jun. 2018	Prof. A. Diacon (TASK) Dr. Anja Reuter (MSF)	Update on Adult MDR-TB treatment Trials
13 Jul. 2018	ChloëShain (UCT)	The Social Markers of TB
24 Aug. 2018	Prof. Graeme Meintjies(UCT)	TB Lymphadenitis: Clinical management
21 Sept. 2018	Dr. Tony Garcia-Pratts (DTTC) Dr V. Mudalay (MSF) Dr A. Reuter (MSF) Dr J. Te Riele(BCH/WCG)	Ethics/Debate: “Do we really need the injectable for managing DRTB?”
12 Oct.2018	Prof. Anneke Hesselning Dr. Tony Garcia-Pratts (DTTC)	DTTC-Update on Paediatric TB treatment Trials
9 Nov.2018	Dr Natalie Beylis (NHLS)	TB diagnostics, discordant results, Heteroresistance and mixed infections (Natalie)

DTTC Academic Meetings 2018

The DTTC Academic Meetings 2018, held fortnightly at the FMHS targeted academic researchers to engage in ground-breaking research initiatives. Speakers from local and abroad were invited to present their area of research in a broad range of relevant topics.

Date	Presenter	Topic
1 Feb. 2018	Cornè Bosch	Molecular diagnosis of M.TB from paediatric stool samples – practice run for masters oral
8 Feb. 2018	Dr. Theresa Mann	Burden and trends of spinal tuberculosis in the Western Cape
22 Feb. 2018	Dr. Lena Ronge	Open or closed Tuberculosis. “Are infants able to spread TB?” - Findings from the European Childhood tuberculosis Archive
1 Mar. 2018	Prof. Helena Rabie	Paediatric HIV current challenges, future opportunities
22 Mar. 2018	Dr. Muhammad Osman	Paediatric XDR-TB Treatment outcomes – A

		systematic review and individual patient data meta-analysis.
05 Apr. 2018	Dr. Florian Marx	Former TB patients in the context of TB and HIV epidemics - need for tailored health interventions?
19 Apr. 2018	Dr. Sue-Ann Meehan	The contribution of a community based HIV counseling and testing (HCT) initiative in working towards increasing access to HIV counseling and testing in Cape Town
03 May 2018	Dr. James Seddon	The impact of household contact management on childhood tuberculosis: a mathematical modelling study
24 May 2018	Dillon Wademan & Hanlie Myburgh	Chronic conditions and care: Intergenerational experiences of living with HIV, TB and Diabetes in South Africa (Dillon) ----- Relationships, responsibility and the state: Understanding uptake of antiretroviral treatment in South Africa (Hanlie)
31 May 2018	Dr. Kyla Comins- TASK	Update on MDR – TB treatment trials in adults
28 Jun. 2018	Dr. Florian Marx	Projecting the population-levels effects of tuberculosis control in South Africa – update from the DTTC – WGDAM -Working group Data Analysis and Modeling
05 Jul. 2018	Dillon Wademan Lario Viljoen Laing de Villiers ----- Prof Kelly Dooley	How health workers motivated People living with HIV (PLHIV) to initiate antiretroviral treatment (ART) at high CD4 counts within the HPTN 071 (PopART) trial (Dillon) ----- Public condition/private affliction: Negotiating comorbidity, confidentiality, and care in South Africa, a narrative from the HPTN 071 (PopART) study (Lario) ----- Stigma, secrecy, social support and HIV service access among transgender and gender-fluid people in South Africa, the HPTN 071 (PopART) study (Laing) ----- Update on adult trials of TB/HIV (Kelly)
12 July	Dr. Celeste De Vaal	Raising ethical issues in the dead: An exploration of ethical challenges in Forensic Medicine
02 Aug. 2018	Graeme Hoddinott and Constance Mubekapi-Musadaidzwa	HIV services for young people aged 10-24; priorities, gaps, and opportunities from the PopART for young people (P-ART-Y) study
16 August	Dr Tony Garcia-Prats	1) Results of the Bedaquiline CRUSH study 2) Emerging data on linezolid PK and safety in children with MDR-TB- feedback- Adult formulation tested ,tablets dissolve in water.
23 Aug. 2018	Prof Andrew Whitelaw	S.aureus epidemiology resistance virulence and diagnosis

20 Sept. 2018	Sociobehavioural science team presenters: Kyla Meyerson, Leletu Busakwe, and Stephanie Jacobs.	1)Acceptability of MDR-TB treatment for children, findings from the MDR PK2 Masterchef. 2)Video presentation of early thoughts on a knowledge, adherence, and social support app for children with TB.
04 Oct. 2018	Dr. Amy Slogrove	Evaluating long term child health outcomes following pregnancy exposures in South Africa - using HIV and antiretroviral drugs as a starting point”
18 Oct. 2018	Dr. Elisa Lopez	Pharmacokinetics of antituberculosis drugs at the site of disease in children with complicated intrathoracic tuberculosis
08 Nov. 2018	Dr Marije van Schalkwyk	CTU Academic Meeting: Drug PK in pregnancy, what we know we don't know
29 Nov.2018	Dr. Sue Purchase	Looking through a different lens: TB in Literature and the Arts

ADVOCACY AND COMMUNITY ENGAGEMENT

World TB Day is an annual joint initiative between the Stop TB Partnership and the WHO Global TB Programme to raise public awareness about the devastating impact of TB. On Friday 23rd March, DTTC organized a World TB Day lunch time event at the FMHS campus in collaboration with TB Proof and TB Alliance. The program included two interactive presentations: *TB prevention in children in the era of TB elimination* (Prof Anneke Hesselring) and *TB prevention in healthcare workers: Caring for the Carers* (Dr Angela Dramowski). The event concluded with a live interview with an adolescent MDR-TB research participant and her mother, explaining the MDR-TB treatment journey from a family perspective. Academic posters were displayed in the hallway for the duration of the day. DTTC staff and CAB members handed out TB information leaflets to FMHS staff and students during the morning to raise general awareness of TB on campus.



Figure 1 DTTC Staff at World TB day, 2018

The DTTC Community Advisory Board (DTTC CAB)

The establishment of a DTTC-CAB with a TB focus was initiated in June 2015 and was officially launched in November 2015, when the first general meeting was held at the Brooklyn Chest Hospital site. Since then, monthly General Meetings are conducted throughout the year. From 2016, the seven Steering Committee members held additional monthly meetings. DTTC CAB activities for January to December 2018 included:

Meetings: The DTTC CAB participated in General meetings; Steering Committee (SC) meetings for the executive body and SUN-CTU CAB Leadership Group (SCCLG) Meetings (i.e with DTTC, FAMCRU and TASK) and a representative participated in every IMPAACT ICAB bi-monthly teleconference call and HPTN CWG monthly teleconference calls including the HPTN 084 study monthly conference calls.

CAB Annual Recruitment and Retention Drive: 14 April 2018 the DTTC CAB hosted and “Open Day” and 22 prospective CAB members attended. Interviews were conducted during May and July. Subsequently, 4 adults and 10 youth were recruited into the DTTC CAB.

HPTN 084 Protocol Review and Study Updates: In February the CAB reviewed the protocol; and educational and marketing materials for the HPTN 084 study. The CLO met with the 084 Monitor to discuss CAB operations. The CAB and CLO met with 084 study staff to provide input; and were involved in activities relating to the call to pause the study for activation and enrolments and the activation.

IMPAACT & HPTN Protocol Review and Study Updates: On 09 June the Study Coordinator presented updates on P1101 and P1026. 14 June the CLO presented a CAB overview to the HPTN 084 team at the Kuilsriver site office.

Network Training: 04–05 February the CAB attended a training workshop hosted by FHI, “Understanding the Clinical Research Process”. Network webinar training workshop invitations for various topics were disseminated and attended where possible.

CAB Youth Development: To raise the voice of our youth 2 youth members were elected to serve on the DTTC CAB Steering Committee during the 25 August Meeting. The youth group have written, produced and directed a 15 minute skit on HIV and TB incorporating a poem authored by one of the members and a song to illustrate the life of young people affected and infected with HIV and TB in the South African context. The production was presented at the 12th International Child TB Training Course. A 14 year-old youth member of the CAB who survived MDR-TB and her mom also shared their experiences with living with MDR-TB at the 12th International Child TB Training course and interacted with course participants thereafter.

International Network Meetings: 14 – 18 May the CAB Chairperson attended the HPTN Annual Meeting in Washington. No funds were available for community representation at the IMPAACT Annual Meeting in June 2018. A video production, “Two Countries; Two Choices” on TB by *Aids-Free World*, which featured 2 of DTTC adolescent research participants, one a CAB member, was screened at the International Aids Conference in Amsterdam, 23 – 27 July 2019.

The Annual Capacity Building Event & Award Ceremony: The CTU CABs (i.e. DTTC, FAMCRU and TASK) held their Annual Capacity Building Retreat on 18 -19 October 2018 at the Tygerberg Campus. This event culminated in the CAB Gala Dinner & Award Ceremony on Saturday, 20 October 2018 at the Bellville Civic Centre. This year we established an award with a floating trophy in honour of, and called the Katleho Mosimanegape Community Achievement Award, which recognizes outstanding leadership, commitment and dedication within the community forum. This year it was awarded posthumously to Katleho Mosimanegape, himself a TB and HIV survivor, who died in an accident on 27 June 2018. The Award will be held in DTTC for 12 months. Representatives of his family received the award at the Gala Dinner on 20 October 2019 at the Bellville Civic Centre.

Annual Dissemination Meeting: On 23 November 2018, the CAB members attended the Annual DTTC Dissemination Meeting, held at the Lord Charles Hotel Somerset West.

DAIDS Programme Officer Site Visit: On 04 September 2018, Eileen Pouliot, the DAIDS Programme Officer met with the community members during a joint CTU CAB Overview presentation at Tygerberg, J8 seminar room.

World TB Day: 23 March 2018, the CAB members participated in the World TB Day programme hosted by DTTC at the Tygerberg campus.

Special extramural events: On 9 October 2018 12 members of the CAB attended the 8th International Desmond Tutu Peace Lecture at the Artscape where guest speaker, Cyril Ramaphosa, addressed the audience. On 20 October 2018 the CLO presented a CAB Overview to US Health Attaché, Steven Smith at the Kuilsriver site office.

The DTTC CAB Budget: In March the CAB SC reviewed the 2018 CAB Budget which was accepted in principle by the DTTC EXCO in April.

The 2019 IMPAACT Budget: The CLOs of DTTC, FAMCRU and TASK met in November 2018 to finalise the 2019 IMPAACT Budget. The final proposal for the R178 000.00 allocation was submitted to the CTU Unit Manager and SU Grants Office on 7 December 2018.

Funding Opportunity - Public engagement Fund: The CAB CLO and two DTTC executive officers met to discuss the funding opportunity with the Wellcome Trust regarding a possible funding opportunity through creative approaches in engaging the public with health research.

Condolences: 27 June 2018, Executive member and Acting-Secretary, Katleho Mosimanegape, passed away in an accident. A vigil was held in the DTTC seminar room on 28 June 2018 and CAB members and DTTC staff visited the family home that evening. CTU CAB members attended the Memorial Service on 3 July 2018. The DTTC CAB and staff participated in a collection of cash and kind for the bereaved family as part of the 18 July 2018 Madiba Day activities.

The HPTN 071 (PopART) CAB

In the HPTN 071 (PopART) trial, each participating clinic had a health Committee that links it with its community. The PopART CAB was established in 2013 with representatives from the 9 sites in which PopART is being conducted. These representatives (2 from each site) were chosen from health committee members and they work as volunteers in making sure that health related issues within their communities and the clinics are addressed properly. The CAB is the link between the communities and the PopART researchers and has a constitution with rules and guidelines as to how to conduct their meetings. The PopART CAB meets once a month where various study related issues are discussed.

The CAB helps the researchers in making sure that community related issues are addressed and that misunderstandings between the community and the researchers are dealt with in a professional way. The CAB takes initiative in setting up these meetings. The CAB also helps in reviewing community related study material like informed consent documents and study questionnaires. In return, DTTC offers trainings for these members to develop them. The PopART CAB members have received training in the following areas:

- GCP training
- Basic HIV knowledge
- Minute and record keeping
- Basic Counselling
- Cancer screening tips

The PopART CAB, Community Engagement team and the Intervention Managers had a Workshop at the Lord Charles Hotel in preparation for the six events of Disseminating Intervention results planned for June /July 2018. The CAB and the teams worked together to find appropriate ways to communicate study results communities and making sure that closed venues are secured for the six dissemination events. The mobilisers are working closely with the CAB members in making sure that all stakeholders are aware of and invited to these events.

- The CAB members have been taking the lead in the establishment of community committees in preparation for disseminations (Intervention and the upcoming Primary Outcomes Dissemination Meeting).
- All the Nine Primary Outcomes Dissemination meetings will be held in March 2019.
- The role of CAB is to use community platforms to invite the relevant stakeholders
- The CAB meetings are held bi-monthly to review progress about these preparations.
- The last CAB for the year was on the 5th of November 2018 where site reports from all community committees were laid down to ensure the readiness of all sites for the Dissemination meeting.

HPTN 071 (PopART) Community Engagement (CE)

The HPTN 071 (PopART) community engagement team were involved in several activities for the final year of the trial. These include the following:

In 2018, the Intervention District Logistic Managers (DLOs) and the Data Coordinators together with the Community Advisory Board members (CABs) for each site formed community working groups in preparation for the Intervention Dissemination meetings for the six communities involved.

- Out of the six, four dissemination meetings were held in June and the remaining two in July, 2018.
- At the end of the Population Cohort (PC) Research Assistant's contracts in June 2018, the DLOs and the CAB helped by members of the CE team started preparing for the Primary Outcomes Community Dissemination meetings to be held in March, 2019.
- Community Committees comprising of 2 CAB members, 1 CE member and 1 PC member were established to work on all site logistics for each site.
- The logistics included securing of venues, identifying community stakeholders to be invited and determining the most appropriate means to invite community members in the relevant sites
- The CE team was also consulting with the events office within the City of Cape Town to ensure that all events followed guidelines.

The HPTN 071 (PopART) P-ART-Y Adolescent Community Advisory Board (ACAB)

The Adolescent CAB advised researchers on how best to implement the P-ART-Y evaluation survey and supported the community-level delivery of optimisations of the PopART intervention package for young people. In 2018 the P-ART- Y CAB members were involved in the general and focused meetings in which study processes and CAB issues were discussed.

The PARTY study team and five ACAB members (Luthando Ngwatyu, Nandipha Anta, Jafta Siyavuaya Nonkondlo, Katleho Mosimanengape and Mhlahli Ngqawule) attend the Annual DTTC Dissemination Meeting held at Stellenbosch University on the 8 December 2017. This meeting brought together various stakeholders from the Western Cape Department of Health, City of Cape Town, and DTTC Paediatrics and Community Advisory boards. The meeting was themed "With Communities, for Communities", with aim of discussing studies currently underway at the centre and sharing lessons learnt. The ACAB had its first meeting on the 3rd of February 2018, and the meeting commenced with young people giving feedback on the DTTC annual dissemination meeting. The ACAB members then reviewed the dissemination plan and suggested ways of reaching young people. ACAB closeout was discussed and it was recommended that members apply to be part of the DTTC CAB. Since then, 7 P-ART-Y ACAB members have been welcomed into the DTTC CAB and continue to engage in CAB meetings.

CONFERENCES

During 2018, personnel from the DTTC participated in several local and international conferences, including the Union conference in The Hague, the International AIDS conference in Amsterdam, the South African TB conference in Durban, the Stellenbosch University research day and several other academic platforms.

PEPFAR Conference. Pretoria, South Africa. 16 January 2018.

- HPTN 071 (PopART) staff presented study findings and lessons learnt

SACEMA seminar. Stellenbosch, South Africa. 9 March 2018

- Sue-Ann Meehan. Community based HIV testing services: using a case study from Cape Town to provide evidence-based lessons learnt for program implementation.

Annual TB Seminar at the Human Sciences Research Council. Cape Town, South Africa, 28 March 2018

- Boffa J. Is prevention better than cure? Perceptions of isoniazid preventive therapy in KwaZulu-Natal.

Pediatric TB Pre-conference Symposium and Round Table Discussion at the 5th South African TB conference. Durban. 12 June 2018

Convened and chaired by the DTTC: Tuberculosis in children: old problems and new solutions

- James Seddon. The evolving epidemiology of TB in children
- Karen du Preez. Children with TB in South Africa: where are they, who are they, and where do we find more of them.
- Marieke van der Zalm. Paediatric TB within the broader lung health context
- Anneke Hesseling. Therapeutic strategies for drug-susceptible and drug-resistant TB in children

5th South African TB Conference. Durban, South Africa. 12 - 15 June 2018

- Sue Purchase. Acceptability and palatability of a novel paediatric dispersible levofloxacin formulation in children

Oral Presentations:

- Karen du Preez, Simon Schaaf, Rory Dunbar, Elisabetta Walters, Alvera Swartz, Regan Solomons, Anneke Hesseling. Complementary hospital-based surveillance strategies to better characterise the epidemiology of tuberculosis in children.
- Boffa J, Mayan M, Mhlaba T, Ndlovu S, Williamson T, Fisher D. Why agency is important when implementing IPT: Lessons from oMakoti in KwaZulu-Natal, South Africa.
- Boffa J, Mayan M, Ndlovu S, Fisher D, Staples S, Sauve R, Williamson T. Is prevention better than cure? Perceptions of isoniazid preventive therapy in KwaZulu-Natal, South Africa.
- Boffa J, Fisher D, Sauve R, Mayan M, Williamson T. The effectiveness of untargeted 6-month IPT to reduce tuberculosis incidence among people living with HIV with and without antiretroviral therapy in KwaZulu-Natal, South Africa.

Poster presentation

- Boffa J, Mayan M, MacDonald H, Cele N, Dhladhla C, Ndlovu S. Creating culturally-appropriate dissemination products in tuberculosis research.

AIDS 2018 Pre-conference and 4th International Conference on the Social Sciences and Humanities in HIV (ASSHH). Amsterdam, Netherlands. 20 – 23 July 2018.

Oral presentations

- L. Viljoen, L. Reynolds, H. Myburgh, G. Hoddinott, V. Bond, on behalf of the HPTN 071 (PopART) team. Public condition/private affliction: negotiating co-morbidity, confidentiality,

and care in South Africa, a case-study from the HPTN 071 (PopART) study .

- N. Peton, C. Mubekapi-Musadaidzwa, D. Wademan, P. Hendricks, G. Carolus, R. Mbaezue, J. Kruger, K. Jennings, C. Gunst, N. Grobbelaar, F. Louis, P. Bock, G. Hoddinott. How health workers motivated People living with HIV (PLHIV) to initiate antiretroviral treatment (ART) at high CD4 counts, the HPTN 071 (PopART) study.
- L de Villiers. L. Reynolds, A. Thomas, L. Busakwe, J. Hargreaves, A. Stangl, V. Bond, P. Bock, G. Hoddinott, on behalf of the HPTN 071 (PopART) study team. Stigma, secrecy, social support and HIV service access among transgender and gender-uid people in South Africa, the HPTN 071 (PopART) study.
- V. Bond, M. Mwamba, N. Vanqa, M. Steinhaus, D. Ziba, D. Milimo, L. Viljoen, T. Mainga, T. Nicholson, H. Ayles, S. Fidler, R. Hayes, P. Bock, J. Hargreaves, G. Hoddinott, J. Seeley and A. Stangl on behalf of the HPTN 071 (PopART) study team. "Self-stigma is the worst kind of stigma": Internalised stigma and navigating HIV care amongst health workers living with HIV in Zambia and South Africa, the HPTN 071 (PopART) stigma ancillary study.

22nd International AIDS Conference. Amsterdam, Netherlands. 23 – 27 July 2018.

Oral presentations

- G. Hoddinott on behalf of the HPTN 071 (PopART) study team. Acceptability of a HIV prevention package among young people: HPTN 071 (PopART) for Youth Study.

Poster presentations

- S.-A. Meehan, D. Wademan, G. Hoddinott, R. Holtman, N. Grobbelaar, J. Kruger, M. Leonard, B. Yang, V. Naidoo, P. Bock, C. Gunst. Implementing community-based adherence clubs for stable HIV-infected patients in South Africa. Lessons learned from patient and health worker experiences.
- S.-A. Meehan, D. Wademan, G. Hoddinott, R. Holtman, N. Grobbelaar, J. Kruger, L. Maschilla, B. Yang, V. Naidoo, P. Bock, C. Gunst. Evaluating the impact of community-based adherence clubs on the clinical outcomes amongst ART patients in the Cape Winelands district of Western Cape Province of South Africa.
- S. Fidler, S. Floyd, B. Yang, M. Phiri, D. McLeod, A. Schaap, R. Sloot, K. Shanaube, S. Griffith, P. Bock, N. Beyers, H. Ayles, R. Hayes, on behalf of the HPTN071(PopART) Study Team. Dramatic reductions in time to ART initiation among HIV+ individuals referred to HIV care following home-based testing services: Experiences from the HPTN071(PopART) trial between 2014 and 2017.
- K. Shanaube, D. Macleod, J. Mwate Chaila, G. Hoddinott, A. Schaap, S. Floyd, C. Mackworth-Young, P. Bock, R. Hayes, S. Fidler, H. Ayles, HPTN071 (PopART) Study Team. HIV care cascade among adolescents in a 'test and treat' community based intervention in Zambia and South Africa: HPTN071 (PopART) for Youth study.
- R. Thomas, S. Kanema, L. Mwenge, S. Floyd, P. Bock, H. Ayles, N. Beyers, S. Fidler, R. Hayes, K. Hauck, HPTN 071(PopART) Study Team. Costs of two rounds of home-based HIV testing and counselling in Zambia: Evidence from the HPTN 071(PopART) study.
- R. Thomas, R. Friebel, K. Barker, L. Mwenge, S. Kanema, N. Vanqa, A. Harper, N. Bell-Mandla, P. Smith, S. Floyd, P. Bock, H. Ayles, N. Beyers, S. Fidler, R. Hayes, K. Hauck, HPTN 071(PopART) Study Team. Work and home productivity of HIV-positive and HIV-negative individuals in Zambia and South Africa: A cross-sectional baseline survey of the HPTN071/PopART trial.
- M. Simwinga, J. Mwate, T. Ng'ombe, S. Belemu, N. Makola, C. Mubekapi-Musadaidzwa, G. Hoddinott, R. White, K. Shanaube, V. Bond, T. Mainga. Adolescent and young people's

participation and representation in clinical trials: Lessons from a community-wide HIV testing and treatment study, the HPTN 071 (PopART) study. (poster discussion).

- M. Mbewe, C. Mackworth-Young, D. Ziba, R. Ndubani¹, B. Chiti, M. Simuyaba, M. Gondwe, K. Shanaube, G. Hoddinott, V. Bond. 'In their shoes': Limited disclosure amongst young people living with HIV stifles their ability to contact others in the same situation, a qualitative cohort HPTN071 (PopART) study in Zambia.
- D. Macleod, B. Yang, S. Floyd, A. Schaap, S. Griffith⁴, K. Shanaube, M. Phiri, R. Sloom, P. Bock, N. Beyers, H. Ayles, S. Fidler, R. Hayes. Retention on ART within the HPTN 071 (PopART) universal testing and treatment programme in Zambia and South Africa.
- J. Hargreaves, A. Stangl, G. Hoddinott, T. Mainga, S. Floyd, K. Sabapathy, H. Jones, L. Viljoen, T. Pliakas, S. Krishnaratne, C. Mubekapi-Musadaidzwa, V. Bond, HPTN (071) PopART Team. The HIV stigma landscape in sub-Saharan Africa: Baseline findings of a mixed-method, comprehensive evaluation nested in the HPTN 071 (PopART) trial.
- R.J. Hayes, S. Floyd, A. Schaap, K. Shanaube, B. Yang, S. Griffith, P. Bock, N. Beyers, H. Ayles, S. Fidler, HPTN 071 (PopART) Study Team. Achieving the first two UNAIDS 90-90-90 targets on completion of a three-year universal testing and treatment (UTT) intervention in the HPTN 071 (PopART) randomised trial in Zambia and South Africa.
- B. Yang, R. Sloom, S. Floyd, F. Esau¹, J. Molaolwa¹, D. Awoniyi, Y. Saunders¹, P. Siboto, L. Gqiba-Tunywa, D. Myburgh, B. Cimi, S. Griffith, P. Bock, H. Ayles, S. Fidler, R. Hayes, N. Beyers, HPTN 071 (PopART) Study Team. HIV testing patterns in two community-based approaches to universal test and treat in the HPTN 071 (PopART) intervention in South Africa.
- K. Sabapathy, C. Mulubwa, C. Mubekapi-Musadaidzwa, V. Bond, G. Hoddinott, H. Stockl, S. Floyd, P. Bock, J. Seeley, H. Ayles, S. Fidler, R. Hayes, HPTN 071 (PopART) Study Group. Intimate partner violence and associated factors in HPTN 071 (PopART) study communities - a comparison by HIV status.

Stellenbosch University 6nd Annual Academic Day. Tygerberg Medical Campus. 29 August 2018.

Oral presentations

- Celeste de Waal. Raising ethical issues in the dead: An exploration of ethical challenges in forensic medicine
- Peter Bock on behalf of the HPTN 071 (PopART) team. Baseline CD 4 count as a predictor of clinical outcomes when providing antiretroviral treatment regardless of CD 4 count at government clinics within the HPTN 071 (PopART) trial.
- Lario Viljoen on behalf of the HPTN 071 (PopART) team. Public condition/ private affliction: Negotiating comorbidity, confidentiality and care in South Africa, a case study from the HPTN 071 (PopART) study.
- Karen du Preez. Ten years of routine paediatric TB surveillance data in South Africa – high disease burden and poor treatment outcomes

Poster presentations

- Sue-Ann Meehan. Evaluating the impact of adherence clubs on the clinical outcome amongst ART patients in the Cape Winelands District of Western Cape Province, South Africa
- Dillon Wademan. Implementing community-based adherence clubs for stable HIV-Infected patients in South Africa. Lessons learned from patient and health worker experiences.
- Bliya Yang. HIV-testing patterns in two community-based approaches to Universal Test and Treat in the HPTN 071 (PopART) intervention in South Africa.

- Mareli Claassens. Mortality amongst HIV-positive female tuberculosis patients in South Africa.
- Constance Mubekapi-Musadaidzwa. Motivating people living with HIV to initiate antiretroviral treatment at high CD 4 counts in three HPTN 071 (PopART) health facilities in the Western Cape, South Africa.
- Kerry Nel. Patterns of facility-based HIV testing service (HTS) at two public health facilities participating in the HPTN 071 (PopART) Universal Test and Treat intervention in Cape Town, South Africa.
- Mark Theart. Using aerial photography in longitudinal community studies
- Jana Winckler. The pharmacokinetics of high dose isoniazid for the prevention or treatment of drug-resistant tuberculosis in HIV-infected and –uninfected children (The SHINE trial)
- Megan Palmer. Use of chest radiographs in a phase 3 randomised controlled efficacy trial for treatment shortening of non-severe drug-susceptible TB in children (The SHINE trial)
- Klassina Zimri. Clinical trial and emotional labour: The role of the research nurse in paediatric MDR-TB studies
- Louwina van der Laan. Pharmacokinetics of intracellular Stavudine-Triphosphate in children after reduced dose: Can we improve Stavudine’s safety profile?
- Nomsa Apleni, Gerald J Maarman, Nomtha Mandla, Peter Bock, Nulda Beyers on behalf of the HPTN 071 (PopART) team. Presenter: Kate Fortuin. Roles of nurses in ensuring quality and effectiveness of blood sample collection.

SACEMA Research Conference. Stellenbosch. 10-13 September 2018

Poster presentation

- Muhammad Osman, Alex Welte, Rosemary Brown, Rory Dunbar, Graeme Hoddinott, Anneke C Hesselning, Florian M Marx. Former tuberculosis patients, a high-risk group for tuberculosis-associated morbidity and mortality in Cape Town, South Africa: a pilot study.

12th Annual Early Career Scientist Convention (ECSC). 17-19 October 2018

Abstract published

- Muhammad Osman, Alex Welte, Rosemary Brown, Rory Dunbar, Graeme Hoddinott, Anneke C Hesselning, Florian M Marx. Former tuberculosis patients, a high-risk group for tuberculosis-associated morbidity and mortality in Cape Town, South Africa: a pilot study.

The 49TH Union World Conference on Lung Health. The Hague, Netherlands. 24-27 October 2018.

Symposium organizer and chair

- M. van der Zalm. Paediatric lung function measurements in low-middle income countries with a high burden of TB/ HIV, malnutrition and environmental exposures.

Symposium presentation

- N Suryavanshi, G. Hoddinott High-quality social science to inform the design and interpretation of paediatric tuberculosis treatment trials

Oral presentations

- M. van der Zalm. Speaker at symposium: “Lung function in children presenting with symptoms suggestive of pulmonary tuberculosis”.
- Garcia-Prats. Pharmacokinetics and pharmacodynamics in designing clinical trials in children
- Garcia-Prats. The current landscape of paediatric trials for the prevention and treatment of DS- and DR-TB: feeding the pipeline

- Garcia-Prats. Meet the Expert Session: Injectable-free regimens, and the role of injectable agents, in the treatment of children with DR-TB
- Garcia-Prats. Pharmacokinetics, safety and optimal dosing of linezolid in children with multidrug-resistant tuberculosis
- Garcia-Prats. Pharmacokinetics, safety and dosing of levofloxacin 100 mg dispersible tablets in children exposed to multidrug-resistant tuberculosis
- S. Schaaff. TB prevention in children in high TB burden settings: implementing the child contact management (CCM) care cascade. Introductory & 2nd talk: Preventive treatment considerations for multidrug-resistant tuberculosis
- S. Schaaff. Update on clinical and programmatic management of multidrug- and extensively drug-resistant TB (MDR-/XDR-TB) oral treatment of MDR-TB in children
- M Osman, EP Harausz, A Garcia-Prats, HS Schaaf, JA Seddon, AC Hesselning. Good treatment outcomes in children with extensively drug-resistant tuberculosis: a systematic review and individual patient meta-analysis.
- Megan Palmer Use of existing tools for entry points and end points in paediatric TB trials: how can we better use the chest radiograph?
- Elisabetta Walters, Pamela Nabeta, Padmapriya Banada, Anne-Marie Demers, Corne Bosch, Gary Reubenson, Naazley Pandor and Lesley Scott. Mycobacterium tuberculosis detection from stool in young children using a novel centrifugation-free method with Xpert MTB/RIF.

Short oral abstract

- M. Osman. Mortality amongst HIV-positive female tuberculosis patients in South Africa
- K. Du Preez M. Osman, P. Naidoo, S. Dlamini, A.C. Hesselning. Ten years of routine paediatric TB surveillance data in South Africa - high disease burden and poor treatment outcomes
- F. Solomon-da Costa, K. Joseph, M. Osman, K. du Preez. Burden, characteristics and treatment outcomes of patients treated for Isoniazid mono-resistant TB in Cape Town, South Africa.

Poster presentations

- S. Schaaf. Culture-confirmed tuberculosis in infants less than 3 months of age: clinical presentation and management
- M Osman, K du Preez, R Dunbar, A Welte, P Naidoo, AC Hesselning. Trends in the South African tuberculosis epidemic with scale-up of TB-HIV integration services.
- M Palmer, E Walters, M vd Zalm, HR Draper, HS Schaaf, P Goussard, J Morrison, RP Gie, AC Hesselning. Could 'non-typical' chest radiographic features in children with culture-confirmed tuberculosis reflect early, less severe disease?
- M Palmer, R Mboizi, V Mulenga, A Kinikar, D Baskaran, M Thomason, A Crook, AC Hesselning and the SHINE trial team. Use of chest radiographs in a phase 3 randomised controlled efficacy trial for treatment shortening of non-severe drug-susceptible TB in children (the SHINE Trial)

SCIENTIFIC MEETINGS, WORKSHOPS AND EVENTS

January 2018

- GATES meeting: Demo project to address the gaps in TB testing
- National TB Network SA Focus on BRIC Countries for TB trials (Anneke Hesselning)

February 2018

- Academic Writing Workshop (Blia Yang, Nomtha Mandla, Kerry Nel, Constance Mubekapi-Musdaidzwa, Rosa Sloom, Mohammed Osman, Gerald Maarman)
- FHI 360 Workshop: Understanding the Clinical Research Process and Principles of Clinical Research (PopART team)
- HPTN071 (PopART) annual workshop in Cape Town. (PopART team)
- Gates Foundation ILTF meeting
- IMPAACT 2005 Regional Meeting

March 2018

- IMPAACT Smart-kids P2020 protocol writing workshop (Anneke Hesselning, Simon Schaaf, James Seddon, Tony Garcia-Prats)
- PhD Graduation gala event (Peter Bock, Florian Marx, Sue-Ann Meehan and Rory Dunbar)
- CAB General Meeting: planning of open day to recruit additional members (Gwynneth Hendricks; DTTC CAB & prospective members)
- South African Social Science and HIV Programme (SASH) event: What does the future of HIV research look like? (Sociobehavioural science team)
- Department of Health in Winelands workshop: lessons learnt from field staff for transmission into policy - budget concerns (PopART team)
- WHO Meeting in Geneva (Anne-Marie Demers, Anneke Hesselning)
- Stigma meeting: Dissemination meeting on clinical level. Fieldworker (CHiPs) data feedback to healthcare services (Kerry Nel)
- World TB Day Event on Tygerberg Campus (DTTC staff and Tygerberg campus staff)
- Gates Foundation ILTFU meeting in Johannesburg (Anneke Hesselning, Muhammad Osman)
- Paediatric TB Meeting in Lithuania (James Seddon, Tony Garcia-Prats)
- Final P-ART-Y CAB meeting before members integrated into DTTC CAB

April 2018

- Mini ORAP Workshop (facilitated by Muhammad Osman)
- Thoracic Meeting in Johannesburg – presentations on preventative therapy and diagnosis in children (Anneke Hesselning, Muhammad Osman)
- CAB Meeting: Recruitment and Retention Drive
- Various research visits: Florian Marx to Europe; Anne-Marie Demers to Peru; James Seddon to the United Kingdom
- APSA meeting in Johannesburg (Constance Mubekapi-Musdadzwa, Graeme Hoddinott)
- HPTN 071 (PopART) Secondary outcomes meeting with Zambian Colleagues (Sue-Ann Meehan)
- HPTN 084 Lab Audit

May 2018

- AURUM Global Funding Meeting in Johannesburg (Anneke Hesselning)
- HPTN Annual Meeting in Washington, USA. (Sue-Ann Meehan, Peter Bock, Blia Yang, Nomtha Mandla, Redwaan Vermaak, Nozi Makola, Jabulile Mantantana, and 2 CAB Members)

- HPTN Annual Community Working Group Meeting in Washington, USA (Nozi Makola)
- Scientific Advisory Board Meeting in Paris. Workshop: Chest X-Rays in Children (James Seddon)
- Research Day – plenary presentation (Nulda Beyers)
- Pre-conference Union Planning Meeting in the Hague (James Seddon)
- TB Think Tank Meeting (Johannesburg). LTFU – finding the missing cases. Improvement of health info exchange by upgrading the HIE for easier data reporting (Muhammad Osman)
- Research Day at UKWANDA – Stellenbosch University Worcester Campus. Nulda Beyers presented.
- Scientific Advisory Board Meeting in Paris: 1st TB-Speed symposium (re TB in children)

June 2018

- IMPAACT Annual Meeting in Washington. (Tony Garcia-Prats, Frieda Verheye-Dua, Anne-Marie Demers, Sharon Mbaba, Simon Schaaf, Anneke Hesseling, Anneen van Deventer)
- Community Dissemination of HPTN071 (PopART)
- CAB general meeting: HPTN meeting feedback and study protocol reviews.
- British academy writing retreat at Goedgedacht farm (Malmesbury). Six of the Sociobehavioural Science Team received sponsorships: Graeme Hoddinott, Laing de Villiers, Dionne Jivan, Rozanne Casper, Nosivuyile Vanqa and Angelique Thomas.
- SUN-CTU Meeting chaired by Prof Mark Cotton.
- ACTG Network Meeting in Washington DC (Annemarie Demers).
- Consultation workshop for Scoping review on ART scale-up in South Africa with the PopART sociobehavioural science team in collaboration with HIV programme implementers and managers at provincial, city, and district levels (Hanlie Myburgh).
- GHIT Funding Presentation Tokyo, Japan (Anneke Hesseling).
- Scalabrini – The team addressed and shared information with foreigners on TB and HIV, chronic illnesses, access to clinics and services available if unemployed.

July 2018

- KNCV MDR-TB Training Roll Out of preventative therapy for MDR-TB exposed children – Indonesia (Presenter: Tony Garcia-Prats).
- HPTN 071 (PopART) Stigma working group workshop at London School of Hygiene and Tropical Medicine (Graeme Hoddinott, Lario Viljoen, Constance Mubekapi-Musadaidzwa, Laing de Villiers, Dillon Wademan).

August 2018

- Cluster Randomized Trials for Evaluation of HIV interventions workshop at FMHS. Facilitated by Prof. Rhoderick Machezano.
- Marieke van der Zalm visited the Wilhelmina Children's Hospital from 22 August to 30 October 2018 for capacity building in Lung Health as part of the HB Thom award received at the end of 2017.
- Graeme Hoddinott and Karen du Preez attended and a multi-stakeholder meeting on behalf of DTTC hosted by TB HIV Care for the South African Assessment of Barriers & Facilitators to TB Services in Johannesburg.

September 2018

- 12th International Child TB Training Course at Goudini ATKV Spa, Rawsonville, Cape.
- SHINE TGM Meeting in Lusaka, Zambia (DTTC Paediatric team)
- Faith Leaders meeting at the Kwazulu Natal Christian Council in Pietermaritzburg (Jody Boffa).
- Basic HIV counselling and testing short course (SETA). US hosted at Ruslamere in Durbanville. Councillors from DTTC Sociobehavioural science and Paediatric teams CPUT and FAMCRU attended.
- Current TB meeting – Adult TB. Complications after treatment and cure. (James Seddon).
- CHEC Module 1.8 Effective Communication. Devon Valley Hotel (Gwynneth Hendricks).
- TB meeting between Sociobehavioural science and Zambart – Quantitative Data and Qualitative data score and Impact on study outcomes. (Graeme Hoddinott).

October 2018

- SACEMA meeting with Muhammad Osman presenting his paper (Muhammad Osman and Anneke Hesselning).
- British Academic Writing workshop in Goedgedacht, Riebeeck Kasteel (Laing de Villiers; Dionne Jivan; Angélique Thomas, Rozanne Casper, Nosi Vanqa).
- Dr. Karen du Preez was selected to attend a World Health Organization Training Workshop for TB Surveillance: Establishing a Roster of Consultants Providing Technical Assistance for Epidemiological Reviews and Data Analysis and use in The African Region, which was held in Kigali, Rwanda (8 to 12 October 2018).
- CTU-CAB Retreat (FMHS). Two day training program involving TASK, FAMCRU and DTTC. A Gala Dinner was held on Saturday 20th Oct at the Bellville Civic Centre. In honour of Katleho the “Katleho Mosimanegape CAB Achievement Award” was established.

November 2018

- Discussions with WHO country representative on Operational Research, Surveillance and ETR.net .in Pretoria (Karen Du Preez)
- Paediatrics and Child Health Academic Day of Excellence (Liz Walters presented on Pulmonary TB)
- Desmond Tutu TB Centre Dissemination meeting at the Lord Charles Hotel. Opening guest Speaker is Professor Mark Cotton, FAMCRU, Department of Paediatrics and Child Health and the topic of his talk, “The state of HIV & Prevention studies in South Africa.
- HPTN 071 (PopART) Stigma Working Group writing workshop in Choma, Zambia (Lario Viljoen, Dillon Wademan, Laing de Villiers, Angélique Thomas, Rozanne Casper)
- LINKEDin study site visits to Gauteng and KwaZulu Natal (Sue-Ann Meehan and Muhammad Osman). Visited NICD, spent time with implementing study partners (Right to Care and IRD), visiting hospitals and a selection of primary healthcare facilities in the Johannesburg Metro and the Ugu district, where the study will be implemented.
- WHO GIC Implementation Guidelines. Dr. James Seddon presented on Implementation of WHO guidelines for the treatment of MDR treatment in children.
- TB Innovations Consortium Meeting in Johannesburg (Anneke Hesselning; Sue-Ann Meehan; Muhammad Osman)

December 2018

- HPTN 071 (PopART) results “unblinding” meeting in Seattle, United States of America (Peter

Bock)

Ongoing 2018

- Joint SUN-CTU CAB Leadership Group Meetings (DTTC CAB EXCO; TASK CAB EXCO; FAMCRU EXCO). Meetings held throughout the year.
- Working Group for Data Analysis & Modeling (WGDAM). WGDAM is a working that aims to produce research output (such as our publication in SAMJ August 2018). They are currently working on a paper led by Muhammad Osman and Florian Marx, which aims to assess the impact of antiretroviral therapy on tuberculosis incidence and mortality in nine South African Provinces using a mathematical model. The group met on a regular basis throughout the year.

VISITORS AT THE DTTC DURING 2018


Date	Visitor	Reason
29 Jan. 2018	Yael Hirsh-Moverman - Assistant Professor in Epidemiology (In ICAP) at the Columbia University Medical Center, Mailman School of Public Health, Columbia University.	Dr Yael Hirsch-Moverman visited the paediatric team to discuss ongoing collaboration and a joint NIH R01 grant application that was submitted in June 2018.
5-9 Feb. 2018	Dr Virginia Bond – Social Scientist at ZAMBART in Zambia	Discussion with Sociobehavioural Science Team
12 Feb. 2018	Vundli Ramokolo – Senior Scientist DOH Systems Research Unit, SA MRC	Discussion with Anneke Hesselning regarding potential post-doc with DTTC
12-15 Feb. 2018	Lily Telisinghe - London School of Hygiene & Tropical Medicine	Visiting PopART, to work on TB case notification data from PopART.
19-23 Feb. 2018	Georgia White – AIDS Free World	Discussion with Anneke regarding filming in SA for TB/HIV advocacy
Feb. 2018	Carl Swenson – UPSALLA Pharmacokinetics	Discussion regarding TB dosing
Mar. 2018	Dr Rafael Saulter and Dr William Probert, Researchers in Infectious Disease Modelling Big Data Institute, Ki La Shing Centre for Health Information and Discovery, Oxford University	IMPAACT Smart-kids P2020 protocol writing workshop
Mar. 2018	Pauline Howell – Senior Medical Officer at Sizwe Tropical Disease Hospital Katie McCarthy - IMPAACT Operations Centre, Science Facilitation FHI360) Leavitt Morrison, Soyeon Kim – Harvard University	IMPAACT Smart-kids P2020 protocol writing workshop
16 Mar. 2018	Jeff Haskins – Otsuka	Meetings with Tony Garcia-Prats and Anneke Hesselning
26-29 Mar. 2018	Yael Hirsch – Assistant Professor Epidemiology, Columbia University Medical Centre	Meeting with Paediatric team
9-13 Apr.2018	Ben Daniels – McGill University's Standardized Patients Project	Assisted Jody Bofita to set up a Quantitative Data Base

17-18 Apr.2018	Ms Mwelwa Phiri and Ms Ramya Kumar	HPTN 071 (PopART) visit
Jun.- Aug. 2018	Rachel Morse – student at Kings College London	Exchange program through partnership between faculty and Department of Social Health and Medicine
06-13 Jul. 2018	Kelly Dooley - John Hopkins University and extraordinary professor at DTTC (Department of Paediatrics)	Pharmacokinetic research meetings / Goudini TB Workshop
06-21 Jul. 2018	Ava Archery (student)	Intern on SHINE study
06-13 Jul. 2018	Sebastian Goodwin-Groen (student)	Intern
03-07 Sept. 2018	Oladapo Alli is PAB senior protocol pharmacist at the Division of AIDS.	DAIDS site visit
03-07 Sept. 2018	Eileen Pouliot - Branch Chief for the Africa and Domestic Partners Branch in the Office of Clinical Site Oversight (OCSO)	DAIDS site visit / CTU visit
17-19 Sept. 2018	Erin Sizemore ; Rosanna Boyd TB Trials Consortium (TBTC)	Site Visit and training
28 Sept. 2018	Teja Stojiljkovic, BARC	Site Visit
03-06 Sept. 2018	Lebogang Tshehla	Regulatory monitoring visit
03-06 Sept. 2018	PPD (IMPAACT)	External monitoring visit
22-26 Oct. 2018	Representatives of Consul General USA, Steven Smit (Health Attaché)	Visiting Kuils River Site office
30-31 Oct. 2018	Cathy Tupman, Global Health Manager and Aimi Vanden-Oever Section Manager for Global Health Imperial College, London- James Seddon	Meetings with key academics and the Grants office; DTTC, Tygerberg Hospital, Brooklynn Chest Hospital
28-30 Nov. 2018	PPD Monitor	Monitoring visits at Kuils River and the DTTC
28–30 Nov. 2018	Dessislava Tarlton (UNITAID) & Ekaterina Rykovanova (WHO)	Evaluation of the Centre and a walk through
31 Nov. 2018	Representatives of Consul General USA, Steven Smit (Health Attaché) and Virginia Blaser	Visited the PopART team to assess project progress on the
28-30 Nov. 2018	WHO-Unitaid (Led by Tony Garcia-Prats)	Visit to PK unit and Faculty doing an evaluation of facility, resources and staff. In depth assessment of all activities.

EMPLOYEES

During 2018 a total of (205) employee contracts ended. The exit of staff included the final annual round of the PC Field remunerators in June 2018. Between July and September, a high number of employees (20) resigned, seeking permanent employment elsewhere. The Centre also employed total of (23) new staff members on different studies, linked to different post levels. Total of (40) staff members could be re-employed, which relates our current HR retention strategy.

Staff Turnover: January 2018 - December 2018



Month	Staff count	End of contract	Resignations	New appoint.	Re-appoint.
Jan – Apr. 2018	330	23	14	6	23
May - Jun. 2018	322	130	7	8	1
Jul. - Sept. 2018	194	25	20	9	9
Oct. 2018	167	3	1	-	1
Nov. 2018	164	14	2	-	4
Dec. 2018	152	10	-	-	2
Jan. 2019	144	-	-	-	-

DTTC GOVERNANCE

DTTC Executive Committee (ExCo)

The DTTC is led by the Director, Distinguished Professor Anneke Hesseling, who is assisted by an Executive Committee (EXCO) of 12 senior scientific and core support DTTC staff members. The Director, who chairs the EXCO, reports to the Executive Head of the Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences as well as the DTTC Governing Board, which is responsible for oversight of the DTTC's strategic management. The governing board is chaired by Professor Andrew Whitelaw, Dept. Medical Microbiology and NHLS, Tygerberg; vice-chair: Professor Wolfgang Preiser: Division Head: Medical Virology. All members of the ExCo committee play an active role in the management of DTTC, making key decisions to ensure the vision and mission of DTTC are maintained and expanded. Members also form part of the scientific strategy team and are responsible for driving the research agenda at DTTC forward, in line with the 3 DTTC research pillars. The role of this team is to provide scientific input into research ideas put forward to the team and collaborate on potential research proposals.

The DTTC ExCo meets once a month. In addition, there is a dedicated scientific strategy meeting convened once a month for the ExCo and additional *ad hoc* member to discuss and plan ongoing and future research priorities and strategies.

Primary focus areas for 2019 will include applying to remain within the DAIDS and TBTC networks which offer core and study specific funding over a 7 year period. In addition DTTC is actively applying for research opportunities to strengthen core funding to support studies being conducted across the DTTC platform.

DTTC EXECUTIVE COMMITTEE ROLES AND RESPONSIBILITIES

Name	Role
Prof Anneke Hesseling	DTTC Director and chair of DTTC ExCo
Dr Tony Garcia- Pratts	Medical director of the Desmond Tutu TB Centre Brooklyn Chest Hospital Paediatric Pharmacokinetics Unit
Dr Marieke van der Zalm	Clinical lead: Paediatric lung health studies
Dr Frieda Verheye-Dua	Regulatory Manager
Prof Simon Schaaf	Lead investigator Paediatric MDR-TB studies
Dr Sue-Ann Meehan	Project Manager and co-investigator
Dr Peter Bock	Lead HIV Prevention research
Dr Muhammad Osman	Lead: Implementation Research
Mr Graeme Hoddinott	Lead Sociobehavioural Scientist
Mrs Sterna Brand	Human Resources Manager
Mr Theo Smith	Logistics /Operations Manager

Dr Rory Dunbar	Data centre manager
Dr AnneMarie Demers	Laboratory Director

RISK MANAGEMENT

Risks related to Human Resources, Finance and Regulatory are being monitored and evaluated on a regular basis.

The DTTC regulatory office will ensure that no study is commenced without appropriate regulatory approval.

The protection of study participant confidentiality remains a high priority for DTTC in our aim to deliver high quality reputable research outputs. DTTC will continue to support staff training in good clinical practice (GCP) and research confidentiality prior to any study commencement. Through constant data monitoring by dedicated data centre staff, dual entry of any research information as well as GCP training, DTTC will continue to mitigate against data fabrication. The regulatory office will also monitor the import of drugs or export of any materials to research partners to ensure no transfer is commenced without appropriate documentation.

Poor marketing and communication to external stakeholders, has resulted in low exposure to the scientific community and funding agencies. DTTC is actively working on a development plan to improve their marketing and communication efforts in order to improve our local and global footprint and develop strategic relationships with new and current external stakeholders.

Accessibility to communities for recruitment and retention of study participants is still a potential risk. DTTC Field offices have been established in various communities and the development of community advisory boards to strengthen the support for DTTC in communities has been implemented to improve accessibility. Strong line management in field offices mitigates against any HR irregularities (attendance, working hours) that may arise.

Sustainability of core support staff is an ongoing risk due to a lack of core funding. Ongoing efforts to obtain core funding is being implemented. Human resource risks relating to the safety of staff training, staff contracts to retain core staff and staff diversity has been reduced.

Political instability and violence or unrest in study communities places staff and patient safety at risk. DTTC has implemented many safety measures but have also identified various other measures to provide safe working conditions for staff. In the first quarter of 2019 all DTTC drivers will be trained and retrained in defensive driving, including highjack prevention and evaluation. The high burden of TB disease and HIV infection among the population served, poses a health risk to DTTC staff. DTTC has taken many infection control measures through modification of vehicles and offices. Infection prevention control (IPC) training has been scheduled to start in February 2019, the aim is to train all DTTC staff in Infection prevention Control measurements. A Baseline Hep B testing campaign for all staff was launched in November 2018. Staff will be tested and vaccinated in line with national guidelines.

To mitigate the risks of temporary staff contracts leading to insecurity, demotivation and often to early exit, the DTTC has adapted all adverts to two year contracts with benefits, unless the appointment is for a specific intervention linked to a shorter term...

DTTC is committed to adhere to SU diversity policies during their recruitment processes. Staff has been identified from disadvantaged backgrounds to be promoted to levels that are more senior.

Enrolment of Principle investigators in formal supervision programs has been implemented to support Master's and PhD students.

DTTC employs a cadre of finance staff who work closely with the faculty research grants management office (RGMO) to ensure no misappropriation of research funds takes place. Regular expenditure allocation, reporting and finance meetings are held to mitigate against any misappropriation. Correct budgeting in collaboration with RGMO will also mitigate against large exchange rate loss

ACKNOWLEDGEMENTS AND FUNDERS



International Collaborators | Funders | Partners





South African Collaborators | Funders | Partners



CITY OF CAPE TOWN
ISIXEKO SASEKAPA
STAD KAAPSTAD



SARChI Chair in Paediatric TB (Hesseling)



Department
for International
Development



WITS REPRODUCTIVE HEALTH & HIV INSTITUTE



SACEMA
DST-NRF Centre of Excellence in Epidemiological Modelling and Analysis



science
& technology
Department:
Science and Technology
REPUBLIC OF SOUTH AFRICA



National
Research
Foundation



Western Cape
Government
Health

BETTER TOGETHER.



Funded by Evidence for HIV Prevention in Southern Africa (EHPSA), a DFID programme managed by Mott MacDonald.



APPENDIX I. RESEARCH OUTPUTS - PUBLICATIONS

DTTC Publications January 2018 – December 2018

1. Allwood BW, **Maarman GJ**, Kyriakakis CG, Doubell, AF. Post-pulmonary tuberculosis complications in South Africa and a potential link with pulmonary hypertension: Premise for clinical and scientific investigations. *S Afr Med J*. 2018 Jun. 26;108(7):12339. doi: 10.7196/SAMJ.2018.v108i7.13359. PubMed PMID: 30004336.
2. Basu-Roy R, Whittaker E, **Seddon JA**, Kampmann B. Tuberculosis susceptibility and protection in children. *Lancet Infect Dis*. 2018 Oct 12. pii: S1473-3099(18)30157-9. doi: 10.1016/S1473-3099(18)30157-9. Epub ahead of print. PubMed PMID: 30322790.
3. **Bock P**, Fatti G, Ford N, Jennings K, Kruger J, Gunst C, Louis F, Grobbelaar N, Shanaube K, Floyd S, Grimwood A, Hayes R, Ayles H, Fidler S, **Beyers N**; HPTN 071 (PopART) trial team. Attrition when providing antiretroviral treatment at CD4 counts >500cells/muL at three government clinics included in the HPTN 071 (PopART) trial in South Africa. *PLoS One*. 2018 Apr 19;13(4):e0195127. doi: 10.1371/journal.pone.0195127. PubMed PMID: 29663952.
4. **Bock P**, Jennings K, Vermaak R, Cox H, Meintjes G, Fatti G, Kruger J, De Azevedo V, Maschilla L, Louis F, Gunst C, Grobbelaar N, **Dunbar R**, Limbada M, Floyd S, Grimwood A, Ayles H, Hayes R, Fidler S, **Beyers N**. Incidence of Tuberculosis among HIV-positive individuals initiating antiretroviral treatment at higher CD4 counts in the HPTN 071 (PopART) trial in South Africa. *J Acquir Immune Defic Syndr*. 2018 Jan 1;77(1):93-101. doi: 10.1097/QAI.0000000000001560. PubMed PMID: 29016524.
5. Bond, V, Ngwenya F, **Thomas A**, Simuyaba M, **Hoddinott G**, Fidler S, Hayes R, Ayles H, Seeley, J; HPTN 071 (PopART) study team. Spinning plates: livelihood mobility, household responsibility and anti-retroviral treatment in an urban Zambian community during the HPTN 071 (PopART) study. *J Int AIDS Soc*. 2018 Jul;21 Suppl 4:e25117. doi.org/10.1002/jia2.25117. PubMed PMID: 30027643.
6. Bond V, Nomsenge S, Mwamba M, Ziba D, Birch A, **Mubekapi-Musadaidzwa C**, **Vanqa N**, **Viljoen L**, Pliakas T, Ayles H, Hargreaves J, **Hoddinott G**, Stangl A, Seeley J; HPTN 071 (PopART) study team. "Being seen" at the clinic: Zambian and South African health worker reflections on the relationship between health facility spatial organisation and items and HIV stigma in 21 health facilities, the HPTN 071 (PopART) study. *Health Place*. 2018 Dec 7. pii: S1353-8292(18)30608-7. doi: 10.1016/j.healthplace.2018.11.006. [Epub ahead of print]. PubMed PMID: 30528346.
7. Bond V, Ngwenya F, Murray E, Ngwenya N, **Viljoen L**, Gumede D, Bwalya C, **Mantantana J**, **Hoddinott G**, Dodd PJ, Ayles H, Simwinga M, Wallman S, Seeley J. Value and Limitations of Broad Brush Surveys Used in Community-Randomized Trials in Southern Africa. *Qual Health Res*. 2018 Dec 17:1049732318809940. doi: 10.1177/1049732318809940. [Epub ahead of print]. PubMed PMID: 30556470.
8. Bradley J, Floyd S, Piwowar-Manning E, Laeyendecker O, Young A, **Bell-Mandla N**, Bwalya J, **Bock P**, Fidler S, Ayles H, Hayes, RJ; HPTN 071(PopART) Study Team. Sexually transmitted bedfellows: exquisite association between HIV and Herpes Simplex Virus Type 2 in 21 Communities in Southern Africa in the HIV Prevention Trials Network 071 (PopART) study. *J Infect Dis*. 2018 Jul 2;218(3):443-452. doi: 10.1093/infdis/jiy178. PubMed PMID: 29659909.
9. Byamungu LN, **du Preez K**, **Walters E**, Nachega JB, **Schaaf HS**. Timing of HIV diagnosis in children with tuberculosis managed at a referral hospital in Cape Town, South Africa. *Int J Tuberc Lung Dis*. 2018 May 1;22(5):488-495. doi: 10.5588/ijtld.17.0613. PubMed PMID: 29663952.
10. Chabala C, Turkova A, Thomason MJ, Wobudeya E, Hissar S, Mave V, **van der Zalm M**, **Palmer M**, Kapasa M, Bhavani PK, Balaji S, Raichur PA, **Demers AM**, **Hoddinott G**, Owen-Powell E, Kinikar A, Musoke P, Mulenga V, Aarnoutse R, McIlleron H, **Hesseling A**, Crook AM, **Cotton M**, Gibb DM;

- SHINE trial team. Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial. *Trials*. 2018 Apr 19;19(1):237. doi: 10.1186/s13063-018-2608-5. PubMed PMID: 29673395.
11. Cranmer LM, **Draper HR**, Mandalakas AM, Kim S, McSherry G, Krezinski E, Coetzee J, Mitchell C, Nachman S, van der Linde M, **Cotton MF, Hesselning AC**; IMPAACT P1041 Team. High incidence of tuberculosis infection in HIV-exposed children exiting an Isoniazid preventive therapy trial. *Pediatr Infect Dis J*. 2018 Oct;37(10):e254-e256. doi: 10.1097/INF.0000000000001946. PubMed PMID: 29462104.
 12. Cruz AT, **Garcia-Prats AJ**, Furin J, **Seddon JA**. Treatment of Multidrug-Resistant Tuberculosis Infection in Children. *Pediatr Infect Dis J*. 2018 Oct;37(10):1061-1064. doi: 10.1097/INF.0000000000002135. No abstract available. PubMed PMID: 30216296.
 13. Denti P, **Garcia-Prats AJ, Draper HR**, Wiesner L, **Winckler J**, Thee S, Dooley KE, Savic RM, McIlleron HM, **Schaaf HS, Hesselning AC**. Levofloxacin population pharmacokinetics in South African children treated for multidrug-resistant tuberculosis. *Antimicrob Agents Chemother*. 2018 Jan 25;62(2). pii: e01521-17. doi: 10.1128/AAC.01521-17. PubMed PMID: 29133560.
 14. Dodd PJ, Yuen CM, Becerra MC, Revill P, Jenkins HE, **Seddon JA**. Potential effect of household contact management on childhood tuberculosis: a mathematical modelling study. *Lancet Glob Health*. 2018 Dec;6(12):e1329-e1338. doi: 10.1016/S2214-109X(18)30401-7. PubMed PMID: 30266570.
 15. **Donald PR**, Diacon AH, Lange C, **Demers AM**, von Groote-Biddlingmeier F, Nardell E. Droplets, dust and guinea pigs: an historical review of tuberculosis transmission research. 1878–1940. *Int J Tuberc Lung Dis*. 2018 Sep 1;22(9):972-982. doi: 10.5588/ijtld.18.0173. PubMed PMID: 30092861.
 16. **du Preez K, Schaaf HS, Dunbar R, Walters E, Swartz A, Solomons R, Hesselning AC**. Complementary surveillance strategies are needed to better characterise the epidemiology, care pathways and treatment outcomes of tuberculosis in children. *BMC Public Health*. 2018 Mar 23;18(1):397. doi: 10.1186/s12889-018-5252-9. PubMed PMID: 29566651.
 17. **du Preez K**, du Plessis L, O'Connell N, **Hesselning AC**. Burden, spectrum and outcomes of children with tuberculosis diagnosed at a district-level hospital in South Africa. *The International Journal of Tuberculosis and Lung Disease*. 2018 Sep 1;22(9):1037-1043. doi: 10.5588/ijtld.17.0893. PubMed PMID: 30092869.
 18. Floyd S, Schaap A, Shanaube K, Macleod D, Phiri M, Griffith S, **Bock P, Beyers N**, Fidler S, Hayes R, on behalf of the HPTN 071 (PopART) study team. Towards 90-90: Findings after two years of the HPTN071 (PopART) universal testing-and-treatment intervention in Zambia. *PLoS One*. 2018; 13(8): e0197904. PubMed PMID: 30096139.
 19. Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghaei P, Bang D, Bastos M, Benedetti A, Bonnet M, Cattamanchi A, Cegielski P, Chien JY, Cox H, Dediccoat M, Erkens C, Escalante P, Falzon D, **Garcia-Prats AJ**, Gegia M, Gillespie SH, Glynn JR, Goldberg S, Griffith D, Jacobson KR, Johnston JC, Jones-López EC, Khan A, Koh WJ, Kritski A, Lan ZY, Lee JH, Li PZ, Maciel EL, Galliez RM, Merle CSC, Munang M, Narendran G, Nguyen VN, Nunn A, Ohkado A, Park JS, Phillips PPJ, Ponnuraja C, Reves R, Romanowski K, Seung K, **Schaaf HS**, Skrahina A, Soolingen DV, Tabarsi P, Trajman A, Trieu L, Banurekha VV, Viiklepp P, Wang JY, Yoshiyama T, Menzies D. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. *Lancet Respir Med*. 2018 Apr;6(4):265-275. doi: 10.1016/S2213-2600(18)30078-X. PubMed PMID: 29595509.
 20. Frigati L, Bekker A, Stroebele S, Goussard P, and **Schaaf HS**. Culture-Confirmed Tuberculosis in South African Infants Younger Than 3 Months of Age: Clinical Presentation and Management of Respiratory Complications. *The Pediatric infectious disease journal*. 2018 Aug 27. doi: 10.1097/INF.0000000000002163. PubMed PMID: 30153235.

21. Furin J, Tommasi M, **Garcia-Prats AJ**. Drug-resistant tuberculosis: will grand promises fail children and adolescents? *Lancet Child Adolesc Health*. 2018 Apr;2(4):237-238. doi: 10.1016/S2352-4642(18)30068-3. Epub 2018 Mar 13. No abstract available. PubMed PMID: 30169295
22. **Garcia-Prats AJ, Draper HR**, Finlayson H, **Winckler J**, Burger A, Fourie B, Thee S, **Hesseling AC, Schaaf HS**. Clinical and cardiac safety of long-term levofloxacin in children treated for multidrug-resistant tuberculosis. *Clin Infect Dis*. 2018 Nov 13;67(11):1777-1780. doi: 10.1093/cid/ciy416. PubMed PMID: 29788331.
23. **Garcia-Prats AJ, Rose PC, Draper HR, Seddon JA**, Norman J, McIlleron HM, **Hesseling AC, Schaaf HS**. Effect of co-administration of Lidocaine on the pain and pharmacokinetics of intramuscular Amikacin in children with multidrug-resistant tuberculosis: a randomized crossover trial. *Pediatr Infect Dis J*. 2018 Dec;37(12):1199-1203. doi: 10.1097/INF.0000000000001983. PubMed PMID: 29561515.
24. **Garcia-Prats AJ**, Svensson EM, Weld ED, **Schaaf HS, Hesseling AC**. Current status of pharmacokinetic and safety studies of multidrug-resistant tuberculosis treatment in children. *Int J Tuberc Lung Dis*. 2018 May 1;22(5):15-23. doi: 10.5588/ijtld.17.0355. PubMed PMID: 29665949.
25. García-Basteiro AL, **Schaaf HS**, Diel R, Migliori GB. Adolescents and young adults: a neglected population group for tuberculosis surveillance. *Eur Respir J*. 2018 Feb 21;51(2). pii: 1800176. doi: 10.1183/13993003.00176-2018. PubMed PMID: 2946721.1.
26. Goussard P, **Gie RP**, Janson J. Lethal fibrosing mediastinitis in a child possibly due to *Mycobacterium tuberculosis*. PMID: 29635837 *Pediatr Pulmonol*. 2018 Jun;53(6):E18-E20. doi: 10.1002/ppul.24012. Epub 2018 Apr 10. DOI: 10.1002/ppul.24012.
27. **Harausz EP, Garcia-Prats AJ**, Law S, **Schaaf HS**, Kredo T, **Seddon JA**, Menzies D, Turkova A, Achar J, Amanullah F, Barry P, Becerra M, Chan ED, Chan PC, Ioana Chiotan D, Crossa A, Drobac PC, Fairlie L, Falzon D, Flood J, Gegia M, Hicks RM, Isaakidis P, Kadri SM, Kampmann B, Madhi SA, Marais E, Mariandyshev A, Méndez-Echevarría A, Moore BK, Nargiza P, Ozere I, Padayatchi N, Ur-Rehman S, Rybak N, Santiago-Garcia B, Shah NS, Sharma S, Shim TS, Skrahina A, Soriano-Arandes A, van den Boom M, van der Werf MJ, van der Werf TS, Williams B, Yablokova E, Yim JJ, Furin J, **Hesseling AC**; Collaborative Group for Meta-Analysis of Paediatric Individual Patient Data in MDR-TB. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. *PLoS Med*. 2018 Jul 11;15(7):e1002591. doi: 10.1371/journal.pmed.1002591. PubMed PMID: 29995958.
28. Hargreaves JR, Krishnaratne S, **Mathema H**, Lilleston PS, Sievwright K, **Mandla N**, Mainga T, **Vermaak R**, Piwowar-Manning E, Schaap A, Donnell D, Ayles H, Hayes RJ, **Hoddinott G**, Bond V, Stangl A; HPTN 071 (PopART) Study Team. Individual and community-level risk factors for HIV stigma in 21 Zambian and South African communities: analysis of data from the HPTN071 (PopART) study. *AIDS*. 2018 Mar 27;32(6):783-793. doi: 10.1097/QAD.0000000000001757. PubMed PMID: 29369164.
29. Hirsch-Moverman Y, Mantell JE, Lebelo L, Wynn C, **Hesseling AC**, Howard AA, Nachman S, Frederix K, Maama LB, El-Sadr WM. Tuberculosis preventive treatment preferences among care givers of children in Lesotho: a pilot study. *Int J Tuberc Lung Dis*. 2018 Aug 1;22(8):858-862. doi: 10.5588/ijtld.17.0809. PubMed PMID: 29991393.
30. **Hoddinott G, Hesseling AC**. Sociobehavioural science is needed to understand the impact of paediatric MDR-TB treatment on children and their families. *Int J Tuberc Lung Dis*. 2018 Jan 1;22(1):4. doi: 10.5588/ijtld.17.0814. PubMed PMID: 29297419.
31. **Hoddinott G, Myburgh H, de Villiers L**, Ndubani R, **Mantantana J, Thomas A**, Mbewe M, Ayles H, **Bock P**, Seeley J, Shanaube K, Hargreaves J, Bond V, Reynolds L; HPTN 071 (PopART) Study Team. Households, fluidity, and HIV service delivery in Zambia and South Africa - an exploratory analysis

- of longitudinal qualitative data from the HPTN 071 (PopART) trial. *J Int AIDS Soc.* 2018 Jul;21 Suppl 4:e25135. doi: 10.1002/jia2.25135. PubMed PMID: 30027687.
32. **Hoddinott G**, Staples S, **Brown R**, Simwinga M, **Mubekapi-Musadaidzwa C**, **Hesseling AC**, **Hendricks G**, **De Koker P**, McKenna L. Community engagement for paediatric MDR-TB clinical trials: principles to support ethical trial implementation. *Int J Tuberc Lung Dis.* 2018 May 1;22(5):40-45. doi: 10.5588/ijtld.17.0356. PubMed PMID: 29665952.
 33. Innes S, **van der Laan L**, Anderson PL, **Cotton M**, Denti P. Can we improve Stavudine's safety profile in children? Pharmacokinetics of intracellular Stavudine Triphosphate with reduced dosing. *Antimicrob Agents Chemother.* 2018 Oct 24;62(11). pii: e00761-18. doi: 10.1128/AAC.00761-18. PubMed PMID: 30104267.
 34. Jacobs C, Goussard P, **Gie RP**. Mycobacterium tuberculosis, a cause of necrotising pneumonia in childhood: a case series. *Int J Tuberc Lung Dis.* 2018 Jun 1;22 (6):614-616. doi: 10.5588/ijtld.17.0570. Epub 2018 Mar 22. PMID: 29566781 DOI: 10.5588/ijtld.17.0570
 35. Kampmann B, **Seddon JA**, Paton J, Nademi Z, Keane D, Williams B, Williams A, Liebeschutz S, Riddell A8, Bernatoniene J, Patel S, Martinez N, McMaster P, Basu-Roy R, Welch SB. Evaluating UK national guidance for screening of children for tuberculosis. A prospective multicenter study. *Am J Respir Crit Care Med.* 2018 Apr 15;197(8):1058-1064. doi: 10.1164/rccm.201707-1487OC. PubMed PMID: 29190430.
 36. Kay A, **Garcia-Prats AJ**, Mandalakas A M. HIV-associated pediatric tuberculosis: prevention, diagnosis and treatment. *Curr Opin HIV AIDS.* 2018 Nov;13(6):501-506. doi: 10.1097/COH.0000000000000500. PubMed PMID: 30286040.
 37. Keshavjee S, Amanullah F, Cattamanchi A, Chaisson R, Dobos KM, Fox GJ, Gendelman HE, Gordon R, **Hesseling A**, Hoi LV, Kampmann B, Kana B, Khuller G, Lewinsohn DM, Lewinsohn DA, Lin PL, Lu LL, Maartens G, Owen A, Protopopova M, Rengarajan J, Rubin E, Salgame P, Schurr E, **Seddon JA**, Swindells S, Tobin DM, Udawadia Z, Walzl G, Srinivasan S, Rustomjee R, Nahid P. Moving toward tuberculosis elimination: critical issues for research in diagnostics and therapeutics for tuberculosis infection. *Am J Respir Crit Care Med.* 2018 Oct 18. doi: 10.1164/rccm.201806-1053PP. [Epub ahead of print] PubMed PMID: 30335466.
 38. Khan PY, Yates TA, **Osman M**, Warren RM, van der Heijden Y, Padayatchi N, Nardell EA, Moore D, Mathema B, Gandhi N, Eldholm V, Dheda K, **Hesseling AC**, Mizrahi V, Rustomjee R, Pym A. Transmission of drug-resistant tuberculosis in HIV-endemic settings. *Lancet Infect Dis.* 2018 Dec 13. pii: S1473-3099(18)30537-1. doi: 10.1016/S1473-3099(18)30537-1. [Epub ahead of print] Review. PubMed PMID: 30554996.
 39. Kim S, **Seddon JA**, **Garcia-Prats AJ**, Montepiedra G. Statistical considerations for pediatric multidrug-resistant tuberculosis efficacy trials. *Int J Tuberc Lung Dis.* 2018 May 1;22(5):34-39. doi: 10.5588/ijtld.17.0358. PubMed PMID: 29665951.
 40. Liu C, Lyon CJ, Bu Y, Deng Z, **Walters E**, Li Y, Zhang L, **Hesseling AC**, Graviss EA, Hu Y. Clinical evaluation of a blood assay to diagnose Paucibacillary tuberculosis via bacterial antigens. *Clin Chem.* 2018 May;64(5):791-800. doi: 10.1373/clinchem.2017.273698. PubMed PMID: 29348166.
 41. **Maarman GJ**. Pulmonary arterial hypertension and the potential roles of metallothioneins: A focused review. *Life Sci.* 2018 Dec 1;214:77-83. doi: 10.1016/j.lfs.2018.10.039. Epub 2018 Oct 22. PubMed PMID: 30355531
 42. Mann TN, **Schaaf HS**, Dunn RN, Dix-Peek S, **du Preez K**, Lamberts RP, du Toit J, Davis JH. Child and adult spinal tuberculosis at tertiary hospitals in the Western Cape, South Africa: 4-year burden and trend. *Epidemiol Infect.* 2018 Dec;146(16):2107-2115. doi: 10.1017/S0950268818002649. Epub 2018 Sep 28. PubMed PMID: 30264687.
 43. **Marx FM**, Yaesoubi R, Menzies NA, Salomon JA, Bilinski A, **Beyers N**, Cohen T. Tuberculosis control interventions targeted to previously treated people in a high-incidence setting: a

- modelling study. *Lancet Glob Health*. 2018 Apr;6(4):e426-e435. doi: 10.1016/S2214-109X(18)30022-6. PubMed PMID: 29472018.
44. **Meehan SA, Sloot R, Draper HR**, Naidoo P, Burger R, **Beyers N**. Factors associated with linkage to HIV care and TB treatment at community-based HIV testing services in Cape Town, South Africa. *PLoS One*. 2018 Apr 2;13(4):e0195208. doi: 10.1371/journal.pone.0195208. eCollection 2018. PubMed PMID: 29608616.
 45. Mohiyuddin T, **Seddon JA**, Thomas HL, Lalor MK. The changing landscape of childhood Tuberculosis in the United Kingdom: A retrospective cohort (2000 to 2015). *Pediatr Infect Dis J*. 2018 Sep 25. doi: 10.1097/INF.0000000000002200. PubMed PMID: 30256311.
 46. **Myburgh H**, Calitz E, Railton JP, Maluleke C, Mashao E, Ketelo P, Jobson G, Grobbelaar CJ, Struthers HE, Peters RPH. Breaking down barriers to tell: A mixed methods study of health worker involvement in disclosing to children that they are living with HIV in rural South Africa. *J Assoc Nurses AIDS Care*. 2018 Nov - Dec;29(6):902-913. doi: 10.1016/j.jana.2018.04.009. Epub 2018 Apr 25. PubMed PMID: 29784521.
 47. Nemes E, **Hesseling AC**, Tameris M, Mauff K, Downing K, Mulenga H, Rose P, **van der Zalm M**, Mbaba S, Van As D, Hanekom WA, Walz G, Scriba TJ, McShane H, Hatherill M; MVA029 Study Team. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected mothers: a phase 2 randomized, controlled trial. *Clin Infect Dis*. 2018 Feb 1;66(4):554-563. doi: 10.1093/cid/cix834. PubMed PMID: 29028973.
 48. Obihara NJ, **Walters E**, Lawrenson J, **Garcia-Prats AJ, Hesseling AC, Schaaf HS**. Tuberculous Pericardial Effusions in Children. *J Pediatric Infect Dis Soc*. 2018 Dec 3;7(4):346-349. doi: 10.1093/jpids/pix087. PubMed PMID: 29096017
 49. Opollo VS, Wu X, Hughes MD, Swindells S, Gupta, A, **Hesseling A**, Churchyard G, Kim S, Lando R, Dawson R, Mave V, Mendoza A, Gonzales P, Kumarasamy N, von Groote-Bidlingmaier F, Conradie F, Shenje J, Fontain SN, **Garcia-Prats A**, Asmelash, A, Nedsuwan S, Mohapi L, Mngqibisa R, Garcia Ferreira AC, Okeyo E, Naini L, Jones L, Smith B, Shah NS. HIV testing uptake among the household contacts of multidrug-resistant tuberculosis index cases in eight countries. *Int J Tuberc Lung Dis*. 2018 Dec 1;22(12):1443-1449. doi: 10.5588/ijtld.18.0108. PubMed PMID: 30606316.
 50. **Purchase SE, Garcia-Prats AJ, De Koker P, Draper HR, Osman M, Seddon JA, Schaaf HS, Hesseling AC**. Acceptability of a Novel Levofloxacin Dispersible Tablet Formulation in Young Children Exposed to Multidrug-Resistant Tuberculosis. *Pediatr Infect Dis J*. 2018 Dec 13. doi: 10.1097/INF.0000000000002268. [Epub ahead of print] PubMed PMID: 30550511.
 51. Rosser A, **Marx FM**, Pareek M. Recurrent tuberculosis in the pre-elimination era. *Int J Tuberc Lung Dis*. 2018 Feb 1;22(2):139-150. doi: 10.5588/ijtld.17.0590. PubMed PMID: 29506610.
 52. Basu-Roy R, Whittaker, E, **Seddon JA**, Kampmann B. Tuberculosis susceptibility and protection in children. *Lancet Infect Dis*. 2018 Oct 12. pii: S1473-3099(18)30157-9. doi: 10.1016/S1473-3099(18)30157-9. PubMed PMID: 30322790.
 53. Sabapathy K, Mulubwa C, **Mathema H, Mubekapi-Musadaidzwa C**, Schaap A, **Hoddinott G**, Hargreaves J, Floyd S, Ayles H, Hayes R; HPTN 071 (PopART) Study Team. Is home-based HIV testing universally acceptable? Findings from a case-control study nested within the HPTN 071 (Pop ART) trial. *Trop Med Int Health*. 2018 Jun;23(6):678-690. doi: 10.1111/tmi.13055. Epub 2018 Apr 16. PubMed PMID: 29608231.
 54. **Schaaf HS, Garcia-Prats AJ**, McKenna L, **Seddon JA**. Challenges of using new and repurposed drugs for the treatment of multidrug-resistant tuberculosis in children. *Expert Rev Clin Pharmacol*. 2018 Mar;11(3):233-244. doi: 10.1080/17512433.2018.1421067. PubMed PMID: 29280409.

55. **Seddon JA**, Weld ED, **Schaaf HS**, **Garcia-Prats AJ**, Kim S, **Hesseling AC**. Conducting efficacy trials in children with MDR-TB: what is the rationale and how should they be done? *The Int J Tuberc Lung Dis*. 2018 May 1;22(5):24-33. doi: 10.5588/ijtld.17.0359. PubMed PMID: 29665950.
56. **Seddon JA**, **Garcia-Prats AJ**, **Purchase SE**, **Osman M**, Demers AM, **Hoddinott G**, Crook AM, Owen-Powell E, Thomason MJ, Turkova A, Gibb DM, Fairlie L, Martinson N, **Schaaf HS**, **Hesseling AC**. Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP). *Trials*. 2018 Dec 20;19(1):693. doi: 10.1186/s13063-018-3070-0. PubMed PMID: 30572905; PubMed Central PMCID: PMC6302301.
57. **Seddon JA**, **Schaaf HS**, Marais BJ, McKenna L, **Garcia-Prats AJ**, **Hesseling AC**, Hughes J, Howell P, Detjen A, Amanullah F, Singh U, Master I, Perez-Velez CM, Misra N, Becerra MC, Furin. Time to act on injectable-free regimens for children with multidrug-resistant tuberculosis. *Lancet Respir Med*. 2018 Sep;6(9):662-664. doi: 10.1016/S2213-2600(18)30329-1. PubMed PMID: 30191832
58. **Seddon JA**, Chiang SS, Esmail H, Coussens AK. The Wonder Years: What Can Primary School Children Teach Us About Immunity to Mycobacterium tuberculosis? *Front Immunol*. 2018 Dec 13;9:2946. doi: 10.3389/fimmu.2018.02946. eCollection 2018. PubMed PMID: 30619306.
59. Seeley J, Bond V, **Yang B**, Floyd S, MacLeod D, **Viljoen L**, Phiri M, Simuyaba M, **Hoddinott G**, Shanaube K, Bwalya C, **de Villiers L**, Jennings K, Mwanza M, Schaap A, **Dunbar R**, Sabapathy K, Ayles H, **Bock P**, Hayes R, Fidler S; HPTN 071 (PopART) study team. Understanding the Time Needed to Link to Care and Start ART in Seven HPTN 071 (PopART) Study Communities in Zambia and South Africa. *AIDS Behav*. 2018 Nov 10. doi: 10.1007/s10461-018-2335-7. [Epub ahead of print]. PubMed PMID: 30415432.
60. **Sloot R**, **Maarman GJ**, **Osman M**, **Marx F**. On Behalf Of The Desmond Tutu Tb Centre-Working Group Data Analysis And Modelling FM. Variation in HIV prevalence and the population-level effects of antiretroviral therapy in reducing tuberculosis incidence in South Africa. *S Afr Med J*. 2018 Jul 25;108(8):12370. doi: 10.7196/SAMJ.2018.v108i8.13394. PubMed PMID: 30182871.
61. Svensson EM, du Bois J, Kitshoff R, de Jager VR, Wiesner L, Norman J, Nachman S, Smith B, Diacon AH, **Hesseling AC**, **Garcia-Prats AJ**. Relative bioavailability of bedaquiline tablets suspended in water: implications for dosing in children. *Br J Clin Pharmacol*. 2018 Jun 27. doi: 10.1111/bcp.13696. [Epub ahead of print] PubMed PMID: 29952141.
62. Swindells S, Gupta A, Kim S, Hughes MD, Sanchez J, Mave V, Dawson R, Kumarasamy N, Comins K, Smith B, Rustonjee R, Naini L, Shah NS, **Hesseling A**, Churchyard G. Resource utilization for multidrug-resistant tuberculosis household contact investigations (A5300/I2003). *Int J Tuberc Lung Dis*. 2018 Sep 1;22(9):1016-1022. doi: 10.5588/ijtld.18.0163. PubMed PMID: 30092866; PubMed Central PMCID: PMC6104641.
63. Thuboy B, Kellermann T, Castel S, Norman J, Joubert A, **Garcia-Prats AJ**, **Hesseling AC**, Wiesner L. The determination of capreomycin in human plasma by LC-MS/MS using ion-pairing chromatography and solid-phase extraction. *Biomed Chromatogr*. 2018 May 3:e4269. doi: 10.1002/bmc.4269. PubMed PMID: 29726023.
64. Vanker A, **van der Laan LE**, **Garcia-Prats AJ**, **Schaaf HS**, Tikiso T, Wiesner L, de Kock M, **Winckler J**, Norman J, McIlleron H, Denti P, **Hesseling AC**. Pharmacokinetics and drug-drug interactions of Lopinavir-Ritonavir administered with first- and second-line antituberculosis drugs in HIV-Infected children treated for multidrug-resistant tuberculosis. *Antimicrob Agents Chemother*. 2018 Jan 25;62(2). pii: e00420-17. doi: 10.1128/AAC.00420-17. PubMed PMID: 29133558.
65. Van Elsland SL, Van Dongen SI, Bosmans JE, **Schaaf HS**, Van Toorn R, Van Furth AM. Cost-effectiveness of home-based vs. in-hospital treatment of paediatric tuberculous meningitis. *Int J Tuberc Lung Dis*. 2018 Oct 1;22(10):1188-1195. doi: 10.5588/ijtld.18.0236. PubMed PMID: 30236187.

66. Vanker A, **Gie RP**, Zar HJ. Earlylife exposures to environmental tobacco smoke and indoor air pollution in the Drakenstein Child Health Study: Impact on child health. *S Afr Med J*. 2018 Feb 1;108(2):71-72. doi: 10.7196/SAMJ.2017.v108i2.13088. PMID: 29429431 DOI: 10.7196/SAMJ.2017.v108i2.13088.
67. **Walters E, Demers AM, van der Zalm M**, Whitelaw A, **Palmer M, Bosch C, Draper HR, Gie RP, Hesselning AC**. Reply to Drancourt, "Culturing Stools To Detect Mycobacterium tuberculosis". *J Clin Microbiol*. 2018 Apr 25;56(5). pii: e00056-18. doi: 10.1128/JCM.00056-18. PubMed PMID: 29695539.
68. **Walters E, van der Zalm MM, Demers AM**, Whitelaw A, **Palmer M, Bosch C, Draper HR, Schaaf HS**, Goussard P, Lombard CJ, **Gie RP, Hesselning AC**. Specimen Pooling as a Diagnostic Strategy for Microbiologic Confirmation in Children With Intrathoracic Tuberculosis. *Pediatr Infect Dis J*. 2018 Nov 9. doi:10.1097/INF.0000000000002240. [Epub ahead of print] PubMed PMID: 30418355.
69. **Walters E**, Scott L, Nabeta P, Demers AM, Reubenson G, Bosch C, David A, **van der Zalm M**, Havumaki J, **Palmer M, Hesselning AC**, Ncayiyana J, Stevens W, Alland D, Denkinger C, Banada P. Molecular Detection of Mycobacterium tuberculosis from Stools in Young Children by Use of a Novel Centrifugation-Free Processing Method. *J Clin Microbiol*. 2018 Aug 27;56(9). pii: e00781-18. doi: 10.1128/JCM.00781-18. Print 2018 Sep. PubMed PMID: 29997199; PubMed Central PMCID: PMC6113478.
70. **Walters E**, Scott L, Nabeta P, **Demers AM**, Reubenson G, **Bosch C**, David A, **van der Zalm M**, Havumaki J, **Palmer M, Hesselning AC**, Ncayiyana J, Stevens W, Alland D, Denkinger C, Banada P. Molecular detection of Mycobacterium tuberculosis from stool in young children using a novel centrifugation-free processing method. *J Clin Microbiol*. 2018 Aug 27;56(9). pii: e00781-18. doi: 10.1128/JCM.00781-18. PubMed PMID: 29997199.
71. Wood LF, Brown BP, Lennard K, Karaoz U, Havyarimana E, Passmore J, **Hesselning AC**, Edlefsen PT, Kuhn L, Mulder N, Brodie EL, Sodora DL, Jaspan HB. Feeding-related gut microbial composition associates with peripheral T cell activation and mucosal gene expression in African infants. *Clin Infect Dis*. 2018 Sep 28;67(8):1237-1246. doi: 10.1093/cid/ciy265. PubMed PMID: 29659737.
72. Yates TA, Ayles H, Leacy FP, Schaap A, Boccia D, **Beyers N**, Godfrey-Faussett P, Floyd S. Socio-economic gradients in prevalent tuberculosis in Zambia and the Western Cape of South Africa. *Trop Med Int Health*. 2018 Apr;23(4):375-390. doi: 10.1111/tmi.13038. PubMed PMID: 29432669.

Other Publications

1. **Schaaf HS**, Marais BJ, Carvalho I, **Seddon JA**. Challenges in childhood tuberculosis. In: ERS Monograph: *Tuberculosis*. Eds. Migliori GB, Bothamley G, Duarte R, Rendon A. European Respiratory Society, Sheffield, UK. 2018:234-262 .
2. Statement on injectable-free regimens for children under the age of 12 years with rifampicin-resistant tuberculosis <http://sentinel-project.org/wp-content/uploads/2018/07/Recommendations-for-Injectable-Free-Regimens-in-Children-with-Rif-Resistant-TB.pdf>
3. Research Priorities for Paediatric Tuberculosis. World Health Organization. https://www.finddx.org/wp-content/uploads/2018/09/Paediatric_TB_ResearchPriorities_FINAL_Web.pdf
4. Roadmap towards ending TB in children and adolescents. World Health Organization <http://apps.who.int/iris/bitstream/handle/10665/275422/9789241514798-eng.pdf>

5. Best Practices in Child and Adolescent TB Care. World Health Organization
<https://www.finddx.org/wp-content/uploads/2018/09/Best-Practices-Child-Adolescent-TB-Care.pdf>

APPENDIX II: STUDENTS – MASTERS, PHD AND POSTDOCTORAL

The following PhD students graduated in 2018:

Dr. Anthony Garcia-Prats

Supervisor: Anneke Hesseling; Simon Schaaf

Dissertation: Optimizing and operationalizing MDR-TB treatment in children

Dr. Elisabetta Walters

Supervisors: Anneke Hesseling; Robert Gie

Dissertation: Novel approaches to diagnosis of TB in children

Dr. Peter Bock

Supervisors: Nulda Beyers, Sarah Fidler (Imperial College)

Dissertation: The impact of POPART intervention on the mortality and AIDS related morbidity amongst HIV positive adults in South Africa

Dr. Florian Marx

Supervisors: Nulda Beyers; Ted Cohen

Dissertations: Mathematical modelling to project the impact of interventions targeted to individuals previously treated for tuberculosis on the trajectory of the tuberculosis epidemic in high-burden settings

Sue-Ann Meehan

Supervisors: Nulda Beyers; Ronelle Burger

Dissertation: The contribution of a community based HIV counseling and testing initiative in working towards increasing access to HIV counseling and testing in Cape Town, South Africa.

Rory Dunbar

Supervisors: Nulda Beyers; Ivor Langley; Pren Naidoo

Dissertation: How can virtual implementation modelling inform the scale-up of new molecular diagnostic tools for tuberculosis?

The following PhD student submitted their dissertations in 2018:

Graeme Hoddinott

Supervisor: Mary van der Riet

Dissertation: Toward a conceptual model of 'the act'; an exercise in theory-generation in the problematic space of school-based HIV prevention through behavior change interventio

DTTC or DTTC-supported students currently registered (2018)

Currently Registered Trainees: Master's Degree					
Name of trainee	Current position	Degree	Supervisor	Research Topic	
Jabulile Mantantana, BPsych	Community Engagement,	MPhil Transdisciplinary Public health and	Graeme Hoddinott	Continuity of ART for people who experience incarceration	
Christopher Mahwire, MEd	Melissa Nel	Social Science Research Apprentice	MPhil Transdisciplinary Public health and development studies (SU)	Graeme Hoddinott	A scale for rapidly ascribing socio-economic status estimates to neighbourhoods using observational and participatory research techniques.
Marcel Kany Kitnge	Nelis Grobbelaar	Programme Director (ANOVA Health)	MPhil Transdisciplinary Public health and development studies (SU)	Graeme Hoddinott	Integrating change to universal HIV-testing and ART regardless of CD4 -count into routine health services
Nozizwe Mai	Dianne van Aswegen	Social Science Research Intern	MA Anthropology (SU)	Shaheed Tayob	Trauma, care and evidence, from the Mosaic centre to the courtroom, gender-based violence and the state in Cape Town, South Africa
Lena Ronge, MD	Kyla Meyerson	Social Science Research Intern	MA Psychology (SU)	Mark Tomlinson Graeme Hoddinott	The experiences of paediatric MDR-TB patients' (0-5 years old) hospitalised for treatment in terms of separation and attachment
Nosivuyile Vanqa	Leletu Busakwe	Social Science Research Intern	MA Anthropology (UWC)	Sakhumzi Mfecane	The experiences of paediatric MDR-TB patients' (14-17 years old) hospitalised for treatment in terms of adolescent social and biological development
Dionne Jivar	Vuyokazi Myoli	Social Science Research Intern	MPhil Transdisciplinary Public health and development studies (SU)	Lindsey Reynolds	Young women's talk about reproductive health service access
	Khanya Mama		MCom (SU)	Ronelle Burger Graeme Hoddinott	TB patients with confirmed diagnoses who decline/delay taking up treatment – exploring why
	Rene Raad	Social Science Research Intern	MA Anthropology	Thomas Cousins	Termination of pregnancy providers' experiences of stigma and care
	Bianca Hamman	Medical microbiology	MSc (SU)	Mae Newton-Foot Marieke vd Zalm	The role of respiratory co-infections and the microbiome in the clinical presentation and response to treatment in South African children with suspected TB

Currently registered PhDs				
Name of trainee	Current position	Degree	Supervisor	Research Topic
Nomtha Mandla, Physio	Project Manager: PopArt	PHD (SU)	Lungiswa Nkonki Peter Bock	Recruitment, participation and retention of research participants in the HPTN 071 Population Cohort, South Africa.
Graeme Hoddinott, MSocSc	Lead Social Scientist	PhD , (UKZN)	Mary Van Der Riet	Toward a conceptual model of 'the act'; an exercise in theory-generation in the problematic space of school-based HIV prevention through behavior change intervention
Martina Mchenga, MPhil	PhD student	PhD (SU)	Ronelle Burger	Vulnerable households and health: evidence from surveys in South Africa and Malawi"
Lario Viljoen, MA	Social Science Researcher	PhD (SU)	Lindsey Reynolds	Young women's sexual decision-making in the context of earlier ART-access
Karen du Preez, MD, MSc	Research Medical Officer	PhD (SU)	Anneke Hesselting Simon Schaaf Pren Naidoo	Complementary surveillance strategies and interventions to inform a tuberculosis care cascade for children
Anne-Marie Demers, MD	Medical Microbiologist	PhD (SU)	Anneke Hesselting Andrew Whitelaw (NHLS)	Use of routine microbiology data in paediatric TB trials
Muhammad Osman, MD, Msc	Research Medical Officer	PhD (SU)	Anneke Hesselting Pren Naidoo Alex Welte	TB-associated mortality in South Africa: longitudinal trends and the impact of health system interventions
Tamaryn Jane Nicholson	Social Science Researcher	PhD (UKZN)	Mike Quayle Mary van der Riet Orla Muldoon	HIV stigma and mass media communication messaging
Louvina van der Laan, MD	Research Medical Officer	PhD (UCT)	Paolo Denti Anthony Garcia-Prats	Pharmacometric modelling as a tool to optimise TB Treatment in children

Post docs current

Name of trainee		Degree	Supervisor	Research Topic
Marieke van der Zalm	Paediatrician	Postdoc (SU)	Anneke Hesselning	Lung function and respiratory pathogens in children with suspected TB
Rosa Sloot	Biostatistician	Postdoc (SU)	Pren Naidoo	Epidemiology- HPTN071 (PopART)

Graduates 2018

Name of trainee	Current position	Degree	Supervisor	Research Topic
Heidi van Deventer, MD	Research Medical Officer	MSc Clin Epid (SU)	Anneke Hesselning	Effect of TB on risk of atopy in children
Celeste de Vaal, MD, DCH	Research Medical Officer	MPhil Bioethics (SU)	Lyn Horn	Ethics of post-mortem studies and notifiable diseases including TB
Catherine Wiseman, MD	Research Medical Officer	MPH (UCT)	Anneke Hesselning	Effect of HIV exposure on risk of TB infection in infants in high-burden communities
Anelet James, MSc Microbiology	DTTC Operations Manager	MBA (USB)	Jako Volschenk	Comparing patient costs for MDR TB and HIV co-infected patients under LPA and Xpert diagnostic algorithms
Anthony Garcia-Prats, MD, Msc	Paediatric PI BCH PK Unit Medical Director	PhD (SU)	Anneke Hesselning Simon Schaaf	Optimizing and operationalizing MDR-TB treatment in children
Elisabetta Walters, MD, MMed	Research Pediatrician	PhD (SU)	Anneke Hesselning Robert Gie	Novel approaches to diagnosis of TB in children
Peter Bock, MBChB (UCT), MRCP (UK), MRCPG (UK) MPH (UCT)	Specialist Family Physician Co-PI: PopArt	PhD (SU)	Nulda Beyers, Sarah Fidler (Imperial College)	The impact of POPART intervention on the mortality and AIDS related morbidity amongst HIV positive adults in South Africa
Florian Marx, MD*	Research Fellow	PhD (SU)	Nulda Beyers Ted Cohen	Mathematical modelling to project the impact of interventions targeted to individuals previously treated for tuberculosis on the trajectory of the tuberculosis epidemic in high-burden settings"
Sue-Ann Meehan, MA (Research Psychology)	Senior Researcher, LINKED-in Project Manager	PhD (SU)	Nulda Beyers Ronelle Burger	The contribution of a community based HIV counseling and testing initiative in working towards increasing access to HIV counseling and testing in Cape Town, South Africa.

Registering for PhDs to start in 2019

Name of trainee	Current position	Degree	Supervisor	Research Topic
Hanlie Myburgh, MA	Social Science Researcher	PhD (UVA)	Ria Reis Lindsey Reynolds	The state and the citizen in the scale-up of HIV services in South Africa
Constance Mubekapi-Musadaidzwa	Social Science Researcher	PHD (SU)	Elona Toska Graeme Hoddinott	HIV interventions for young people in southern Africa
Dillon Wademan	Social Science Research Officer	PhD (SU)	Graeme Hoddinott Lindsey Reynolds	Family chronicity and intergenerational syndemics in the chronic management of TB, HIV, and diabetes
Laing de Villiers	Social Science Research Officer	PhD (SU)	Leslie Swartz Graeme Hoddinott	Identity fluidity on the margins of Cape Winelands communities
Rozanne Casper	Social Science Research Officer	PhD (RU)	Catriona Macleod Graeme Hoddinott	Young women's negotiation of gender identity in South Africa
Angelique Thomas	Social Science Research Officer	PhD (UCT)	Lindsey Reynolds Graeme Hoddinott	Maintaining intimacy and boundaries by women who sell sex in the Western cape
Isabelle de Wandel, MD	Medical Officer	PhD (SU)	Anneke Hesselning Marieke Van der Zalm	TB and Lung Health
Megan Palmer, MD, FCP	Paediatrician	PhD (SU)	Anneke Hesselning Pierre Goussard James Seddon	Validity of chest radiographic reading methods in children with suspected tuberculosis
Jennifer Hughes	Research Medical Officer	PhD (SU)	Anthony Garcia-Prats Anneke Hesselning	MDR-TB treatment strategies in adults and children

APPENDIX III: MEDIA INTERACTION (TELEVISION, VIDEO, RADIO, PRINTED MEDIA)

The DTTC has been active in media, both in printed and radio. The centre was represented in a video screening at the 22nd International AIDS conference in Amsterdam, 2 printed news articles and three radio interviews.

Video screening:

- "Two Countries, Two Choices": a 30 minute documentary film on TB in which two DTTC research child participants are featured was released by the organisation, AidsFree World, at the 22nd International AIDS Conference in Amsterdam. 27 July 2018. Ref: <https://vimeo.com/280906730>.

Newspaper articles:

- "Weerstandige TB: So slag terapie vir kinders", Elsabie Brits, Die Burger. 18 August 2018.
- Latoya – Independent Newspaper. Interview related to an article on TB. Anneke Hesselning. 21 August 2018.

Radio:

- Elliot Sylvester and Nicola Brand – CapeTalk. Interview with Anneke Hesselning. 22 August 2018.

- Treating MDR-TB in children. Radio Sonder Grense – Mari Hudson. Interview with Anneke Hesselning. 29 August 2018.
- Improvements in TB, SA leading the way globally. Cape Talk. Interview with James Seddon, DTTC. 27 September 2018.